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Abstract 
The Target of Rapamycin Complex 1 (TORC1) is a key and conserved regulator of 
cell growth and proliferation.  The xenobiotic compound rapamycin is a potent 
inhibitor of TORC1 in yeast.  The EGO complex, a non-essential activator of 
TORC1 is required for recovery of cells following rapamycin treatment.  Why?  
Here, we find that rapamycin is in fact only a partial inhibitor of yeast TORC1; 
wild-type cells are able to maintain slow proliferation in the presence of high 
concentrations of the drug (i.e. concentrations multiple times the minimum 
inhibitory concentration).  We find that this residual, rapamycin-insensitive, 
proliferation is dependent on the EGO complex and on TORC1 activity.  We show 
that the ability of cells to maintain slow proliferation in the presence of 
rapamycin dictates their ability to recover.  We find that rapamycin is not 
actively detoxified in yeast; instead, rapamycin is cleared by dilution-by-
proliferation.  The cell-associated intracellular pool of rapamycin is stable, 
decreasing only very slowly following washout of the drug and only diminishing 
at the rate of cell proliferation.  The rapamycin-insensitive growth rate also 
persists long after rapamycin washout, indeed, until cells recover from the drug.  
The rapamycin-insensitive growth rate is not only able to quantitatively account 
for the observed kinetics of recovery from the drug in wild-type cultures, but 
also explains the severity of the ego- recovery defect.   
We contributed to a large-scale genetic screen seeking mutants that, like ego- 
mutants, fail to recover from rapamycin treatment.  We find that loss of any one 
of 10 proteins identified results in a rapamycin recovery defect and a slow 
rapamycin-insensitive growth rate.  Our data propose important or novel roles of 
the core HOPS/CORVET complex, threonine biosynthesis, Vps15p, Vsp34p, Ccr4p 
and Dhh1p activities in modulating the activity or efficiency of TORC1.   
Overall our results reveal that rapamycin is only a partial inhibitor of yeast 
TORC1, that persistence of the drug within the cell limits recovery and that 
rapamycin is not actively detoxified in yeast.  Instead, recovery occurs due to 
dilution-by-proliferation and distribution of the drug among an increasing 
number of progeny cells.  We also identify a set of potentially novel regulators 
of TORC1 activity.  
3 
 
Table of Contents 
Abstract 2 
Table of Contents _____________________________________________________ 3 
List of Tables _________________________________________________________ 8 
List of Figures ________________________________________________________ 9 
Acknowledgements ___________________________________________________ 12 
Author’s Declaration __________________________________________________ 13 
Contribution of Others to Data _________________________________________ 13 
List of Abbreviations __________________________________________________ 14 
1 Introduction ________________________________________________ 15 
 TOR Complexes _____________________________________________ 15 1.1
 Rapamycin _________________________________________________ 16 1.2
 Detoxification of rapamycin in mammalian systems ______________ 16 1.2.1
 Drug detoxification mechanisms in yeast _______________________ 17 1.2.2
 The Target of Rapamycin Complex 1 ___________________________ 18 1.3
 Composition of TORC1 _______________________________________ 18 1.3.1
 TORC1 localisation __________________________________________ 18 1.3.2
 Upstream of TORC1 _________________________________________ 20 1.4
 TORC1 in response to environmental stress _____________________ 21 1.4.1
 TORC1 in response to nutrient cues ____________________________ 22 1.4.2
1.4.2.1 The EGO Complex ___________________________________________ 22 
1.4.2.2 The SEA Complex ___________________________________________ 23 
1.4.2.3 Vam6p as a Guanine Exchange Factor for the EGO complex ________ 27 
1.4.2.4 TORC1 activation by leucyl-tRNA synthetase ____________________ 27 
1.4.2.5 TORC1 regulation by PI(3,5)P2 ________________________________ 30 
 The mammalian Target Of Rapamycin 1 (mTORC1) _______________ 32 1.5
 mTORC1 composition ________________________________________ 32 1.5.1
 mTORC1 in response to nutrient cues __________________________ 34 1.5.2
1.5.2.1 mTORC1 localisation _________________________________________ 34 
1.5.2.2 mTORC1 activation by Rheb __________________________________ 34 
1.5.2.3 mTORC1 activation by Rag GTPases and Ragulator _______________ 35 
1.5.2.4 The ‘inside-out’ model of mTORC1 activation ___________________ 37 
1.5.2.5 Regulation of mTORC1 by GATOR ______________________________ 40 
1.5.2.6 Regulation of mTORC1 by Leucyl-rRNA synthetase _______________ 40 
 Downstream of yeast TORC1 __________________________________ 43 1.6
 Regulation of translation initiation ____________________________ 43 1.6.1
 Regulation of ribosome biosynthesis ___________________________ 43 1.6.2
4 
 
 Regulation of amino acid permeases at the cell surface ___________ 45 1.6.3
 Regulation of autophagy _____________________________________ 46 1.6.4
 Regulation of starvation-induced gene transcription ______________ 47 1.6.5
 Sch9p and Tap42p ___________________________________________ 48 1.6.6
 Comparison of yeast down-stream functions of TORC1 with the 1.6.7
down-stream functions of mTORC1 ____________________________ 49 
 Phenotype of ego- mutants ___________________________________ 50 1.7
 Aims of this project _________________________________________ 52 1.8
2 Materials and Methods _______________________________________ 53 
 Growth conditions ___________________________________________ 53 2.1
 Yeast cultures ______________________________________________ 53 2.2
 Creating double mutants _____________________________________ 53 2.2.1
 Transformation _____________________________________________ 56 2.3
 Bacterial transformation _____________________________________ 56 2.3.1
 Yeast transformation ________________________________________ 56 2.3.2
 Switching the kanamycin selection marker ______________________ 56 2.3.3
 Sporulation and dissection ____________________________________ 56 2.4
 Sporulation and dissection ____________________________________ 56 2.4.1
 Determining the mating type _________________________________ 58 2.4.2
 Genotyping haploids with regards to auxotrophic markers _________ 58 2.4.3
 Creating kog1∆ts haploids _____________________________________ 58 2.5
 Spot assay for recovery ______________________________________ 59 2.6
 Methylene blue staining ______________________________________ 59 2.7
 Amino acid uptake __________________________________________ 59 2.8
 Measuring culture densities and calculating the growth rate _______ 60 2.9
 Culture density as measured by Coulter counter _________________ 60 2.9.1
 Culture density as measured by optical spectrometry _____________ 60 2.9.2
 Calculating the growth rate __________________________________ 60 2.9.3
 Autophagy assay ____________________________________________ 61 2.10
 Mass spectrometry __________________________________________ 61 2.11
 Translation assay ___________________________________________ 62 2.12
 Measuring and predicting recovery time from rapamycin __________ 63 2.13
 Experimentally measuring recovery time _______________________ 63 2.13.1
 Predicting the recovery time _________________________________ 63 2.13.2
 Databases __________________________________________________ 64 2.14
 GO Term analysis ___________________________________________ 64 2.14.1
 Physical interaction analysis __________________________________ 64 2.14.2
 Sensitivity to rapamycin______________________________________ 64 2.15
 FM4-64 staining and confocal microscopy _______________________ 65 2.16
5 
 
 FM4-64 staining _____________________________________________ 65 2.16.1
 Confocal microscopy_________________________________________ 65 2.16.2
 Statistics __________________________________________________ 65 2.17
3 Testing various models that could explain why ego- mutants fail 
to recover from rapamycin treatment __________________________ 67 
 Introduction ________________________________________________ 67 3.1
 Results ____________________________________________________ 69 3.2
 Establishing the ego- phenotype under our laboratory conditions ___ 69 3.2.1
 Methylene blue staining ______________________________________ 70 3.2.2
 Uptake of amino acids _______________________________________ 72 3.2.3
 Testing gap1∆ null mutants for recovery from rapamycin__________ 80 3.2.4
 Testing recovery of ego- mutants from various TORC1 3.2.5
inactivating treatments ______________________________________ 82 
 Do known multidrug detoxification pathways have a role in 3.2.6
recovery from rapamycin? ____________________________________ 84 
 Conclusion _________________________________________________ 88 3.3
4 Rapamycin-insensitive TORC1 activity __________________________ 94 
 Introduction ________________________________________________ 94 4.1
 Results ____________________________________________________ 95 4.2
 Wild-type cells proliferate in the presence of a high 4.2.1
concentration of rapamycin (200 ng/mL) _______________________ 95 
 Rapamycin treatment induces autophagy in wild-type and in 4.2.2
ego1∆ cells ________________________________________________ 102 
 Proliferation of wild-type cells in various high concentrations of 4.2.3
rapamycin ________________________________________________ 104 
 Can ego- mutant cells proliferate in the presence of high 4.2.4
concentrations of rapamycin? ________________________________ 105 
 Does the proliferation rate of ego1Δ mutants vary with the 4.2.5
concentration of rapamycin, when present at high 
concentrations? ____________________________________________ 107 
 Are all subunits of the EGO complex required to support 4.2.6
rapamycin-insensitive proliferation? __________________________ 109 
 Are Tor1p and Tco89p required for rapamycin-insensitive 4.2.7
proliferation? ______________________________________________ 114 
 Growth rate of kog1ts in the presence of a high concentration of 4.2.8
rapamycin ________________________________________________ 116 
 Can yeast cells proliferate in the complete absence of Kog1p? ____ 121 4.2.9
 Rapamycin-insensitive TORC1 activity is inhibited by caffeine ____ 123 4.2.10
 Ego1p is required for rapamycin-insensitive translation __________ 126 4.2.11
 Growth rate of caf20∆ and eap1∆ in the presence of a high 4.2.12
concentration of rapamycin _________________________________ 128 
 Do wild-type cultures of various genetic backgrounds have a 4.2.13
rapamycin-insensitive growth rate? ___________________________ 129 
6 
 
 Conclusion ________________________________________________ 132 4.3
5 Rapamycin-insensitive proliferation underpins recovery from 
rapamycin ________________________________________________ 136 
 Introduction _______________________________________________ 136 5.1
 Results ___________________________________________________ 136 5.2
 Can we invoke a rapamycin recovery defect in wild-type cells? ___ 136 5.2.1
 The rapamycin-insensitive growth rate persists following washout 5.2.2
of the drug ________________________________________________ 139 
 Monitoring rapamycin in cells using mass spectrometry __________ 141 5.2.3
 Can ego- mutants recover from rapamycin? ____________________ 149 5.2.4
 Can we quantify the recovery time? ___________________________ 154 5.2.5
 How does the recovery time vary with concentration of 5.2.6
rapamycin? ________________________________________________ 156 
 Does the rapamycin-insensitive growth rate explain the recovery 5.2.7
time? _____________________________________________________ 160 
 Does a rapamycin-insensitive growth rate correlate with 5.2.8
recovery? _________________________________________________ 164 
 Conclusion ________________________________________________ 166 5.3
6 Identifying other potential regulators of TORC1 ________________ 171 
 Introduction _______________________________________________ 171 6.1
 Results ___________________________________________________ 171 6.2
 Summary of the primary screen ______________________________ 171 6.2.1
 Analysis of the results of the primary screen ___________________ 172 6.2.2
 GO Term enrichment in the primary mutant set ________________ 175 6.2.3
6.2.3.1 GO term enrichment in the ‘single-hit’ mutant set ______________ 178 
 Protein-protein interactions among the gene products of the 6.2.4
mutant set from the primary screen __________________________ 181 
 Selection of mutants for secondary screening __________________ 183 6.2.5
 Secondary screen: Recovery from rapamycin ___________________ 185 6.2.6
6.2.6.1 Threonine biosynthesis mutants ______________________________ 186 
6.2.6.2 Endosomal trafficking mutants _______________________________ 186 
6.2.6.3 Regulation of transcription mutants ___________________________ 189 
6.2.6.4 Summary _________________________________________________ 189 
 Tertiary screen I: Viability of null mutants in the presence of 6.2.7
rapamycin ________________________________________________ 189 
 Tertiary screen II: Rapamycin-insensitive growth rate ___________ 191 6.2.8
6.2.8.1 Threonine biosynthesis mutants ______________________________ 191 
6.2.8.2 Endosomal trafficking mutants _______________________________ 194 
6.2.8.3 Regulation of transcription mutants ___________________________ 196 
6.2.8.4 Summary _________________________________________________ 196 
7 
 
 Selectivity to rapamycin treatment ___________________________ 196 6.2.9
 Recovery from rapamycin of ego1∆ pep3∆ double mutants _______ 198 6.2.10
 The rapamycin-insensitive growth rate of hops/corvet- ego- 6.2.11
double mutants ____________________________________________ 200 
 Could a vacuolar morphology defect explain the requirement of 6.2.12
the core HOPS/CORVET complex in rapamycin recovery? _________ 202 
 Conclusion ________________________________________________ 206 6.3
7 Discussion _________________________________________________ 210 
 Rapamycin does not fully inactivate TORC1 ____________________ 210 7.1
 Is rapamycin-insensitive activity due to a subset of TORC1 not 7.2
bound to rapamycin? _______________________________________ 211 
 The mechanism of rapamycin ‘detoxification’ __________________ 212 7.3
 Identifying other potential regulators of TORC1 ________________ 213 7.4
 Mutants of translational regulators ___________________________ 213 7.4.1
 Mutations of the HOM proteins _______________________________ 214 7.4.2
 The Vps15-Vps34 complex ___________________________________ 214 7.4.3
 The core HOPS/CORVET complex _____________________________ 216 7.4.4
 How much TORC1 activity is insensitive to rapamycin? ___________ 219 7.5
 Does all nutrient signalling to TORC1 act via the EGO complex? ___ 220 7.6
 Future work _______________________________________________ 221 7.7
 The large-scale genetic screen _______________________________ 221 7.7.1
 TORC1 activity_____________________________________________ 223 7.7.2
 Identify new regulators of TORC1 _____________________________ 224 7.7.3
 How does rapamycin enter the cell? __________________________ 224 7.7.4
 What are the rapamycin-insensitive functions of TORC1? _________ 225 7.7.5
 Conclusion ________________________________________________ 225 7.8
References _________________________________________________________ 226 
8 
 
List of Tables 
Table 2.1 List of Strains used throughout the thesis _____________________ 55 
Table 2.2 List of the plasmids used in this thesis _______________________ 57 
Table 3.1 Methylene blue staining of cells treated with rapamycin ________ 73 
Table 3.2 Chronological lifespan of ego- mutants from Powers et al. 
(2006) ___________________________________________________ 92 
Table 4.1 Germination and proliferation of kog1Δ/WT diploids in the 
absence and presence of rapamycin (200 ng/mL) _____________ 122 
Table 5.1 Recovery from various concentrations of rapamycin with 
varying treatment times __________________________________ 153 
Table 5.2 Comparison of the calculated slope of the recovery time to 
the observed rapamycin-insensitive doubling time ____________ 165 
Table 6.1 Null mutants identified from each run of the primary screen 
with a colony formation defect ____________________________ 173 
Table 6.2 The number of null mutants identified across the three runs 
that were scored as having at least a mild rapamycin recovery 
defect _________________________________________________ 174 
Table 6.3 The gene name and ORF number of mutants identified in at 
least two runs of the primary screen ________________________ 176 
Table 6.4 Enrichment of GO terms identified in our primary mutant set __ 177 
Table 6.5 The gene names for which the null mutants were significantly 
enriched in the primary screen by GO Term analysis __________ 179 
Table 6.6 Enrichment of GO Terms of the mutant set found only in any 
one run of the primary screen _____________________________ 180 
Table 6.7 Null mutants selected for secondary screening _______________ 184 
Table 6.8 Percentage of cell death following exposure to rapamycin _____ 192 
Table 6.9 Summary of the results of the secondary screens _____________ 207 
9 
 
List of Figures 
Figure 1.1 The components of TORC1 _________________________________ 19 
Figure 1.2 The EGO complex _________________________________________ 24 
Figure 1.3 The SEA complex _________________________________________ 26 
Figure 1.4 Vam6p regulates TORC1 activity via the EGO complex __________ 28 
Figure 1.5 The leucyl-tRNA synthetase activates the EGO complex ________ 29 
Figure 1.6 The signalling molecule PI(3,5)P2 activates TORC1 _____________ 31 
Figure 1.7 The components of mTORC1 and signalling by Rheb ____________ 33 
Figure 1.8 The Rag GTPases regulate mTORC1 with the aid of the 
Ragulator complex ________________________________________ 36 
Figure 1.9 The V-ATPase promotes mTORC1 activity _____________________ 39 
Figure 1.10 The components, and signalling to mTORC1, of the GATOR 
complex _________________________________________________ 41 
Figure 1.11 Leucyl-tRNA synthetase promotes mTORC1 activity ____________ 42 
Figure 1.12 The downstream TORC1 signalling pathway ___________________ 44 
Figure 3.1 Loss of any subunit of the EGO complex results in a rapamycin 
recovery defect phenotype _________________________________ 71 
Figure 3.2 Uptake of amino acids following rapamycin treatment _________ 75 
Figure 3.3 Uptake of amino acids into wild-type and gtr2Δ cells relative 
to their own uptake of untreated cells _______________________ 77 
Figure 3.4 Loss of Gap1p does not result in a rapamycin recovery defect ___ 81 
Figure 3.5 Testing sensitivity of yeast to caffeine _______________________ 83 
Figure 3.6 Recovery of ego- from TORC1 inactivating treatments __________ 85 
Figure 3.7 Recovery from rapamycin of null mutants involved in 
multidrug resistance ______________________________________ 87 
Figure 4.1 Proliferation of wild-type cells in the constant presence of 
rapamycin (200 ng/mL) ____________________________________ 97 
Figure 4.2 The rapamycin-insensitive growth rate of wild-type cells is not 
altered by previous exposure to rapamycin ___________________ 99 
Figure 4.3 Sensitivity of naïve or recovered wild-type cultures to various 
concentrations of rapamycin ______________________________ 101 
Figure 4.4 Autophagy is induced upon treatment of yeast cells with high 
concentrations of rapamycin ______________________________ 103 
Figure 4.5 Growth rate of wild-type cultures in various high 
concentrations of rapamycin ______________________________ 106 
Figure 4.6 Proliferation of ego1Δ cells in the constant presence of 
rapamycin (200 ng/mL) ___________________________________ 108 
Figure 4.7 Growth rate of wild-type and ego1Δ cultures in various high 
concentrations of rapamycin ______________________________ 110 
Figure 4.8 The growth rate of ego- mutants in the presence of a high 
concentration rapamycin _________________________________ 112 
10 
 
Figure 4.9 Growth rate of wild-type, ego1Δ and gtr2Δ cultures in 20 and 
200 ng/mL rapamycin ____________________________________ 113 
Figure 4.10 Proliferation of tor1Δ and tco89Δ cells in the constant 
presence of rapamycin (200 ng/mL) ________________________ 115 
Figure 4.11 The growth rate of tco89Δ cells in 20 and 200 ng/mL 
rapamycin ______________________________________________ 117 
Figure 4.12 Growth rate of kog1ts in the constant presence of rapamycin 
(200 ng/mL) ____________________________________________ 119 
Figure 4.13 Growth rate of kog1ts in 20 and 200 ng/mL rapamycin _________ 120 
Figure 4.14 Growth rate of wild-type and ego1∆ cultures treated with a 
high concentration of rapamycin and sub-inhibitory 
concentration of caffeine _________________________________ 125 
Figure 4.15 Translation rates of rapamycin and cycloheximide treated 
wild-type and ego1Δ mutant cells __________________________ 127 
Figure 4.16 The rapamycin-insensitive growth rates of caf20∆ and eap1∆ 
cultures in the presence of rapamycin (200 ng/mL) ___________ 130 
Figure 4.17 The rapamycin-insensitive growth rate of wild-type strains of 
various genetic backgrounds _______________________________ 131 
Figure 5.1 Recovery of wild-type cells from rapamycin treatment in the 
presence of caffeine _____________________________________ 138 
Figure 5.2 Recovery of wild-type cells from rapamycin when expressing a 
caffeine resistant tor1I1954V allele in the presence of caffeine __ 140 
Figure 5.3 The rapamycin-insensitive growth rate of cultures maintains 
after washout of the drug _________________________________ 142 
Figure 5.4 Recovery of wild-type and ego1∆ from 400 ng/mL rapamycin _____ 144 
Figure 5.5 Uptake of rapamycin into wild-type and ego1Δ cells __________ 146 
Figure 5.6 Cell associated rapamycin during a ‘recovery phase’ from 
rapamycin treatment _____________________________________ 147 
Figure 5.7 Increase in culture density during recovery from rapamycin ____ 148 
Figure 5.8 The total intracellular concentration of rapamycin present 
during the ‘recovery phase’ _______________________________ 150 
Figure 5.9 Recovery of wild-type and ego- mutants from various 
concentrations of rapamycin ______________________________ 152 
Figure 5.10 Observing cultures recovering from rapamycin treatment ______ 155 
Figure 5.11 Demonstrating how the lag time to recovery was determined __ 157 
Figure 5.12 The time at which wild-type and ego1Δ cells recover from 
various concentrations of rapamycin ________________________ 159 
Figure 5.13 Extrapolating recovery time to the origin ____________________ 161 
Figure 5.14 The predicted and experimentally observed recovery times for 
wild-type and ego1Δ cultures from various high concentrations 
of rapamycin treatment __________________________________ 163 
Figure 5.15 Recovery of tor1Δ, eap1Δ wild-type (W303, EG123), and 
tco89Δ from rapamycin treatment __________________________ 167 
Figure 6.1 Protein-protein interactions among the primary protein set ____ 182 
11 
 
Figure 6.2 Recovery from rapamycin of hom2∆ and hom3∆ mutants_______ 187 
Figure 6.3 Recovery from rapamycin of endosomal trafficking mutants ____ 188 
Figure 6.4 Recovery from rapamycin of regulation of transcription 
representatives __________________________________________ 190 
Figure 6.5 The rapamycin-insensitive growth rate of hom2∆ and hom3∆ 
mutant cultures _________________________________________ 193 
Figure 6.6 The rapamycin-insensitive growth rate of pep3∆, pep5∆, 
vps16∆, vps33∆, vps15∆, vps34∆ and shp1∆ mutant cultures ____ 195 
Figure 6.7 The rapamycin-insensitive growth rate of ccr4∆, dhh1∆ and 
ctk1∆ mutant cultures ____________________________________ 197 
Figure 6.8 The fold decrease in growth rate in the presence of rapamycin 
compared to equivalent untreated cultures __________________ 199 
Figure 6.9 Rapamycin recovery of ego1∆ pep3∆ double mutants from 
various concentrations of the drug _________________________ 201 
Figure 6.10 The rapamycin-insensitive growth rate of ego1∆ pep3∆ double 
mutant cultures _________________________________________ 203 
Figure 6.11 Representative images of FM4-64 staining in wild-type, ego1∆, 
pep3∆, ego1∆ pep3∆ and ypt7∆ cells ________________________ 205 
Figure 7.1 The role of Hom2p and Hom3p in threonine biosynthesis and 
their potential role in TORC1 activation _____________________ 215 
Figure 7.2 The upstream TORC1 signalling pathway showing the role of 
the core HOPS/CORVET complex ___________________________ 217 
12 
 
Acknowledgements 
I would like to thank Dr. Joe Gray for presenting me with the opportunity to 
undertake such a fascinating project, with continued support and advice 
throughout the PhD.  I express my gratitude also to the Biotechnology and 
Biological Sciences Research Council for funding this project. 
I am grateful to Musab Bhutta, Christine Merrick, Lisa Blackwood, Sue Krause and 
Josie McGhie for their friendship and support over the last four years, it has 
been invaluable.  
I would also like to thank Dr. Burgess of the University of Glasgow Polyomics 
Facility for his time and expertise with regards to optimising the mass 
spectrometer and enabling us to observe the cell-associated pool of 
rapamycin.  These results proved incredibly important for the progress of the 
project.  My gratitude also goes to Dr. McInerny for the use of the Coulter 
counter which provided a plethora of interesting results.  I would also like to 
extend my thanks to Dr. Thumm, Dr. Powers, Dr. Kamada and Dr. Dokudovskaya 
for their kind donations of plasmids and yeast strains. 
My deepest thanks goes to my family, Bev, Ian, Katie and Lizzie for their eternal 
love and support. And to Chris, for his immeasurable love and encouragement.
13 
 
Author’s Declaration 
I declare that the work presented in this thesis is my own, unless otherwise 
stated.  It is entirely of my own composition and has not, in whole or in part, 
been submitted for another degree.  
Stephanie Kaye Evans 
January 2015 
 
Contribution of Others to Data 
The data presented in Figure 5.5, Figure 5.6 and Figure 5.8 was carried out with 
the aid of Dr. Burgess and Dr. Weidt of the University of Glasgow Polyomics 
Centre.  Optimisation of the conditions required to detect rapamycin by mass 
spectrometry and the running of samples on the mass spectrometer was carried 
out by Dr. Burgess and myself.  The identification of rapamycin peaks and 
determination of signal intensities were carried out by Dr. Burgess or Dr. Weidt.  
Further analysis of the identified rapamycin signal peaks was carried out by 
myself.   
The large-scale genetic screen, the results of which are analysed in Chapter 6, 
was carried out by Dr. Poon, Dr. Singer and Dr. Johnston at Dalhousie University, 
Canada, in collaboration with Dr. Gray.  Scoring of colony formation was carried 
out by image analysis and Dr. Poon, all further analysis was carried out by 
myself. 
14 
 
List of Abbreviations 
caf Caffeine 
CORVET class C cORe Vacuole and Endosomal Tethering 
CPM Counts Per Minute 
EGO Exit from GrOwth arrest 
FBPase Fructose 1,6-bisphosphatase 
GAP GTPase Activating Protein 
GATOR Gap Activity TOwards Rags 
GEF Guanine nucleotide Exchange Factor 
GFP Green Fluorescent protein 
GSE Gap1 Sorting in the Endosome 
GTPase Guanosine TriPhosphatase 
HOPS HOmotypic fusion and Protein Sorting 
LRS Leucyl-tRna Synthetase 
PAS Pre-Autophagosomal Structure 
PtdIns(3) Phosphatidylinositol 3-phosphate 
PI(3,5)P2 PhosphatIdylinositol 3,5-bisphosphate  
PDR Pleiotropic Drug Resistance 
rap Rapamycin 
ROS Reactive Oxygen Species 
SD Synthetic Defined media 
SDS PAGE SDS-PolyacrylAmide Gel Electrophoresis 
SEA SEh1 Associated 
SEACAT SEA Complex Activating Torc1 
SEACIT SEA Complex Inhibiting Torc1 
TAP Tandem Affinity Purification 
TORC1 Target Of Rapamycin Complex 1 
TORC2 Target Of Rapamycin Complex 2 
V-ATPase Vacuolar ATPase 
Vid Vacuole import and degradation 
YP Yeast extract and Peptone media 
YPD Yeast extract, Peptone and Dextrose media (note, glucose is used 
instead)  
15 
 
1 Introduction 
 TOR Complexes 1.1
All eukaryotic cells contain two highly conserved Target Of Rapamycin 
Complexes, TORC1 and TORC2.  For most organisms, the two complexes contain 
the same Tor protein (mTor in the case of mammals); however, Saccharomyces 
cerevisiae differs in that it has two copies of the TOR gene, TOR1 and TOR2 
(Wullschleger et al. 2006).  This TOR gene duplication is likely to have occurred 
during the whole yeast genome duplication (Wolfe & Shields 1997).  Tor1p is 
exclusively found in TORC1 whilst Tor2p is predominantly associated with TORC2 
but can also function in TORC1 (Loewith et al. 2002; Martin & Hall 2005). 
The TOR Complexes regulate cell growth and proliferation in response to 
environmental conditions.  TORC1 controls both cell growth (the increase in cell 
mass) and proliferation (the increase in cell number) predominantly in response 
to nutrient availability but also in response to environmental stresses (Takahara 
& Maeda 2012; De Virgilio & Loewith 2006b).  External growth factors and 
hormones, for example insulin and insulin-like growth factors, also regulate 
mammalian mTORC1 (Wullschleger et al. 2006).  TORC2 regulates the spatial 
growth of cells by regulating both the actin cytoskeleton and membrane 
organisation via sphingolipid biosynthesis (Loewith & Hall 2011).  The mode of 
action of the TOR complexes appears to be conserved across eukaryotic cells 
(Schmelzle & Hall 2000).   
Treatment of wild-type yeast cells with rapamycin results in cells entering a G0 
arrest similar to that seen in starved cells (Barbet et al. 1996; Heitman et al. 
1991; Zaragoza et al. 1998).  The G0 arrest of wild-type cells induced by 
rapamycin treatment is reversible and cells are able to return to proliferation 
following removal of the “rapamycin block” (Dubouloz et al. 2005).  However, 
null mutants have been identified that fail to resume proliferation following 
rapamycin treatment, for example loss of any component of the EGO complex 
(Binda et al. 2009; Dubouloz et al. 2005).  The basis behind the failure of ego- 
mutants to recover from rapamycin treatment is currently unknown and is the 
major focus of the work described in this thesis. 
16 
 
 Rapamycin 1.2
Rapamycin is a secondary metabolite of the soil-dwelling bacterium 
Streptomyces hygroscopicus from Easter Island (Vézina et al. 1975).  Rapamycin 
is named after Easter Island, also known as Rapa Nui (Vézina et al. 1975).  
Rapamycin was originally identified as an antifungal agent due to its potent 
inhibition of yeast proliferation.  It was soon discovered that the TOR1 complex 
was the intracellular target of the drug (Heitman et al. 1991).  Rapamycin has 
therefore been extensively used to study the TORC1 pathway in numerous 
species.  Rapamycin is a somewhat unusual drug with regards to its mode of 
action: to target and inactivate TORC1, rapamycin must first bind the cyclophilin 
protein Fpr1p (FKBP12 in mammals), a cis-trans prolyl isomerase thought to be 
important for protein folding (Heitman et al. 1991; Koltin et al. 1991).  The cis-
trans activity of Fpr1p is not required for TORC1 inhibition, instead the binary 
rapamycin-Fpr1p complex binds to Tor1p, thereby inhibiting TORC1 activity 
(Lorenz & Heitman 1995). 
It was hoped that rapamycin could be used as a clinical antifungal agent, but 
was initially discounted due to undesirable side effects; it was found that 
rapamycin was also a potent inhibitor of proliferation of mammalian cells 
(Sehgal 2003).  It was soon realised that inhibiting proliferation of mammalian 
cells meant that rapamycin could instead be used clinically as an 
immunosuppressant.  Rapamycin (under its clinical name sirolimus) is currently 
used in a number of applications, including that as an immunosuppressant 
following transplant operations.  It is hoped that rapamycin will also be used to 
treat cancer and metabolic diseases, for example diabetes (Benjamin et al. 
2011; Sehgal 2003).  The use of rapamycin to disrupt cancer cells in clinical trials 
has so far not proven successful; it would appear that the effectiveness of 
rapamycin is unpredictable with regards to the inhibition of proliferation 
(Benjamin et al. 2011). 
 Detoxification of rapamycin in mammalian systems 1.2.1
A number of cellular mechanisms exist in eukaryotic cells to overcome 
xenobiotic compounds and these mechanisms appear conserved across phyla.  
With regards to rapamycin detoxification, little is known about how this drug is 
17 
 
metabolised in cells, either yeast or mammalian.  Some evidence has suggested 
that rapamycin is a substrate for the cytochrome P450 CYP3A4 enzyme in 
mammalian liver hepatocytes (Anzenbacher & Anzenbacherova 2001; Guengerich 
1999; Li et al. 1995) but how non-hepatocyte mammalian cells degrade 
rapamycin, or indeed how rapamycin is transported to the liver in whole 
organisms remains unknown.  It is possible that the cytochrome P450 CYP3A4 
acts in collaboration with the efflux transporter P-glycoprotein (P-gp); extensive 
overlap in the substrates of CYP3A4 and P-gp have been reported, with 
rapamycin being one such substrate (see review: Linardi & Natalini 2006). 
 Drug detoxification mechanisms in yeast 1.2.2
Whilst a number of drug detoxification mechanisms exist in yeast, none so far 
has strongly identified rapamycin as a substrate.  It is possible that rapamycin is 
detoxified in yeast either by being metabolised by cytochrome P450s (similar to 
the case thought to pertain in mammalian cells), targeted for sequestering in 
the vacuole through the addition of a glutathione tag or exported from the cell 
by members of the pleiotropic drug resistance pathway. 
Physical metabolism of toxic substances can be carried out by two mechanisms 
in yeast: the cytochrome P450s and glutathione conjugation.  Two cytochrome 
P450s have so far been identified in yeast, Erg5p and Erg11p (Erg11p is 
conserved across all phyla) (Kelly et al. 1997; Werck-reichhart & Feyereisen 
2000).  In yeast, the cytochrome P450s are involved in ergosterol biosynthesis in 
addition to their role as monooxygenases to metabolise toxic substances through 
hydroxylation (Bossche & Koymans 1998; Crešnar & Petrič 2011).  The addition of 
a glutathione tag to toxic compounds results in sequestration into the vacuole, 
thus reducing the toxic effects.  The conjugation of a xenobiotic compound with 
glutathione targets the compound for transport to the vacuole through GS-X 
pumps (Szczypka 1996). 
A large network of proteins (over 20 have been identified) are involved in the 
export of toxic substances and are collectively known as the pleiotropic drug 
resistance network (PDR).  The PDR network comprises of transcription factors, 
ABC transporter/efflux pumps and accessory proteins (Moye-Rowley 2003; Prasad 
& Goffeau 2012).  Two of the earliest transcription factors to be identified were 
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Pdr1p and Pdr3p.  Loss of Pdr1p results in profound drug hypersensitivity 
whereas loss of Pdr3p results in moderate hypersensitivity to xenobiotic 
compounds (Moye-Rowley 2003).  One of the key downstream targets of Pdr1p 
was found to be the ABC efflux transporter Pdr5p (Moye-Rowley 2003; Prasad & 
Goffeau 2012).  Not only is Pdr5p an exporter for xenobiotic compounds (for 
example cycloheximide) but it is also temporally regulated to export toxic 
metabolites that accumulate during cell growth (Moye-Rowley 2003; Prasad & 
Goffeau 2012).  The ABC transporter pumps are able to export a wide range of 
seemingly unrelated substrates (Prasad & Goffeau 2012). 
 The Target of Rapamycin Complex 1 1.3
 Composition of TORC1 1.3.1
The TOR Complexes were identified as the targets of the antifungal agent 
rapamycin.  However, only TORC1 is inhibited by the presence of rapamycin and 
the TORC1 pathway is the focus of this thesis.  The yeast Target of Rapamycin 
Complex 1 is composed of four subunits; Tor1p, Kog1p, Lst8p and Tco89p 
(Loewith et al. 2002; Reinke et al. 2004; Wedaman & Reinke 2003) (Figure 1.1).  
Kog1p and Lst8p are both essential proteins whilst Tor1p and Tco89p are not 
(Reinke et al. 2004).  Tor1p is non-essential due to partial redundancy between 
Tor1p and Tor2p.  In the absence of Tor1p, Tor2p is able to function in TORC1 
and maintain some downstream function, however the redundancy is 
unidirectional and Tor1p is not able to function in place of Tor2p in the TORC2 
complex (Loewith et al. 2002). 
 TORC1 localisation 1.3.2
Numerous studies have been carried out to localise TORC1 within the cell (for 
example Alibhoy & Chiang 2010; Aronova & Wedaman 2007; Berchtold & Walther 
2009; Brown et al. 2010; Binda et al. 2009; Kunz et al. 2000; Urban et al. 2007).  
It is generally agreed that Tor1p, Tco89p and Kog1p are bound to a membrane; 
however, some disagreement exists with regards to which membrane these 
proteins, and by inference TORC1, localises.   
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Figure 1.1 The components of TORC1 
TORC1 consists of four subunits, Tor1p, Kog1p, Tco89p and Lst8p.  Kog1p and 
Lst8p are essential proteins whereas Tor1p and Tco89p are not.  In the absence 
of Tor1p, Tor2p is able to function in TORC1 and maintain some downstream 
activity. 
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A number of studies have found TORC1 to be present at the plasma membrane, 
with some distinct puncta in the cytoplasm that could not always be associated 
with known structures (Alibhoy & Chiang 2010; Aronova & Wedaman 2007; Kunz 
et al. 2000).  Li et al. (2006) also found Tor1p to be distributed in the cytoplasm 
in addition to localisation in the nucleus.  Alternatively, studies have found 
components of TORC1 to be associated either with the vacuole or structures 
adjacent to the vacuole, most likely to be vesicles (Binda et al. 2009; Kira et al. 
2014; Urban et al. 2007; Wedaman & Reinke 2003).  It is now generally accepted 
that TORC1 mainly resides, and is active, at the cytoplasmic face of the vacuolar 
membrane (Loewith & Hall 2011).  Through tethering the TORC1 downstream 
target Sch9p to the vacuole, Urban et al. (2007) were able to demonstrate that 
TORC1 is indeed active in this position. 
More recent studies by Takahara & Maeda 2012 and Yan et al. 2012a have found 
that in response to certain stress conditions, the association of TORC1 with the 
vacuolar membrane is disrupted.  Takahara & Maeda (2012) found that TORC1 
was sequestered into stress granules in response to heat shock.  The removal of 
TORC1 from the membrane is thought to prolong TORC1 inactivation during this 
stress.  Yan et al. (2012a) also found that TORC1 was removed from the vacuolar 
membrane following activation of the Rho1p stress response.  Binding of the 
Rho1p GTPase to TORC1 when activated (by Rom2p) due to stress environments 
resulted in disruption of TORC1 localisation at the vacuolar membrane (Yan et 
al. 2012a).  It is possible that Rho1p targets TORC1  to stress granules, but this 
possibility has not yet been investigated.  Again it appears that removal of 
TORC1 from the vacuolar membrane is a mechanism to prolong TORC1 
inactivation, allowing cells time to recover from the initiating stress before 
resuming active growth and proliferation.  These discoveries may explain why 
some groups found TORC1 to be distributed throughout the cytoplasm; the 
conditions of their experiments may have inadvertently resulted in activation of 
the environmental stress pathway.  
 Upstream of TORC1 1.4
TORC1 has been shown to respond to stimuli such as nutrient availability, heat 
shock, high temperature and redox stress (Loewith & Hall 2011).  Little is 
currently known about how these environmental conditions are signalled to 
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TORC1 and the main focus of studies so far has been to understand the 
mechanism by which amino acid availability is sensed.  A number of complexes 
and proteins that signal to TORC1 have been identified and will be discussed in 
more detail below.  However, a number of gaps in our understanding of the 
TORC1 signalling pathway exist that are yet to be identified.  
 TORC1 in response to environmental stress 1.4.1
A recent study suggests that spatiotemporal regulation of TORC1 occurs 
following heat shock (Takahara & Maeda 2012).  Stress granules can form in 
yeast under conditions in which translation is stalled, such as a period of heat 
shock (Buchan & Parker 2009).  The composition of stress granules can vary 
depending on the initiating stress, however often include ribosomal subunits, 
translation initiation factors, and proteins involved in cell signalling (Buchan & 
Parker 2009).  Takahara & Maeda (2012) found that the TORC1 component Kog1p 
was associated with stress granules during a period of recovery following heat 
stress.  The sequestering of TORC1 into stress granules is thought to maintain 
TORC1, and therefore the cell, in an inactive state during recovery from the 
heat stress to prevent DNA damage.  Takahara & Maeda (2012) found that the 
length of time TORC1 remained inactive was dependent on the time it took for 
stress granule dissociation to occur following the re-initiation of translation.  It 
is worth noting that TORC1 itself was inactivated in response to heat stress 
before being relocalised to the stress granules.  The mechanism by which TORC1 
is inactivated by heat shock remains elusive but could involve Rho1p (Takahara & 
Maeda 2012; Yan et al. 2012a; Yan et al. 2012b). 
TORC1 appears to be a direct target of the small GTPase Rho1p in response to a 
number of environmental stresses that initiate the cell wall integrity signalling 
pathway (Yan et al. 2012a; Yan et al. 2012b).  Activation of Rho1p GTPase by 
the GEF Rom2p (Ozaki et al. 1996) results in the binding of Rho1p to the Kog1p 
subunit of TORC1 in a region normally bound by Tap42p, a direct downstream 
target of TORC1 (Yan et al. 2012a).  The interaction between Kog1p and Rho1p 
results in dissociation and subsequent activation of Tap42p leading to the 
induction of Tap42p downstream functions which includes stress induced gene 
transcription (Beck & Hall 1999a).  Not only does Rho1p disrupt the interaction 
between Kog1p and Tap42p, but it also results in dissociation of TORC1 from the 
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membrane resulting in further inactivation of TORC1.  The stress-induced 
binding of Rho1p to TORC1 was found to occur for less than 15 minutes, yet the 
reassociation of TORC1 to the membrane took approximately 90 minutes (Yan et 
al. 2012a; Yan et al. 2012b).  It is possible that removing TORC1 from the 
vacuolar membrane provides an additional regulatory mechanism for the 
complex. 
 TORC1 in response to nutrient cues 1.4.2
1.4.2.1 The EGO Complex 
The EGO complex (Exit from rapamycin-induced GrOwth arrest (Dubouloz et al. 
2005)) was identified by the De Virgilio group and appears to activate TORC1 in 
response to amino acid availability (Binda et al. 2009; Dubouloz et al. 2005; 
Zhang et al. 2012).  The EGO complex is a non-essential complex composed of 
four subunits: Ego1p, Ego3p, Gtr1p and Gtr2p (Binda et al. 2009; Dubouloz et al. 
2005) (Figure 1.2A).  When identifying proteins involved in amino acid permease 
trafficking Gao & Kaiser (2006) also identified all four members of the EGO 
complex in conjunction with a fifth protein, Ltv1p, which they termed the GSE 
complex.  However, it is the four-subunit EGO complex that is generally 
regarded as an activator of TORC1 (Loewith & Hall 2011).  Loss of any member of 
the EGO complex results in an inability to resume proliferation following 
rapamycin treatment.  This phenotype will form the basis of this thesis. 
The Gtr1p and Gtr2p subunits of the EGO complex are Ras-related GTPases 
(Hirose et al. 1998; Sekiguchi et al. 2001) that can activate TORC1 (Binda et al. 
2009; Dubouloz et al. 2005) (Figure 1.2A & B).  The binding of GTP and GDP to 
Gtr1p and Gtr2p regulates TORC1 activity, but in a complicated way; when Gtr1p 
is bound to GTP and Gtr2p is bound to GDP the EGO complex activates TORC1 
whereas when Gtr1p is bound to GDP and Gtr2 is bound to GTP TORC1 is 
inactivated (Binda et al. 2009; Kira et al. 2014).  Ego1p is thought to anchor the 
EGO complex to the vacuolar membrane through myristoylation of the N-
terminus (Gao et al. 2005).  Indeed, Gao et al. (2005) found Gtr1p to be soluble 
and localised to the cytosol in mutants lacking Ego1p.  Ego3p is also thought to 
be required for assembly and localisation of the EGO complex at the vacuole 
(Zhang et al. 2012).  Ego3p exists as a homodimer in cells (Zhang et al. 2012) 
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and it is thought that this dimerisation is necessary for localisation of Ego3p to 
the vacuolar membrane and for its interaction with the membrane anchor Ego1p 
(Zhang et al. 2012).  It would appear that the localisation of Gtr2p is dependent 
on the presence of Gtr1p (Sekiguchi et al. 2001), and the localisation of Gtr1p to 
the membrane is dependent on the presence of Ego1p (Gao et al. 2005).  The 
correct formation of the EGO complex is therefore dependent on the presence of 
every subunit (Sekiguchi et al. 2014). 
The non-essential nature of the EGO complex suggests that it is not necessarily 
the only mechanism by which TORC1 is activated by nutrient sensing.  Stracka et 
al. (2014) have found that the EGO complex activates TORC1 in response to a 
high quality nitrogen source but the presence of elevated levels of glutamine 
were able to sustain TORC1 activity in a Gtr1/2p independent manner.  
However, potential alternative activators of TORC1 in response to nutrients 
remain elusive; as will be seen below, nearly all nutrient dependent regulators 
of TORC1 identified so far appear to act, at least in part, via the EGO complex. 
1.4.2.2 The SEA Complex 
The SEh1 Associated (SEA) complex is an eight subunit complex that localises to 
the vacuolar membrane and has been found to regulate TORC1 activity in a 
nutrient dependent manner (Dokudovskaya et al. 2011; Neklesa & Davis 2009; 
Panchaud et al. 2013b).  The eight subunits (Iml1p (Sea1p), Npr2p, Npr3p, 
Seh1p, Sec13p, Sea2p, Sea3p and Sea4p) of the SEA complex form two functional 
sub-complexes, containing either three or five of the SEA proteins, that have 
different roles with regards to modulating TORC1 activity (Dokudovskaya et al. 
2011; Neklesa & Davis 2009; Panchaud et al. 2013a).  The Iml1p-Npr2p-Npr3p 
sub-complex inhibits TORC1 activity and is called SEACIT (SEA Complex Inhibiting 
Torc1) (Figure 1.3A & B).  The other five membered sub-complex promotes 
TORC1 activity and is called SEACAT (SEA Complex Activating Torc1) (Panchaud 
et al. 2013a) (Figure 1.3A & B)  The two sub-complexes will be discussed in more 
detail below. 
The SEACIT components Npr2p and Npr3p (as a complex together) were originally 
identified by Neklesa & Davis (2009) following a genome-wide screen to identify 
potential regulators of TORC1.    
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Figure 1.2 The EGO complex 
A: The EGO complex consists of four subunits Ego1p, Ego3p, Gt1p and Gtr2p all 
of which are non-essential.  Ego1p and Ego3p tether the EGO complex to the 
vacuolar membrane whilst Gtr1p and Gtr2p are GTPases that regulate TORC1 
activity.  When Gtr1p is bound to GTP and Gtr2p is bound to GDP the EGO 
complex is active.  When the inverse is true the EGO complex is inactive. 
B: Under conditions of plentiful nutrients Gtr1p is bound to GTP whilst Gtr2p is 
bound to GDP and promotes TORC1 activity.  The EGO complex is inactive under 
starvation conditions. 
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Npr2p and Np3p were subsequently found to be associated with the other six SEA 
complex proteins as part of the larger SEA complex structure (Dokudovskaya et 
al. 2011) (Figure 1.3A).  Neklesa & Davis (2009) found that Npr2p and Npr3p 
acted upstream of TORC1 and promoted its activity.  The Npr2-Npr3 complex 
was found to be required for TORC1 inhibition in response to poor nutrient 
conditions; cells lacking either Npr2p or Npr3p failed to respond correctly to 
starvation conditions by maintaining active TORC1 (Neklesa & Davis 2009).  Loss 
of the Iml1p SEACIT subunit results in cells with high TORC1 activity, compared 
to that of wild-type cells, as assayed by Sch9p phosphorylation (Panchaud et al. 
2013b).  It was found that Iml1p, Npr2p and Npr3p co-localised in a trimeric 
complex that is tethered at the vacuolar membrane through the tethering 
properties of Iml1p (Dokudovskaya et al. 2011; Panchaud et al. 2013b; Wu & Tu 
2011).   
It is thought that the SEACIT complex acts as a GTPase-Activating Protein (GAP) 
towards the Gtr1p subunit of the EGO complex.  Localisation of SEACIT to the 
vacuolar membrane is dependent on the presence of the EGO complex 
(Panchaud et al. 2013b) and loss of either Gtr1p or Gtr2p negated the increase in 
TORC1 activity seen in cells lacking a member of the SEACIT complex (Panchaud 
et al. 2013b).  Overproduction of Iml1p resulted in a decrease in GTP-associated 
Gtr1p leading  to the conclusion that Iml1p has GAP activity towards Gtr1p 
(Panchaud et al. 2013b).  It is therefore thought that SEACIT acts as an inhibitor 
of the EGO complex to regulate the activity of TORC1 (Figure 1.3B). 
It appears that the members of SEACAT act redundantly to promote TORC1 
activity and in cells lacking all of Sea2p, Sea3p and Sea4p or in cells lacking 
Seh1p a reduction in TORC1 activity is observed (Panchaud et al. 2013a; 
Panchaud et al. 2013b).  The reduction of TORC1 activity in cells lacking SEACAT 
is dependent on the presence of SEACIT leading to a model in which SEACAT acts 
as an inhibitor of SEACIT which in turn acts as an inhibitor of the EGO complex 
(and therefore TORC1 activity) (Panchaud et al. 2013a) (Figure 1.3B).  More 
research is required to confirm the role, and mechanism of action, of the SEACIT 
and SEACT complexes in the TORC1 signalling pathway. 
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Figure 1.3 The SEA complex 
A: The SEA complex consists of eight subunits which are divided into two 
functional sub-complexes.  SEACIT (SEA Complex Inhibiting Torc1) consists of 
Iml1p, Npr2p and Npr3p.  SEACAT (SEA Complex Activating Torc1) consists of 
Sea2p, Sea3p, Sea4p, Seh1p and Sec13p.  Iml1p tethers the whole SEA complex 
to the cytoplasmic face of the vacuolar membrane.  
B: In the presence of nutrients the SEACAT complex inhibits the SEACIT complex 
which has GAP activity towards EGO.  The inhibition of the SEACIT complex thus 
promotes TORC1 activity when cells are in conditions of plentiful nutrients. 
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1.4.2.3 Vam6p as a Guanine Exchange Factor for the EGO complex 
Functional GTPases require both a GAP and a Guanine Exchange Factor (GEF) to 
moderate their activity.  Iml1p acts as a GAP towards Gtr1p (Panchaud et al. 
2013b); Vam6p acts as a GEF towards Gtr1p (Binda et al. 2009) (Figure 1.4).  It is 
currently thought that the GTP-bound status of Gtr1p overrides that of Gtr2p 
with regards to TORC1 activity.  Vam6p (Vps39p) was originally identified in the 
TORC1 signalling pathway by Zurita-Martinez et al. (2007) following a screen 
searching for null mutations that were synthetic lethal or had reduced fitness in 
combination with a null tor1∆ mutation.  Vam6p is a member of the HOPS 
complex (Homotypic fusion and Protein Sorting) which is involved in membrane 
trafficking to the vacuole (Solinger & Spang 2013).  It is not known whether the 
role of Vam6p as a GEF to Gtr1p is carried out as part of the HOPS complex or as 
an additional separate role of the protein.  It is possible that the HOPS complex 
has a role in TORC1 activity, especially as loss of any member of the core HOPS 
complex was identified as being synthetic lethal in combination with a tor1∆ null 
mutation (Zurita-Martinez et al. 2007). 
1.4.2.4 TORC1 activation by leucyl-tRNA synthetase 
The leucyl-tRNA synthetase has also been found to have a role in regulating 
TORC1 activation, again via the EGO complex.  Bonfils et al. (2012) found that 
the leucyl-tRNA synthetase, Cdc60p, interacts with the Gtr1p subunit of the EGO 
complex in a leucine dependent manner.  Bonfils et al. (2012) propose a model 
in which charged leucyl-tRNA synthetase binds to Gtr1p, via the Cdc60p editing 
domain CP1, to prevent GTP hydrolysis of Gtr1p thus maintaining TORC1 activity 
(Figure 1.5).  It appears that Cdc60p does not possess obvious GAP or GEF 
activity domains or functions; rather it behaves as an inhibitor of GAP activity 
towards Gtr1p, performed by an as yet unknown protein.  No interaction 
between Cdc60p and Gtr2p has been observed (Bonfils et al. 2012) suggesting a 
second protein could be involved in maintaining Gtr2p in the GDP bound form to 
promote TORC1 activity.  Alternatively, it is possible that through its interaction 
with Gtr1p, Cdc60p is in close enough proximity to aid hydrolysis of Gtr2p-GTP 
(Segev & Hay 2012).  It is unclear why so far only a leucyl tRNA-synthetase has 
been identified that modulates TORC1 activity.   
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Figure 1.4 Vam6p regulates TORC1 activity via the EGO complex 
The Vam6p component of the HOPS complex has GEF activity towards Gtr1p of 
the EGO complex.  Under conditions of plentiful nutrients Vam6p activates the 
EGO complex which in turn activates TORC1. 
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Figure 1.5 The leucyl-tRNA synthetase activates the EGO complex 
In the presence of leucine the charged leucyl-tRNA synthetase (Cdc60p) interacts 
with the Gtr1p sub-unit of the EGO complex to prevent GTP hydrolysis.  
Inhibition of GTP hydrolysis by Cdc60p maintains the EGO complex in an active 
state resulting in active TORC1. 
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One possibility is that leucine is used as a ‘master sensor’ for the state of all 
amino acids within the cell due to it being the most frequently used amino acid 
in the yeast proteome (Bonfils et al. 2012).  Another possibility is that Cdc60p is 
one of the most abundant aminoacyl-tRNA synthetases and this may account for 
its predominant  role (Bonfils et al. 2012).  A third possibility is that multiple 
other tRNA-synthetases interact with TORC1 but that these interactions have yet 
to be identified. 
1.4.2.5 TORC1 regulation by PI(3,5)P2 
It would appear that the majority of research into upstream regulators of TORC1 
activity has found the EGO complex to be key for proper TORC1 regulation.  
However, the EGO complex is not essential in yeast, whereas TORC1 activity is 
(Barbet et al. 1996; Dubouloz et al. 2005; Heitman et al. 1991).  The viability of 
cells lacking the EGO complex suggests that there must be alternative methods 
of activating TORC1 other than via the EGO complex, a deduction also proposed 
by Stracka et al. (2014).  One such alternative signalling molecule has been 
found to regulate TORC1 activity: the signalling phospholipid PI(3,5)P2 
(Phosphatidylinositol 3,5-bisphosphate) (Jin et al. 2014) (Figure 1.6).  Jin et al. 
(2014) found that null fab1∆ mutants, which are unable to synthesise PI(3,5)P2, 
were hypersensitive to the effects of rapamycin.  The method by which PI(3,5)P2 
potentially regulates TORC1 has not been fully identified, however Jin et al. 
(2014) propose three methods by which PI(3,5)P2 could regulate TORC1.  (1) It is 
possible that PI(3,5)P2 directly activates TORC1 through direct binding of the 
TORC1 subunit Kog1p.  (2) It is possible that PI(3,5)P2 acts as a platform on the 
vacuolar membrane for the localisation of TORC1, its regulators and downstream 
targets, for example the EGO complex and Sch9p (the latter of which was found 
to directly interact with PI(3,5)P2) (Jin et al. 2014).  (3) Activity of the vacuolar 
V-ATPase may be required to signal amino acid availability to TORC1; a role of 
the V-ATPase in signalling to mTORC1 has been identified and will be discussed 
later.  Activity of the V-ATPase requires the correct acidification of the vacuole 
which is lost in cells lacking PI(3,5)P2.   
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Figure 1.6 The signalling molecule PI(3,5)P2 activates TORC1 
Through a currently unknown mechanism (hence a dashed line), the presence of 
PI(3,5)P2 is required for TORC1 activity.  It is possible PI(3,5)P2 directly 
interacts with Kog1p to promote TORC1 activity, or is a landing pad to bring 
TORC1, upstream regulators and downstream effectors together. 
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Whilst an involvement of V-ATPase activity in the yeast TORC1 signalling 
pathway has not been uncovered so far, instability of the V-ATPase has been 
reported in cells lacking Ego1p (Gao et al. 2005) suggesting that the function of 
the V-ATPase and the EGO complex could be linked, either for vacuole stability 
or for TORC1 signalling. 
 The mammalian Target Of Rapamycin 1 (mTORC1) 1.5
The conserved TORC1 signalling pathway is present in every eukaryotic species 
tested (Wullschleger et al. 2006).  Whilst some elements of the mTORC1 
pathway appear to be conserved with those found in yeast, a number of 
differences in the regulation of mTORC1 appear to have occurred. 
 mTORC1 composition 1.5.1
The mammalian Target Of Rapamycin Complex 1, mTORC1, comprises of mTOR, 
Raptor which is the mammalian homolog of yeast Kog1p, mLST8 which is the 
mammalian homolog of yeast Lst8p, PRAS40 and Deptor (Jewell & Guan 2013; 
Laplante & Sabatini 2009) (Figure 1.7A). 
In addition to regulation by nutrient availability, mTORC1 is also regulated by 
stress, energy levels, hormones and growth factors such as insulin and insulin-
like growth factors (Wullschleger et al. 2006).  The TSC1-TSC2 complex is central 
in regulating mTORC1 in response to external factors, for example growth 
factors.  The TSC1-TSC2 complex acts as a GAP towards the TORC1 activator 
Rheb thus promoting mTORC1 activity (Inoki & Guan 2006) (Figure 1.7B).  The 
regulation of mTORC1 in response to nutrient availability and the similarities 
with the yeast TORC1 signalling pathway will be considered in more detail here. 
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Figure 1.7 The components of mTORC1 and signalling by Rheb 
A: mTORC1 comprises of five subunits: mTOR, Raptor, Deptor, mLst8 and 
PRAS40.  Raptor is the mammalian homolog of Kog1p in yeast and mLst8 is the 
mammalian homolog of yeast Lst8p.  
B: Rheb activates mTORC1 in response to activation by the TSC1-TSC2 complex 
which is in turn regulated by the presence of extracellular signals for example 
hormones and growth factors.    
C: Translocation of mTORC1, in response to amino acids, to lysosomal 
membranes containing active Rheb results in activation of mTORC1. 
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 mTORC1 in response to nutrient cues 1.5.2
1.5.2.1 mTORC1 localisation 
Relocalisation of mTORC1 within the cell is an important mechanism of 
regulation for mTORC1 activation.  mTORC1 is membrane bound, most likely to 
that of the lysosome (the functional equivalent of the yeast vacuole) (Korolchuk 
et al. 2011; Poüs & Codogno 2011).  It appears that the intracellular position of 
the lysosomes carrying mTORC1 also affect the activity of mTORC1.  Korolchuk 
et al. (2011) suggest that when nutrients are abundant, mTORC1 is located on 
lysosomes near the plasma membrane possibly where the upstream signals of 
mTORC1 are located.  However, when cells are starved of amino acids the 
lysosomes bearing mTORC1 are found to be perinuclear; which Korolchuk et al. 
(2011) believe may aid the fusion of autophagosomes to lysosomes. Korolchuk et 
al. (2011) also found that reactivation of mTORC1 after starvation was hindered 
in cells that were unable to relocate the mTORC1 bound lysosomes to the cell 
periphery.  Whilst the physical localisation of the lysosomes within a cell appears 
to regulate mTORC1 activity, the physical relocation of mTORC1 onto the 
membrane is also a crucial regulatory tool as will be discussed in more detail in 
the next section. 
1.5.2.2 mTORC1 activation by Rheb 
mTORC1 is activated by the small GTPase Rheb, located on the lysosomal 
membrane (Long et al. 2005; Sancak et al. 2007) (Figure 1.7C).  Unlike yeast 
TORC1, mTORC1 activity is partially moderated by its translocation onto the 
lysosomal membrane where Rheb resides (Binda et al. 2009; Korolchuk et al. 
2011; Sancak et al. 2010; Sancak et al. 2008).  This translocation occurs only in 
response to the presence of amino acids and is not dependent on the activity 
status of Rheb or the presence of growth factors (Sancak et al. 2010).  Under 
starvation conditions, when mTORC1 is inactive, mTOR1 is found distributed 
throughout the cytoplasm in small puncta (Sancak et al. 2008).  Following amino 
acid stimulation mTOR1 is relocalised to the perinuclear region as well as to 
large lysosomal structures.  On the other hand Korolchuk et al. (2011) found 
mTORC1 to be associated with lysosomes at the cell periphery upon the addition 
of amino acids.  Korolchuk et al. (2011) found that the peripheral localisation of 
lysosomes containing mTORC1 is not sufficient to activate the complex in the 
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absence of upstream signals yet tethering mTORC1 to lysosomes (and only 
lysosomes) is sufficient to override amino acid starvation with regards to 
mTORC1 activity, but not regulation by insulin (Sancak et al. 2010).  Regulation 
of mTORC1 by Rheb is not conserved with budding yeast: they lack an equivalent 
Rheb gene (Wullschleger et al. 2006). 
1.5.2.3 mTORC1 activation by Rag GTPases and Ragulator 
The translocation of mTORC1 onto the lysosomal membrane in response to amino 
acid stimulation is regulated by the Rag GTPases, which are orthologous to the 
Gtr proteins in yeast (Sancak et al. 2010; Sancak et al. 2008).  Four Rag GTPases 
have been identified in mammalian cells; RagA and RagB are orthologs of Gtr1p 
and RagC and RagD are orthologs of Gtr2p (Hirose et al. 1998; Yang et al. 2013).  
As observed in yeast, the Rag GTPases exist in heterodimers to signal to 
mTORC1; RagA or RagB associates with RagC or RagD (Kim et al. 2008).  The Rag 
GTPases reside on a lysosomal membrane in an apparently amino acid 
independent manner (Sancak et al. 2010).  Again, as seen in yeast when 
RagA/RagB are bound to GTP and RagC/RagD are bound to GDP mTORC1 activity 
is promoted (Figure 1.8A). 
The Ragulator complex aids the Rag GTPases in their regulation of mTORC1 
(Figure 1.8B).  The Ragulator complex was originally identified as a trimeric 
complex comprising of p18, p14 and MP1 that are encoded by LAMTOR1, 
LAMTOR2 and LAMTOR3 respectively (Sancak et al. 2010).  A further two 
proteins were identified that function in the Ragulator complex and were 
subsequently termed LAMTOR4 (C7orf59) and LAMTOR5 (HBXIP) (Bar-Peled et al. 
2012) (Figure 1.8C).  The Ragulator complex appears to have two roles with 
regards to regulating the Rag GTPases that are discussed below.   
One role of the Ragulator complex is to tether the Rag GTPases to the lysosomal 
membrane (Sancak et al. 2010) and Ragulator is therefore thought to have a 
similar role to that of the Ego proteins in yeast.  Indeed, Kogan et al. (2010) and 
Zhang et al. (2012) found that there is high structural conservation between the 
p14-MP1 heterodimer and the homodimer of Ego3p, suggesting that Ego3p and 
the p14-MP1 heterodimer have potentially conserved functions.   
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Figure 1.8 The Rag GTPases regulate mTORC1 with the aid of the Ragulator 
complex 
A: Mammalian cells have four Rag GTPases which form heterodimers; RagA or RagB 
associates with RagC or RagD.  When active, RagA/RagB is bound to GTP whilst 
RagC/RagD is bound to GDP.  
B: When amino acids are abundant, the Rag GTPases promote TORC1 activity by 
relocating mTORC1 to lysosomes containing active Rheb.  The Rag GTPases are tethered 
to the lysosomal membrane via interaction with the Ragulator complex.  The Ragulator 
complex also promotes TORC1 activity by acting as a GEF to the RagA/RagB GTPases 
thus maintaining their activity.  
C: The Ragulator complex comprises of five subunits which appear to be separated into 
two heterodimers, MP1-p14 and LAMTOR4-LAMTOR5 which are tethered by p18.  The 
p18 subunit also tethers the Ragulator complex to the lysosomal membrane.   
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The p18 subunit of the Ragulator holds the two heterodimers, p14-MP1 and 
LAMTOR4-LAMTOR5 together thus creating the pentameric complex.  The P18 
subunit also binds Ragulator to the Rag GTPases and is the subunit through which 
the Ragulator-Rag GTPases are tethered to the lysosome (Bar-Peled et al. 2012; 
Nada et al. 2009; Sancak et al. 2010).  Sancak et al. (2010) found that 
interactions, both within the trimeric Ragulator complex, and between the 
trimeric Ragulator and Rag GTPases were not affected in response to amino acid 
availability.  Bar-Peled et al. (2012) however, did not find this to be the case 
with regards to the pentameric Ragulator complex.  Bar-Peled et al. (2012) 
found that under starvation conditions the interaction between Ragulator and 
Rag GTPases was strengthened, yet in the presence of amino acids these 
interactions were weakened.  The interaction between Ragulator and mTORC1 
increased upon amino acid stimulation, consistent with mTORC1 activation (Bar-
Peled et al. 2012).  The interaction between p14, p18 and MP1 (the trimeric 
Ragulator) and between the Rag GTPases did not appear to alter in response to 
amino acid availability.  In cells lacking the Ragulator complex, mTORC1 is 
inactive due to the inability of the Rag GTPases, and therefore mTORC1, to 
reside at the lysosome, even when stimulated with amino acids (Sancak et al. 
2010).   
A second role of the pentmeric Ragulator complex is to act as a GEF towards 
RagA/RagB thus maintaining active TORC1 (Bar-Peled et al. 2012) (Figure 1.8B).  
Sancak et al. (2010) found that the p18 subunit (of p18, p14 and MP1 that were 
tested) specifically interacted with the RagB-RagD GTPase heterodimer in vitro.  
More research into the potential GEF properties of the Ragulator complex is 
required.  It appears that the human ortholog of Vam6p (hVPS39), which has a 
role as a GEF for Gtr1p in yeast (Binda et al. 2009), does not have a role in 
mammalian mTORC1 signalling (Bar-Peled et al. 2012). 
1.5.2.4 The ‘inside-out’ model of mTORC1 activation 
It is known that the TORC1 and mTORC1 pathways respond to nutrients, in 
particular amino acid availability, but how nutrients are sensed remains 
uncertain.  A model has been proposed in mammalian cells in which amino acids 
are sensed by an ‘inside-out’ mechanism.  This ‘inside-out’ model suggests that 
amino acid accumulation in the lysosome triggers signalling to, and activation of, 
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mTORC1 (Zoncu et al. 2011) (Figure 1.9).  It is thought that the activity of the V-
ATPase, i.e. the ATP hydrolysis of V1 and associated rotation of the stalk sub-
complex, signals to mTORC1 via interaction with, and regulation of, the 
Ragulator complex (Zoncu et al. 2011).  The V1 domain of the V-ATPase has been 
shown to interact with the Rag GTPases and both the V1 and V0 domains of the 
V-ATPase have been shown to directly associate with the Ragulator complex 
through the P18 subunit (Zoncu et al. 2011).  It appears that the interaction 
between V1, Ragulator and Rag GTPases varies depending on the internal 
concentration of amino acids: the interaction is strengthened under deprived 
amino acid conditions and is weakened when amino acids are plentiful (Bar-
Peled et al. 2012; Zoncu et al. 2011). 
Bar-Peled et al. (2012) propose two possibilities to explain the variation in 
interaction strength between the V-ATPase complex, the Ragulator complex and 
the Rag GTPases in response to the intracellular concentration of amino acids.  
One possibility is that the Ragulator-Rags are found in two states, either 
interacting weakly or strongly with each other, depending on amino acid 
availability.  Deprivation of amino acids results in a strong interaction between 
Ragulator and the Rag GTPases, preventing the binding of the Rag GTPases to 
mTORC1 and therefore resulting in reduced mTORC1 activity.  When cells are 
stimulated with amino acids, the Ragulator complex promotes the binding of 
GTP to RagA and RagB leading to a conformational change, this change could 
potentially weaken the interaction between Ragulator and the Rag GTPases and 
expose an mTORC1 binding site thus promoting mTORC1 activation.  A second 
proposal by Bar-Peled et al. (2012) suggests that the regulated interaction 
between Ragulator and Rag GTPases may be required for transition of the Rag 
GTPases on and off the lysosomal membrane.  The tight binding of Ragulator to 
the Rag GTPases during starvation conditions could tether them to the lysosomal 
membrane.  In the presence of amino acids the interaction between the 
Ragulator and Rag GTPases weakens and therefore could allow the Rag GTPases 
to dissociate from the lysosome, bind to mTORC1 and shuttle the complex back 
to the lysosomal membrane where it can be activated by Rheb.  More work is 
required to determine whether either of these models can explain the changes 
in interaction intensity between the upstream signalling complexes of the 
mTORC1 pathway in response to amino acid availability. 
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Figure 1.9 The V-ATPase promotes mTORC1 activity 
It is thought that the V-ATPase complex signals nutrient availability via the 
‘inside-out’ model in which amino acid accumulation in the vacuole drives 
activity of the V-ATPase.  Active V-ATPase is able to promote Ragulator activity 
and thus mTORC1 activity via the Rag GTPases. 
40 
 
 
1.5.2.5 Regulation of mTORC1 by GATOR 
A further complex in the mTORC1 amino acid sensing pathway has also been 
identified, the GATOR complex (Gap Activity TOwards Rags) which is proposed to 
down regulate mTORC1 activity (Bar-Peled et al. 2013).  The GATOR complex 
comprises of eight subunits and exists as two sub-complexes: GATOR1 (Depdc5, 
Nprl2 and Nprl3) and GATOR2 (Mios, Wdr24, Wdr59, Seh1L and Sec13) (Bar-Peled 
et al. 2013) (Figure 1.10A).  The GATOR complex shows functional similarity to 
the SEA complex identified in yeast, which is also split into two function-based 
sub-complexes SEACIT (GATOR1) and SEACAT (GATOR2) (Bar-Peled et al. 2013; 
Panchaud et al. 2013a).  The GATOR complex is tethered to the lysosomal 
membrane through the DEPDC5 subunit (Bar-Peled et al. 2013).  The two sub-
complexes of GATOR have distinct roles; it appears that GATOR2 acts to inhibit 
the action of GATOR1 which in turn has GAP activity towards RagA/RagB thus 
down-regulating mTORC1 activity under unfavourable growth conditions (Bar-
Peled et al. 2013; Panchaud et al. 2013a) (Figure 1.10B). 
1.5.2.6 Regulation of mTORC1 by Leucyl-rRNA synthetase 
As has been identified in yeast, a role for the leucyl-tRNA synthetase (LRS) in 
regulating mTORC1 activity has been found in mammalian cells.  Han et al. 
(2012) found that LRS specifically interacts with both raptor and mTOR and is 
required for the relocalisation of mTORC1 to the lysosome.  It was also found 
that LRS directly interacts with RagD-GTP to promote GTP hydrolysis (Han et al. 
2012), this is in contrast to the discovery that Cdc60p interacts with Gtr1p in 
yeast (Bonfils et al. 2012).  The interaction of LRS with RagD, which did not 
require t-RNA charging, appears to occur in a leucine-dependent manner and 
results in LRS functioning as a GAP for RagD, thus promoting mTORC1 activity 
(Figure 1.11).  It would appear that LRS is also able to respond to isoleucine 
stimulation in activating mTORC1, suggesting that LRS may be a central amino 
acid sensor within the cell (Han et al. 2012). 
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Figure 1.10 The components, and signalling to mTORC1, of the GATOR 
complex 
A: The GATOR complex is comprised of eight subunits that are split into two 
functional sub-complexes: GATOR1 and GATOR2.  GATOR1 consists of Depdc5, 
Nprl2 and Nprl3 whilst GATOR2 consists of Mios, Wdr24, Wdr59, Sec13 and 
Seh1L.  The GATOR complex is tethered to the lysosomal membrane by the 
Depdc5 subunit.  
B: Under optimal growth conditions, the GATOR2 sub-complex inhibits the 
activity of the GATOR1 sub-complex.  GATOR1 has GAP activity towards the Rag 
GTPases and can therefore down-regulate their activity, and as such that of 
mTORC1, when starved of amino acids. 
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Figure 1.11 Leucyl-tRNA synthetase promotes mTORC1 activity 
When charged with leucine, the leucyl-tRNA synthetase (LRS) is able to interact 
with both mTORC1 and RagD.  LRS has GAP activity towards RagD thus 
maintaining mTORC1 activity under optimal growth conditions. 
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 Downstream of yeast TORC1 1.6
TORC1 regulates cell growth and proliferation in response to nutrient availability 
and environmental stresses.  When amino acids are plentiful, TORC1 is active 
and promotes anabolic processes such as the initiation of translation, ribosome 
biosynthesis and the expression of specific, high-affinity amino acid permeases 
at the cell surface (De Virgilio & Loewith 2006b).  Inactivation of TORC1 results 
in the promotion of catabolic processes, including the induction of autophagy, 
the up-regulation of starvation induced gene transcription and the switch from 
specific to general amino acid permeases at the cell surface (Beck et al. 1999; 
De Virgilio & Loewith 2006b).  The inactivation of TORC1 culminates in cells 
entering a quiescent-like G0 state (Barbet et al. 1996; Rohde et al. 2001).  The 
majority of studies investigating the down-stream functions of TORC1 involve 
either starving cells of amino acids or treating them with rapamycin. 
 Regulation of translation initiation 1.6.1
The initiation of translation is regulated by TORC1 and is inhibited in cells 
treated with rapamycin (Barbet et al. 1996; Urban et al. 2007).  A study by 
Cherkasova & Hinnebusch (2003) has shown that rapamycin treatment leads to 
phosphorylation of the translation initiation factor eIF2α, resulting in its 
inactivation and the subsequent inhibition of protein synthesis (Figure 1.12).  
Berset et al. (1998) demonstrated that rapamycin treatment results in the 
degradation of the translation initiation factor eIF4G, possibly through loss of its 
interaction with eIF4E.  The loss of interaction between eIF4G and eIF4E can 
result from the activation of eIF4E binding proteins (4E-BPs) that disrupt the 
interaction between eIF4G and eIF4E to inhibit translation (Figure 1.12).  It is 
thought that the activation of 4E-BP1 is the mechanism by which mTORC1 
inhibits translation in mammalian cells (Feldman et al. 2009) (see later). 
 Regulation of ribosome biosynthesis 1.6.2
The biogenesis of ribosomes is a major consumer of cellular energy (Martin et al. 
2006) and TORC1 activity is required to maintain transcription of genes encoding 
ribosomal proteins, as well as synthesising and processing 35S precursor mRNA 
(Li et al. 2006; Powers & Walter 1999).   
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Figure 1.12 The downstream TORC1 signalling pathway 
Active TORC1 promotes anabolic activities (including protein synthesis, 
transcription of ribosomal DNA, and the expression of specific amino acid 
permeases at the cell surface) and prevents catabolic activities (the induction of 
stress induced gene transcription, the induction of autophagy and the expression 
of general amino acid permeases at the cell surface).  When TORC1 is inactive, 
due to poor amino acid and nutrient availability, anabolic processes are down-
regulated and catabolic processes are promoted.   
Dashed lines represent interactions that are not well established and may 
involve additional proteins. 
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Cells treated with rapamycin, or starved for nitrogen, show an immediate 
reduction in the transcription of ribosomal protein mRNA that does not require 
de novo protein synthesis (Cardenas et al. 1999; Hardwick et al. 1999; Neklesa & 
Davis 2009; Powers & Walter 1999) (Figure 1.12).  The down-regulation of genes 
encoding proteins involved in ribosome biogenesis is due to inhibition of Pol I 
and Pol III and a reduction in the activity of Pol II at ribosomal gene promoters 
(Powers & Walter 1999).  Li et al. (2006) found that shuttling of the Tor1p 
protein in and out of the nucleus played a role in the regulation of 35S mRNA 
transcription.  Under optimal growth conditions Tor1p was found to be localised 
in the nucleus and associated with the 35S rDNA promoter region.  However, in 
cells treated with rapamycin, Tor1p dissociates from the 35S promoter region 
and exits the nucleus (Li et al. 2006).  It is thought that the TORC1 downstream 
targets, Sch9p and Tap42p activate synthesis of ribosomal protein mRNA; this 
will be discussed later. 
 Regulation of amino acid permeases at the cell surface 1.6.3
Exponentially growing cells consume a large amount of energy and require 
nutrients, such as amino acids, to maintain growth.  Extracellular amino acids 
can be imported to supplement those made by the yeast themselves, or in the 
case of auxotrophs, provide nutrients which the cell cannot make.  Exponentially 
growing cells express specific high-affinity amino acid permeases at the cell 
surface (De Virgilio & Loewith 2006b) for example the tryptophan and histidine 
permeases Tat2p and Hip1p; conversely cells in starvation conditions instead 
express general low-affinity amino acid permeases at the cell surface, an 
example being Gap1p  (Beck et al. 1999b) (Figure 1.12). Specific and general 
amino acid permeases are inversely regulated at the level of protein sorting and 
stability in response to nutrient (amino acid, nitrogen or carbon) availability 
(Beck et al. 1999b; Schmidt et al. 1998).  In exponentially growing cells, specific 
amino acid permeases are transported to, and are active at, the plasma 
membrane.  Under TORC1 inactivating conditions, the specific amino acid 
permeases are removed from the plasma membrane, transported to the vacuole 
and degraded (Beck et al. 1999b).  When cells are in optimal growth conditions, 
general amino acid permeases are cycled to the vacuole and degraded 
immediately following synthesis due to ubiquitination by Npi1p (Springael & 
André 1998).  When TORC1 is inactivated, Gap1p is phosphorylated by Npr1p 
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protecting it from ubiquitination and allowing the accumulation of Gap1p at the 
cell surface (Beck et al. 1999b; Schmidt et al. 1998).  The localisation of Gap1p 
at the cell surface replaces the specific permeases (e.g., Tat2p) which are 
degraded in the vacuole (Beck et al. 1999b; Schmidt et al. 1998).  The up-
regulation of Gap1p at the cell surface appears to occur in conjunction with the 
increase in complex sphingolipid synthesis upon TORC1 inactivation due to 
phosphorylation of Orm1p and Orm2p by Npr1p (Shimobayashi et al. 2013).  The 
exact mechanism by which Npr1p is regulated by TORC1 is unclear (Jacinto et al. 
2001), but it is likely that Tap42p is involved (Schmidt et al. 1998).  In the 
absence of TORC1 activity, Npr1p is rapidly dephosphorylated leading to the 
degradation of Tat2p and the expression of general amino acid permeases at the 
cell surface (Schmidt et al. 1998). 
 Regulation of autophagy 1.6.4
Autophagy is a process utilised by cells to increase the availability of free amino 
acids and as such is increased upon TORC1 inactivation, a response normally 
reserved for starvation conditions (Raught et al. 2001; Zaman et al. 2008).  
When cells are in conditions of plentiful nutrients, and TORC1 is active, 
autophagy is repressed.  However, when TORC1 is inactivated, autophagy is 
induced leading to the creation of autophagic bodies that are transported to the 
vacuole and the contents degraded (Shin & Huh 2011); continued autophagy 
results in cells containing enlarged vacuoles (Brown et al. 2010).  The 
phosphorylation of Atg13p by TORC1 regulates autophagy (Kamada et al. 2000; 
Kamada et al. 2010) (Figure 1.12).  When TORC1 is active Atg13p is 
phosphorylated preventing it from interacting with Atg1p.  When TORC1 is 
inactivated however, Atg13p is rapidly dephosphorylated and binds to Atg1p 
resulting in an active Atg13p-Atg1p complex that promotes PAS formation (Pre-
Autophagosomal Structure) (Kamada et al. 2000; Kamada et al. 2010; Shin & Huh 
2011).  The formation of the PAS also appears to involve the phosphatidylinositol 
3-phosphate (PtdIns(3)) kinase complex I which is composed of Vps34p, Vps15p, 
Atg6p and Atg14p (Obara & Ohsumi 2011; Suzuki & Ohsumi 2010).  The human 
homolog of Vps34p, hVps34, is thought to be involved in mTORC1 signalling via a 
currently unknown mechanism (Yang et al. 2013).   
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TORC1 has also been shown to regulate autophagy in response to glucose 
starvation.  Fructose 1,6-bisphosphatase (FBPase) is induced upon glucose 
starvation and targets cargo proteins to the vacuole via the Vid pathway 
(vacuole import and degradation) (Alibhoy & Chiang 2010).  Depriving cells of 
glucose results in the interaction of TORC1 with FBPase, predominantly via 
Tco89p, thus preventing degradation of FBPase and allowing cargo proteins to be 
transported to the vacuole (Figure 1.12).  Upon TORC1 reactivation, FBPase is 
released from TORC1 promoting the degradation of FBPase and subsequently 
inhibiting the Vid pathway (Alibhoy & Chiang 2010; Brown et al. 2010). 
 Regulation of starvation-induced gene transcription 1.6.5
As described above, the inactivation of TORC1 results in a general decrease in 
protein synthesis.  In contrast, the transcription of genes involved in the 
Nitrogen Discrimination Pathway have been found to be up-regulated following 
nitrogen starvation or rapamycin treatment (Beck & Hall 1999; Cardenas et al. 
1999; Hardwick et al. 1999).  The GATA transcription factors Gln3p and Gat1p 
have been identified to regulate starvation-induced gene translation (Beck & 
Hall 1999; Cardenas et al. 1999; Hardwick et al. 1999) (Figure 1.12).  Treatment 
of cells with rapamycin causes a rapid increase in the transcription of genes 
regulated by Gln3p and Gat1p; within 10 minutes of rapamycin treatment a 10-
fold increase in some gene transcripts is seen (Beck & Hall 1999).  Hardwick et 
al. (1999) found that the strongest effects on starvation induced gene 
transcription occurred within 15-30 minutes following the addition of rapamycin, 
suggesting that the regulation of these genes does not depend on de novo 
protein synthesis.  Indeed, it was found that under conditions in which TORC1 is 
inactive, Gln3p and Gat1p are localised to the nucleus and are relocated to the 
cytoplasm upon TORC1 reactivation (Beck & Hall 1999; Hardwick et al. 1999).  
Gln3p has been shown to be tethered to the cytoplasm by interaction with Ure2p 
which is regulated by TORC1 (Beck & Hall 1999).  Under conditions in which 
TORC1 is active Ure2p is phosphorylated by the TORC1 downstream targets 
Tap42p/Sit4p which results in it binding to, and retaining, Gln3p in the 
cytoplasm.  When TORC1 is inactivated, Ure2p is rapidly dephosphorylated 
resulting in its dissociation from Gln3p and the transportation of Gln3p to the 
nucleus (Beck & Hall 1999; Cardenas et al. 1999; Hardwick et al. 1999).  Ure2p is 
found in the cytoplasm regardless of TORC1 activity status (Beck & Hall 1999). 
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 Sch9p and Tap42p 1.6.6
The majority of the downstream TORC1 functions identified so far are mediated 
through two branches of TORC1 signalling: Sch9p and Tap42p.  The induction of 
autophagy however occurs via direct phosphorylation of Atg13p and appears 
independent of Sch9p or Tap42p (Kamada et al. 2010). 
Dephosphorylation of Sch9p (a result of inactive TORC1) results in the down-
regulation of protein synthesis (Huber et al. 2009) and ribosome biogenesis 
(Jorgensen & Rupeš 2004).  Active Sch9p inhibits the function of several 
downstream transcriptional repressors for example Maf1p, Stb3p, Dot6p and 
Tod6p that predominantly regulate the expression of ribosomal genes (Huber et 
al. 2009).  When Sch9p is inactivated by dephosphorylation, ribosomal gene 
transcripts are decreased leading to an overall decrease in protein synthesis.  
Sch9p also directly interacts with Rim15p to inhibit stress responses by tethering 
Rim15p in the cytoplasm (Wanke et al. 2008).  Rim15p is a central regulator in 
the adaption of cells to poor nutrient conditions and is controlled by a number of 
upstream regulators, one of which is TORC1 via Sch9p (Swinnen et al. 2013).  
Upon activation, Rim15p is translocated to the nucleus and promotes 
transcription factors (for example Msn2p and Msn4p) that initiate stress induced 
gene transcription  (Swinnen et al. 2013) (Figure 1.12).  It has recently been 
shown that recruitment of Sch9p to the vacuolar membrane requires PI(3,5)P2 
which could implicate PI(3,5)P2 in having a downstream function of TORC1, in 
addition to its potential activating activity (Jin et al. 2014). 
The release of Tap42p from TORC1 results in its inactivation and the induction of 
stress-induced gene transcription partially via regulation of the transcription 
factors Msn2p and Msn4p that target stress response genes (Düvel et al. 2003).  
The translocation of the transcription factor Gln3p to the nucleus following 
TORC1 inactivation is possibly regulated by Tap42p/Sit4p (Beck & Hall 1999; 
Düvel et al. 2003) (Figure 1.12).  The phosphorylation of Npr1p and therefore 
switch from specific to general amino acid permeases at the cell surface is also 
under the control of Tap42p by a currently unknown mechanism (Schmidt et al. 
1998) (Figure 1.12).  When active, Tap42p is found in a trimeric complex with a 
second regulatory subunit and a catalytic subunit (most often Sit4p in TORC1 
signalling) but this association is disrupted by the presence of rapamycin or when 
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TORC1 is inactive (Di Como & Arndt 1996).  A point mutation in TAP42 (tap42-11) 
or overexpression of Sit4p can render cells semi-resistant to the effects of 
rapamycin (Di Como & Arndt 1996). 
 Comparison of yeast down-stream functions of TORC1 1.6.7
with the down-stream functions of mTORC1 
Due to the essential and conserved nature of the TORC1 signalling pathway, the 
fundamental downstream functions are similar across all eukaryotic cells.  The 
mTORC1 pathway regulates cell growth and proliferation predominantly through 
the regulation of protein synthesis.  The downstream proteins regulated by 
mTORC1 are also involved in regulating other cell growth and proliferation 
signalling pathways, for example c-Myc is a transcription faction regulated by 
mTORC1 that subsequently regulates genes involved in cell growth (Schmelzle & 
Hall 2000).  In cases where regulation is lost, the downstream pathways of 
mTORC1 have been implicated in cancer development (Guertin & Sabatini 2007; 
Schmelzle & Hall 2000). 
Regulation of protein synthesis by mTORC1 is predominantly governed by two 
signalling branches originating from direct targets of mTORC1; those 
downstream of S6 Kinase (S6K) (the homolog of Sch9p) and those downstream of 
4E-BP1 (Inoki & Guan 2006; Laplante & Sabatini 2009; Raught et al. 2001; 
Schmelzle & Hall 2000).  When the S6 Kinase is active, following phosphorylation 
by mTORC1, S6K promotes mRNA biogenesis, cap-dependent translation and the 
translation of ribosomal proteins (Laplante & Sabatini 2009; Raught et al. 2001).  
When mTORC1 is inactivated, S6K is dephosphorylated leading to inhibition of 
protein synthesis, similar to that seen in yeast cells.  It is worth noting that 
mTORC1 is not the only method by which S6K is phosphorylated and it is thought 
that S6K is a central regulator of protein synthesis in response to various 
environmental cues (Raught et al. 2001). 
In addition to regulation by S6K, the regulation of translation by mTORC1 is also 
carried out via the eIF4E Binding Protein 1 (4E-BP1) (Raught et al. 2001).  
Translation initiation factors are required to aid the start of translation in 
mammalian cells and help guide the ribosome to the 5’ end of the mRNA.  Two 
such translation initiation factors are eIF4E and eIF4G (Feldman et al. 2009).  To 
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enable translation to start, eIF4E and eIF4G must be bound together at the 5’ 
cap of mRNA.  Translation can be inhibited by the binding of 4E-BP1 to eIF4E 
thus preventing the interaction between eIF4G and eIF4E (Feldman et al. 2009).  
When phosphorylated by mTORC1 4E-BP1 is unable to interact with eIF4E and 
translation is permitted.  When mTORC1 activity is lost, 4E-BP1 is 
dephosphorylated and is therefore able to compete with eIF4G and prevent 
translation (Feldman et al. 2009). 
As mentioned previously, it was hoped that rapamycin could be used clinically to 
inhibit cancerous cells but clinical trials resulted in inconsistent responses to 
rapamycin treatment.  Studies carried out by Feldman et al. (2009) and Thoreen 
et al. (2009) using novel ATP-inhibitors of mTORC1 have found that rapamycin is 
in fact an incomplete inhibitor of mTORC1 activity, especially with regards to 
the phosphorylation of 4E-BP1.  Feldman et al. (2009) and Thoreen et al. (2009) 
used different ATP-inhibitors of mTORC1 (pp242 or Torin1 respectively) and 
found that the dephosphorylation of 4E-BP1 was much more dramatic following 
treatment with the ATP-inhibitors than that following treatment with 
rapamycin.  The identification of potential substrate selectivity with regards to 
mTORC1 inhibition in the presence of rapamycin could lead to a number of novel 
downstream targets and functions of mTORC1 being identified that were 
overlooked in cells treated with rapamycin. 
One such example of a down-stream function of mTORC1 that could be further 
understood by using alternative mTORC1 inhibitors is the role of mTORC1 in the 
induction of autophagy.  The role of yeast TORC1 in initiating autophagy is clear, 
however the role of mTORC1 in inducing autophagy is less so.  Thoreen et al. 
(2009) found that mammalian cells treated with rapamycin resulted in a weak 
induction of autophagy, however cells treated with Torin1 resulted in a strong 
induction of autophagy.  The mechanism by which mTORC1 regulates autophagy 
remains unclear but it is possible that phosphorylation, by mTORC1, of ULK1 and 
ATG13 may be involved (Jewell & Guan 2013). 
 Phenotype of ego- mutants 1.7
Loss of any component of the EGO complex (which we term ego-) in yeast results 
in cells that are unable to resume proliferation following rapamycin treatment 
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(Binda et al. 2009; Dubouloz et al. 2005).  Part of the aims of this project are to 
understand why loss of the EGO complex results in a rapamycin recovery defect.  
A number of prior studies have been carried out to investigate the phenotype of 
ego- mutants, especially in response to rapamycin treatment and are discussed 
below. 
Key phenotypes of TORC1 signalling have been compared between wild-type and 
ego- mutants in the absence or presence of rapamycin.  Firstly, the 
phosphorylation of the TORC1 downstream target Sch9p was observed in wild-
type and ego- cells either during exponential growth or following rapamycin 
treatment.  Through the use of a gel-shift assay Binda et al. (2009) found that 
cells lacking any component of the EGO complex had lower basal TORC1 activity 
compared to that of wild-type cells.  The low TORC1 activity in ego- mutants 
was comparable to cells lacking Tco89p, a component of TORC1 (Binda et al. 
2009).  Upon TORC1 inactivation, either following rapamycin or caffeine 
treatment, a complete dephosphorylation of Sch9p was observed and appeared 
similar in both wild-type and ego- cells. 
Dubouloz et al. (2005) tested the response of ego- mutants to a number of 
hallmarks of inactive TORC1 and compared to wild-type cells.  Dubouloz et al. 
(2005) concluded that mutants lacking the EGO complex appeared to respond to 
rapamycin treatment in a manner similar to that of wild-type cells.  The 
hallmarks of inactive TORC1 tested included the transcription of stress response 
genes, the accumulation of glycogen, the induction of autophagy and the 
inhibition of protein synthesis (Dubouloz et al. 2005).  A number of these 
conditions were also tested following a “recovery period” in which cells were 
washed into fresh media following treatment with rapamycin and incubated.  
Consistent with the inability of ego- mutants to resume proliferation following 
rapamycin treatment (i.e. the rapamycin recovery defect), hallmarks of inactive 
TORC1 also failed to recover (i.e. return to the state found in untreated cells), 
including low protein synthesis rate, autophagy and high glycogen levels.  By 
contrast, these hallmarks had returned to basal levels in wild-type cells 
following removal of rapamycin (Dubouloz et al. 2005).  Shin & Huh (2011) also 
found that autophagy was maintained longer in nitrogen-starved gtr2∆ cells than 
in wild-type cells; they concluded that the maintenance of autophagy was a 
result of weak TORC1 activity in gtr2∆ cells (Nicolas Panchaud et al. 2013) and 
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therefore an inability to efficiently reactivate TORC1 following the accumulation 
of amino acids from the autophagy process.  If null mutants of the EGO complex 
appear to respond in a manner similar to that of wild-type cells when treated 
with rapamycin why do ego- cells fail to recover from rapamycin treatment? 
 Aims of this project 1.8
The EGO complex has been identified as an upstream regulator of yeast TORC1, 
indeed nearly every mechanism of TORC1 activation in yeast appears to 
converge on the EGO complex.  Whilst null mutants of the EGO complex are 
viable and appear to have no strong phenotype, following treatment with 
rapamycin null mutants of the EGO complex fail to recover (Binda et al. 2009; 
Dubouloz et al. 2005).  This project aims to explore the origin of the rapamycin 
recovery defect. 
The mechanism by which rapamycin is detoxified in yeast (and for the most part 
mammalian cells) is not known. We will explore what happens to the 
intracellular pool of rapamycin in yeast following a rapamycin treatment period. 
Finally, upstream regulators of yeast TORC1 in response to nutrients remain 
elusive and knowledge of the amino acid signalling pathway in yeast is not as 
well developed as that of mammalian cells (itself still far from complete).  We 
will attempt to identify potential novel regulators of TORC1 by identifying null 
mutants that phenocopy loss of the EGO complex. 
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2 Materials and Methods 
 Growth conditions 2.1
All chemicals were purchased from Sigma (Dorset, UK) unless otherwise 
specified. 
Cells were grown in either rich or selective synthetic minimal media as required.  
Rich media (YPD) comprised of yeast extract (1%), peptone (2%) and glucose 
(2%), solid media was created through the addition of agar (2%).  Synthetic 
media (SD) was created using Difo yeast nitrogen base with the addition of 
glucose (2%) and the appropriate nutrients.  Media lacking carbon (YP) comprised 
of yeast extract (1%) and peptone (2%). 
Unless otherwise stated overnight liquid cultures were grown at room 
temperature with agitation, experimental growth temperatures were as stated 
in the results section.  Cultures grown on solid media were incubated at either 
28°C or 30°C unless otherwise stated. 
 Yeast cultures 2.2
All yeast haploid cultures used (except where specified) were in the BY4743 
genetic background.  Diploids were obtained from the yeast deletion collection 
in which every non-essential gene has replaced with a KanMX4 cassette (Giaever 
et al. 2002).  Note that a “magic marker” cassette is also present in the 
background of this deletion collection which can confer leucine and histidine 
prototrophy in the MATa haploid, the auxotrophic state of leucine and histidine 
was not tested (Tong et al. 2001).  See Table 2.1 for a list of all strains used. 
 Creating double mutants 2.2.1
Double mutants were created by patching two null mutants of interest, with 
opposite mating types and differing drug resistance markers (see 2.3), onto a 
plain YPD plate and incubating at 30˚C overnight.  The resulting colony was 
patched onto selective media to select for diploids resistant to both G418 and 
Nat.  Diploids were subsequently sporulated and dissected (see 2.4.1).   
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Strain 
Number 
Genetic 
Background 
Mutation Genotype 
5549 BY4743 atg11∆ MAT? his3∆ leu2∆ ura3∆ atg11∆::KanMX4 
5550 BY4743 atg11∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ atg11∆::KanMX4 
5551 BY4743 atg11∆ MAT? his3∆ leu2∆ ura3∆ atg11∆::KanMX4 
5283 BY4743 caf20∆ caf20∆::KanMX4 
5284 BY4743 caf20∆ caf20∆::KanMX4 
5285 BY4743 caf20∆ caf20∆::KanMX4 
5563 BY4743 ccr4∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ ccr4∆::KanMX4 
5564 BY4743 ccr4∆ MAT? his3∆ leu2∆ ura3∆ met15∆ lys2∆ ccr4∆::KanMX4 
5565 BY4743 ccr4∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ ccr4∆::KanMX4 
5605 BY4743 ctk1∆ ctk1∆::KanMX4 
5606 BY4743 ctk1∆ ctk1∆::KanMX4 
5607 BY4743 ctk1∆ ctk1∆::KanMX4 
5568 BY4743 dhh1∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ dhh1∆::KanMX4 
5569 BY4743 dhh1∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ dhh1∆::KanMX4 
5570 BY4743 dhh1∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ dhh1∆::KanMX4 
5245 BY4743 eap1∆ eap1∆::KanMX4 
5246 BY4743 eap1∆ eap1∆::KanMX4 
5247 BY4743 eap1∆ eap1∆::KanMX4 
4839 BY4743 ego1∆ MATa his3∆ leu2∆ ura3∆ met15∆ ego1∆::KanMX4 
4840 BY4743 ego1∆ MATα his3∆ leu2∆ ura3∆ met15? lys2∆ ego1∆::KanMX4 
4841 BY4743 ego1∆ 
MATα his3∆ leu2∆ ura3∆ lys2∆ met15∆ 
ego1∆::KanMX4 
4851 BY4743 ego1∆ MATa his3∆ leu2∆ ura3∆ met15∆ ego1∆::Nat 
5617 BY4743 
ego1∆ 
pep3∆ 
ego1∆::Nat pep3∆::KanMX4 
5618 BY4743 
ego1∆ 
pep3∆ 
ego1∆::Nat pep3∆::KanMX4 
5619 BY4743 
ego1∆ 
pep3∆ 
ego1∆::Nat pep3∆::KanMX4  
4821 BY4743 ego3∆ MATα his3∆ leu2∆ ura3∆ lys2∆ ego3∆::KanMX4 
4822 BY4743 ego3∆ MATa his3∆ leu2∆ ura3∆ lys2∆ ego3∆::KanMX4 
4823 BY4743 ego3∆ MATα his3∆ leu2∆ ura3∆ met15∆ ego3∆::KanMX4 
1384 By4743 gap1∆ MATa his3∆ leu2∆ met15∆ ura3∆ gap1∆::KanMX4 
4824 BY4743 gtr1∆ MATα his3∆ leu2∆ ura3∆ lys2∆ gtr1∆::KanMX4 
4825 BY4743 gtr1∆ MATα his3∆ leu2∆ ura3∆ met15∆ gtr1∆::KanMX4 
4826 BY4743 gtr1∆ MATa his3∆ leu2∆ ura3∆ lys2∆ gtr1∆::KanMX4 
4831 BY4743 gtr2∆ MATα his3∆ leu2∆ ura3∆ lys2∆ gtr2∆::KanMX4 
4832 BY4743 gtr2∆ MATα his3∆ leu2∆ ura3∆ met15∆ gtr2∆::KanMX4 
4833 BY4743 gtr2∆ MATa his3∆ leu2∆ ura3∆ lys2∆ gtr2∆::KanMX4 
5537 BY4743 hom2∆ MAT? his3∆ leu2∆ ura3∆ hom2∆::KanMX4 
5538 BY4743 hom2∆ MAT? his3∆ leu2∆ ura3∆ hom2∆::KanMX4 
5539 BY4743 hom2∆ MAT? his3∆ leu2∆ ura3∆ hom2∆::KanMX4 
5659 BY4743 hom3∆ hom3∆::KanMX4 
5660 BY4743 hom3∆ hom3∆::KanMX4 
5661 BY4743 hom3∆ hom3∆::KanMX4 
4922 BY4743 
kog1∆ 
pkog1-105 
kog1∆::KanMX4 pkog1ts 
5225 BY4743 npl3∆ npl3∆::KanMX4 
5235 BY4743 npl3∆ npl3∆::KanMX4 
5236 BY4743 npl3∆ npl3∆::KanMX4 
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5332 BY4743 pep3∆ MATa his3∆ leu2∆ ura3∆ met15∆ pep3∆::KanMX4 
5333 BY4743 pep3∆ MATα his3∆ leu2∆ ura3∆ met15? pep3∆::KanMX4 
5334 BY4743 pep3∆ MATα his3∆ leu2∆ ura3∆ met15∆ pep3∆::KanMX4 
3180 BY4743 pep5∆ pep5∆::KanMX4 
5543 BY4743 pib2∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ pib2∆::KanMX4 
5544 BY4743 pib2∆ MAT? his3∆ leu2∆ ura3∆ pib2∆::KanMX4 
5545 BY4743 pib2∆ MAT? his3∆ leu2∆ ura3∆ lys∆ pib2∆::KanMX4 
5581 BY4743 shp1∆ MAT? his3∆ leu2∆ ura3∆ met15∆ lys2∆ shp1∆::KanMX4 
5582 BY4743 shp1∆ MAT? his3∆ leu2∆ ura3∆ met15∆ shp1∆::KanMX4 
5583 BY4743 shp1∆ MAT? his3∆ leu2∆ ura3∆ shp1∆::KanMX4 
5555 BY4743 snx4∆ MAT? his3∆ leu2∆ ura3∆ snx4∆::KanMX4 
5556 BY4743 snx4∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ snx4∆::KanMX4 
5557 BY4743 snx4∆ MAT? his3∆ leu2∆ ura3∆ lys2∆ snx4∆::KanMX4 
4420 BY4743 tco89∆ 
MATα his3∆ leu2∆ ura3∆ met15∆ lys2∆ 
tco89∆::KanMX4 
4424 BY4743 tco89∆ MATa his3∆ leu2∆ ura3∆ met15∆ tco89∆::KanMX4 
4490 BY4743 tor1∆ MATa his3∆ leu2∆ ura3∆ lys2? met15? tor1∆::KanMX4 
4837 BY4743 vam6∆ MATa his3∆ leu2∆ ura3∆ lys2∆ vam6∆::KanMX4 
4838 BY4743 vam6∆ MATα his3∆ leu2∆ ura3∆ met15∆ vam6∆::KanMX4 
5499 BY4743 vam6∆ his3∆ leu2∆ ura3∆ vam6∆::nat 
5675 BY4743 vam7∆ vam7∆::KanMX4 
5676 BY4743 vam7∆ vam7∆::KanMX4 
5379 BY4743 vps15∆ MATa his3∆ leu2∆ ura3∆ vps15∆::KanMX4 
5380 BY4743 vps15∆ MATα his3∆ leu2∆ ura3∆ vps15∆::KanMX4 
5381 BY4743 vps15∆ MATa his3∆ leu2∆ ura3∆ vps15∆::KanMX4 
5351 BY4743 vps16∆ MATα his3∆ leu2∆ ura3∆ met15∆ vps16∆::KanMX4 
5352 BY4743 vps16∆ MATa his3∆ leu2∆ ura3∆ lys2∆ vps16∆::KanMX4 
5353 BY4743 vps16∆ MATa his3∆ leu2∆ ura3∆ vps16∆::KanMX4 
5763 BY4743 vps33∆ vps33∆::KanMX4 
5764 BY4743 vps33∆ vps33∆::KanMX4 
5765 BY4743 vps33∆ vps33∆::KanMX4 
2474 BY4743 vps34∆ his3∆ leu2∆ ura3∆ vps34∆::KanMX4 
0161 W303 Wild-type MATa 
0205 EG123 Wild-type MATa 
1367 BY4743 Wild-type MATa his3∆ leu2∆ ura3∆ met15∆ 
5599 BY4743 yke2∆ yke2∆::KanMX4 
5600 BY4743 yke2∆ yke2∆::KanMX4 
5601 BY4743 yke2∆ yke2∆::KanMX4 
4842 BY4743 ypt7∆ MATα his3∆ leu2∆ ura3∆ met15∆ ypt7∆::KanMX4 
4843 BY4743 ypt7∆ MATa his3∆ leu2∆ ura3∆ met15∆ ypt7∆::KanMX4 
5434 BY4743 ypt7∆ ypt7∆::KanMX4 
    
Table 2.1 List of Strains used throughout the thesis 
All strains used throughout the thesis are shown, in alphabetical order by 
mutation.  The mating type and auxotrophic markers are shown if known, a ? 
indicates unknown information.  Note that the background strain BY4743 is the 
diploid background from which the haploid cells were generated. 
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Resulting dissected haploids were tested for G418 and Nat sensitivity and double 
null mutants confirmed by their resistance to both drugs. 
 Transformation 2.3
 Bacterial transformation 2.3.1
Chemically competent DHα cells (Invitrogen, Paisley, UK) were transformed 
following the manufactures instructions. 
 Yeast transformation 2.3.2
Exponentially growing overnight cultures were transformed using a standard 
lithium acetate protocol as set out in Gietz et al. (1995).  Table 2.2 shows a list 
of the plasmids used in this study and the references from which the plasmids 
were obtained. 
 Switching the kanamycin selection marker 2.3.3
To change the KanMX4 selection marker to that of Nat (nourseothricin), 
exponentially growing haploid cultures were transformed with a PCR amplified 
Nat cassette.  The PCR product was amplified from a plasmid created by 
Goldstein & McCusker (1999) to replace the KanMX4 cassette by homologous 
recombination with a cassette conferring alternative drug resistance, in this case 
Nat resistance.  Following the transformation procedure, instead of plating 
directly onto selective plates, cultures were plated onto plain YPD and 
incubated overnight at 30˚C.  The following day colonies were replica plated 
onto selective Nat plates and incubated overnight at 30˚C.  Cells which had 
undergone homologous recombination were confirmed by both their ability to 
grow in the presence of Nat and their loss of resistance to G418. 
 Sporulation and dissection 2.4
 Sporulation and dissection 2.4.1
Diploid cells were incubated in liquid sporulation media (potassium acetate 
(0.3%), raffinose (0.02%)) at room temperature until tetrads were observed by 
microscopy (usually 2-3 days).   
57 
 
Plasmid number Backbone plasmid Gene Reference 
pG514 pRS316 
kog1-105 
(kog1ts) 
(Nakashima et al. 2008) 
pG535 pRS316 PGK1-GFP (Welter et al. 2010) 
pG497 ? 3HA-TOR1 (Reinke et al. 2006) 
pG498 ? 3HA-tor1I1957V (Reinke et al. 2006) 
    
Table 2.2 List of the plasmids used in this thesis 
The plasmids used during the course of this thesis, listed in alphabetical order 
for the gene they carry.  The reference from which the plasmids were obtained 
is also shown.  ? indicates that the plasmid backbone is unknown. 
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Cells were pelleted, resuspended in zymolyase (0.5 mg/mL) and incubated at 
30°C for 10-12 min before ice-cold Tris-sorbitol (Tris (10 mM), sorbitol (1 M)) was 
added.  Dissections were carried out on YPD 4% agar plates (unless otherwise 
stated). 
 Determining the mating type 2.4.2
The mating types for newly created haploids were determined by mating the null 
mutant haploids to the ‘a’ and ‘α’ mating tester strains on YPD plates and 
incubating at 30˚C overnight.  The resulting culture was patched onto synthetic 
dropout media lacking any amino acid supplements and again incubated 
overnight at 30˚C.  The mating type of the haploid of interest was determined 
by observing complementation between the mating tester and the haploid of 
interest on the dropout media; the mating type was inferred from that of the 
mating tester if complementation, and therefore colony formation, was 
observed. 
 Genotyping haploids with regards to auxotrophic markers 2.4.3
The genotype of specific auxotrophic markers was also determined for freshly 
created haploids.  Haploid cells were patched onto synthetic media lacking 
either methionine or lysine and plates incubated at 30˚C overnight.  Haploids 
were prototrophic for the marker of interest if colony formation was observed 
and auxotrophic if the cultures failed to grow on the selective media.  Note, 
these strains also contain the “magic marker” cassette which confers leucine 
and histidine prototrophy depending on the mating type of the cell (Tong et al. 
2001).  The phenotype of haploids with regards to leucine and histidine was not 
tested. 
 Creating kog1∆ts haploids 2.5
Heterozygous diploid kog1Δ/KOG1 cells were transformed with a plasmid borne 
temperature sensitive kog1ts allele (pkog1ts (Table 2.2) (Nakashima et al. 2008)) 
and sporulated as described in 2.4.1.  Tetrads were dissected onto YPD 4% agar 
plates and kog1Δ null mutants carrying pkog1ts were identified by their ability to 
grow in the presence of G418.  To induce the temperature-sensitive phenotype 
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kog1∆-pkog1ts cultures were grown for a day prior to the experimental start at 
either the permissive (22°C) or non-permissive (37°C) temperature during which 
they were maintained in exponential growth by dilution into fresh YPD media 
when necessary. 
 Spot assay for recovery 2.6
When in exponential growth phase, cultures were normalised by OD600nm, as 
specified in the Figure legends, and drugs added at the concentrations 
stipulated.  Cultures were incubated at room temperature or 28°C with agitation 
as specified, unless otherwise stated.  Cells were washed three times in fresh 
media (unless otherwise specified) by pelleting cells through centrifugation 
followed by resuspension in fresh YPD media (unless otherwise stated).  Ten-fold 
serial dilutions were created into fresh YPD which were spotted (5 µL) onto YPD 
plates and incubated at either 28˚C or 30˚C for two days after which the plates 
were scanned. 
 Methylene blue staining 2.7
Exponentially growing cultures were treated (or not) with rapamycin (200 
ng/mL) for the times stipulated.  Aliquots of culture were mixed with methylene 
blue (final concentration 0.02% w/v) and spotted onto a glass slide.  Control 
cultures of heat-killed cells (85˚C for 10 minutes) were also included.  Staining 
was observed by microscopy and a minimum of 200 cells were counted per 
sample. 
 Amino acid uptake 2.8
Exponentially growing cultures were treated (or not) with rapamycin (200 
ng/mL).  Cultures were normalised to an OD600nm of ~0.25 in 1 mL, pelleted and 
concentrated in YPD (75 μL) to which 35S labeled methionine and 35S labeled 
methionine cysteine (22 μCi) (EasyTag EXPRESS35S Protein Labeling Mix, Perkin 
Elmer, Massachusetts, USA) was added and cells incubated at room temperature 
for 5 minutes.  Cultures were washed six times with ice-cold methionine (75 mM) 
and cysteine (75 mM) using micro centrifuge filters (Corning Costar, Sigma-
Aldrich, Dorset, UK).  Retained cell-associated radiation was measured by 
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Scintillation counter (Beckman Coulter, High Wycombe, UK).  Control samples of 
medium alone, i.e. YPD containing no cells, and to which radiation was added 
were also included; the Count Per Minute (CPM) measurement from these 
controls was subtracted from the CPM of each sample.  
 Measuring culture densities and calculating the 2.9
growth rate 
 Culture density as measured by Coulter counter 2.9.1
Exponentially growing cultures were treated (or not) in YPD and incubated at 
room temperature with agitation.  To measure the culture density at specified 
times, aliquots of each culture were removed and sonicated for 5 sec before 
being added to 10 mL isoton liquid.  The volume of sonicated culture added to 
the isoton was dependent on the density of the culture and was adjusted to 
ensure the number of cells present was within the accurate detection range; the 
cell numbers counted per culture were subsequently normalised.  The number of 
cells counted per sample, within a size range of 2.51-8.58 µm, were measured 
by a Coulter counter in 500 µL samples, three repeats were measured per 
sample and the average calculated.  The mean cell size was measured between 
3.258-8.436 µm. 
 Culture density as measured by optical spectrometry 2.9.2
Exponentially growing cultures were treated (or not) in YPD and incubated at 
28°C with agitation.  At specified times, samples were removed and the culture 
density measured at OD600nm. 
 Calculating the growth rate 2.9.3
The culture density measurements at each time point, either determined by 
Coulter counter or optical spectrometry, were converted into the log2 and the 
growth rate was determined as the linear regression line (using the Excel slope 
function) of two observed culture density measurements between two specified 
time points, as specified in the Figure legends.  The growth rate was calculated 
during a period when the growth rate was stable. 
61 
 
 Autophagy assay 2.10
Cells expressing a plasmid-borne copy of PGK1-GFP were chemically lysed 
according to Welter et al. (2010), briefly: Cell pellets normalised for OD600nm 
were collected by centrifugation and resuspended in ice-cold water (1 mL) to 
which lysis buffer (150 μL; NaOH (1.85 M), β-mercaptoethanol (7.5% v/v)) was 
added, mixed by vortex and samples incubated on ice for 10 min.  Ice-cold TCA 
(150 μL of 50% TCA w/v) was added and the samples incubated for a further 10 
min on ice before being centrifuged at full speed for 10 min.  Precipitated 
pellets were washed twice in ice-cold acetone (1 mL), dried at room 
temperature then resuspended in SDS sample buffer (Tris-HCl pH 6.8 (50 mM), 
SDS (2% w/v), glycerol (10% v/v), β-mercaptoethanol (1% v/v), bromophenol 
blue) and stored at -20˚C. 
Proteins were separated on a NuPAGE 12% Bis-Tris gel with MES running buffer 
(Invitrogen, Paisley, UK) and transferred to a PVDF membrane according to 
manufactures instructions.  Membranes were probed with an anti-GFP primary 
antibody (Santa Cruz, Heidelberg, Germany) and a hydrogen peroxidase 
secondary antibody was used.  Development was carried out using an ECL 
development kit (GE Healthcare) according to the manufacturer’s instructions.  
Bands were visualised by autoradiography. 
 Mass spectrometry 2.11
Exponentially growing cultures were treated (or not) with rapamycin (400 
ng/mL). At each time point cell pellets equivalent to 10 OD600nm units were 
collected by centrifugation.  To extract rapamycin, the cell pellets were washed 
three times in ice-cold water before cells were lysed by vortexing in 200 μL ice-
cold water and an equal volume of glass beads for six cycles of 30 sec vortex and 
30 sec on ice.  Rapamycin was extracted five times into neat ethyl acetate (250 
μL) (Fisher, Loughborough, UK) by vortexing for 30 sec prior to centrifugation for 
2 min at 16,000 g. The organic layers were collected and pooled.   
The following description was provided by Dr. Burgess of the University of 
Glasgow Polyomics Facility who optimised the mass spectrometry procedure (in 
collaboration with myself). 
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Mass spectrometry was carried out at the University of Glasgow Polyomics 
Facility and consisted of:   Extracted sample (10 μL) was injected onto an 
Ultimate 3000 RSLC system (Thermo, Hemel Hempstead, UK) equipped with an 
Acclaim 5um 2.1 x 150 mm C18 column.  The separation gradient ran from 5% 
acetonitrile, 95% water to 50% acetonitrile, 50% water in 20 minutes, followed 
by a wash at 95% acetonitrile, 5% water for 6 minutes and 6 minutes 
reequilibration at 95% water, 5% acetonitrile. Mass spectrometry detection was 
performed on a Q-Exactive (Thermo, Hemel Hempstead, UK) in negative 
ionization mode at 70,000 resolution. Identity of rapamycin was confirmed by 
retention time, mass and fragment pattern matching to an authentic standard. 
Quantification was performed using Quan Browser version 2.2 (Thermo, Hemel 
Hempstead, UK) and was carried out by Dr. Burgess and Dr. Weidt at the 
University of Glasgow Polyomics Facility.  
 Translation assay 2.12
Following treatment of exponentially growing cultures, a cell pellet equivalent 
to ~2 OD600nm units was collected and resuspended in SD lacking methionine (1 
mL).  35S-labeled methionine and 35S-labeled cysteine (22 μCi) (EXPRE35S35S 
Protein Labeling Mix, Perkin Elmer, Massachusetts, USA) was added and cells 
incubated at room temperature for 10 min with shaking.  Cells were pelleted 
and lysed using NaOH (1 M) in solution with methionine (10 mM) and cysteine (10 
mM) with β-mercaptoethanol (0.5% v/v) and incubated on ice for 10 min.  Ice-
cold TCA (final concentration 10% w/v) was added and samples incubated on ice 
for a further 10 min.  TCA precipitable material was washed three times in ice-
cold acetone before being resuspended in SDS buffer (see 2.10).  Peptide-
associated radiation was measured by scintillation counter (Beckman Coulter, 
High Wycombe, UK).  Media-only controls to which radiation was added and the 
TCA extraction procedure performed were included; the subsequent CPM 
obtained from the control was subtracted from the CPM of each sample. 
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 Measuring and predicting recovery time from 2.13
rapamycin 
 Experimentally measuring recovery time 2.13.1
Exponentially growing cultures were treated with rapamycin for two hours in 
YPD at room temperature with agitation.  Following the two hour ‘treatment 
phase’, cells were washed three times in fresh YPD (as explained in 2.6) 
(rapamycin washout), inoculated into fresh medium and incubated at room 
temperature with agitation for a ‘recovery phase’.  During a 48 hour recovery 
phase, the culture density was measured by Coulter counting (as explained in 
2.9).  The culture density of untreated cultures and those in the continuous 
presence of rapamycin were also measured as controls.  The recovery time was 
measured as the lag time for the growth rate of recovering cultures to switch 
from that resembling continuously treated cultures to that of untreated 
cultures; this is explained in more detail in Chapter 5. 
 Predicting the recovery time 2.13.2
The recovery time of cultures from various concentrations of rapamycin was 
calculated using the following formula:  
 
   tR = tDT x log2 [rap]treatment + a 
 where: tR   predicted recovery time (hrs) 
   tDT   observed doubling time in the constant   
     presence of a high concentration   
     of rapamycin (far in excess of the minimum  
     inhibitory concentration) (hrs) 
   [rap]treatment the concentration of rapamycin in the media  
     during the treatment phase (ng/mL) 
   a  constant (hrs), a “fudge-factor” derived from  
     the best fit of the initial trajectory of tR to the 
     experimentally observed recovery times  
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The context of this equation is explained in more detail in Chapter 5. 
 Databases 2.14
 GO Term analysis 2.14.1
To identify potentially enriched GO terms within our dataset of null mutants 
identified in a primary screen (see Chapter 6 for more detail) we utilised the 
Saccharomyces Genome Database’s (SGD) GO Term finder program 
(www.yeastgenome.org/cgi-bin/GO/goTermFinder.pl).  This program searches a 
query list of genes to identify enriched GO terms within that set compared to 
those known in the background.  Enrichment is determined by statistical 
significance with a cut-off limit of p<0.01 (note p-values are automatically 
calculated using a Bonferroni Correction to reduce the potential for false 
positives due to the requirement of multiple hypothesis testing).  The GO Term 
Finder searches were carried out in January 2014, the website warns that due to 
regular updates and additions to GO terms, the results of a particular search 
may vary depending on the time between repeats. 
 Physical interaction analysis 2.14.2
To test for any known physical interactions within out dataset we utilised the 
Osprey software (Breitkreutz et al. 2003).  The information Osprey uses to 
visualise known interactions within a query set of proteins is derived from the 
Saccharomyces Genome Database.  It is worth noting that the Osprey software 
does not appear to have been updated for some time and more recently 
identified interactions between proteins are not shown. 
 Sensitivity to rapamycin 2.15
Exponentially growing cultures were normalised for OD600nm in YPD and incubated 
in the presence of various concentrations of rapamycin in a 24 well plate at 28˚C 
with agitation.  An endpoint assay was carried out measuring the OD600nm 6 hours 
after the addition of rapamycin.  The OD600nm of cultures was normalised to that 
of untreated controls. 
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 FM4-64 staining and confocal microscopy 2.16
 FM4-64 staining 2.16.1
To visualise vacuoles within the cell, exponentially growing cultures were 
treated (or not) with rapamycin and incubated at 28˚C with agitation for the 
time specified in the Figure legend.  Aliquots of each culture were concentrated 
in YPD (50 µL; with rapamycin where appropriate) to which the vacuolar stain 
FM4-64 (2 µM final concentration) was added.  Cells were incubated for 30 
minutes at 30˚C in the dark.  YPD (1 mL; with or without rapamycin) was added 
and cells pelleted.  The pellets were resuspended into YPD media (5 mL; with or 
without rapamycin) and incubated in the dark at 28˚C with agitation for 90 
minutes.  Following the incubation period cells were washed once with water (1 
mL), resuspended in complete synthetic media (25 µL) and kept on ice in the 
dark until microscopy analysis.  Note: Cells were resuspended in synthetic media 
to be observed by microscopy to reduce the potential for background 
autofluorescence. 
 Confocal microscopy 2.16.2
A Zeiss Confocor LSM510 confocal microscope was used to detect FM4-64 staining 
within cells.  An argon laser was used with an excitation wavelength between 
505 and 530 nm and an emission wavelength of 560 nm.  All images were taken 
using a 63x oil-immersed objective.  A merge of the bright field and fluorescent 
image will be shown.  Backgrounds were adjusted to increase visibility of the 
stain. 
 Statistics 2.17
Error Bars: All quantitative experiments were repeated at least three times and 
the average calculated.  Error bars denote the standard error of the mean 
(S.E.M.) which was calculated from the following formula: 
   S.E.M. =  SD     
     √(N) 
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 where: S.E.M.  standard error of the mean  
   SD  standard deviation  
   N  number of replicates 
p-values: Statistical significance was calculated using Student’s t-test.  The tests 
were carried out using a two-tailed, type three test between two results.  A 
two-tailed, type three t-test is used to determine whether two means are 
different from each other, regardless of the direction, and when the two 
samples are of unequal variance.  Statistical significance was applied when the 
p-value was less than 0.05. 
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3 Testing various models that could explain 
why ego- mutants fail to recover from 
rapamycin treatment 
 Introduction 3.1
The EGO complex, which consists of four subunits; Ego1p, Ego3p, Gtr1p and 
Gtr2p, is currently thought to be an activator of TORC1 in response to nutrient 
availability (Binda et al. 2009; Dubouloz et al. 2005; Gao & Kaiser 2006).  TORC1 
activity is essential for yeast proliferation.  However the EGO complex is not 
essential: null mutants are viable.  Yet, null mutants lacking any of the four 
members of the complex appear to be completely unable to recover from 
rapamycin treatment (Binda et al. 2009; Dubouloz et al. 2005). 
Why does loss of the EGO complex result in a selective failure to recover from 
rapamycin treatment?  Here, we consider four models that could explain the 
phenotype seen in ego- mutants in response to rapamycin and are set out below. 
Loss of Viability Model  
Selective loss of viability in the presence of rapamycin has been shown to occur 
in mutants defective in the cell wall integrity pathway (Krause & Gray 2002).  It 
is possible that this is also the case for cells lacking the EGO complex. 
Permease Switch Model  
One physiological effect of inactive TORC1 is the exchange of specific (e.g. 
Tat2p) for general (e.g. Gap1p) amino acid permeases at the cell surface (Beck 
et al. 1999).  The EGO complex could be required for the trafficking of general 
amino acid permeases in yeast. 
It is possible that ego- mutants are able to internalise the specific amino acid 
permeases but fail to express the general amino acid permeases at the cell 
surface when treated with rapamycin.  This failure would result in cells lacking 
any amino acid permeases at the cell surface following rapamycin treatment.  
Whilst loss of amino acid permeases at the cell surface of prototrophic strains 
may not have dramatic consequences, the laboratory strains used are 
auxotrophic for a number of amino acids.  Due to the inability of auxotrophic 
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cells to synthesise all the amino acids they require, the presence of amino acid 
permeases at the cell surface is of great importance.  The lack of amino acid 
permeases at the cell surface of rapamycin treated ego- mutant cells could 
result in ego- mutants entering a state of starvation.  This prolonged starvation 
state would present as an inability to recover from rapamycin treatment.  
There is some controversy regarding the role of the EGO complex in the 
transport of Gap1p to the cell surface.  Gao & Kaiser (2006) showed that the 
EGO complex (which they termed the GSE complex in association with a fifth 
protein Ltv1p) is required to transport Gap1p to the plasma membrane upon 
transfer of cells to poor nitrogen sources.  However, Binda et al. (2009) found 
that ego- mutants were able to transport Gap1p to the plasma membrane when 
given a poor nitrogen source.  Binda et al. (2009) suggested that the difference 
between the two studies was due to the strain backgrounds used; the strain used 
by Gao & Kaiser (2006) carried a loss-of-function allele at the PER1 locus which 
has been associated with abnormal responses of amino acid permeases to 
nitrogen signals.  The strains used throughout this thesis are wild-type at the 
PER1 locus.   
It is also possible that the EGO complex is required, not necessarily for 
transport, but for activity of the general amino acid permeases at the cell 
surface.  If this were the case, rapamycin treatment of ego- mutants would also 
result in ego- cells arresting in a permanent state of starvation and thus 
appearing unable to recover from rapamycin.  
TORC1 Reactivation Model  
It is possible that the EGO complex is selectively required to reactivate TORC1 
from any inactivated state, induced either chemically or by nutrient starvation.  
If the EGO complex is required to reactivate TORC1 following rapamycin 
treatment, loss of the EGO complex would result in cells with constitutively 
inactive TORC1 following exposure to the drug.  Such cells would be unable 
recover from rapamycin treatment 
Rapamycin Detoxification Model  
The EGO complex could be required for detoxification of rapamycin in yeast, 
either in association with a known detoxification mechanism or via a novel 
69 
 
process.  If the EGO complex is required for detoxification of rapamycin, we 
predict that loss of the complex would result in a build-up of the drug within 
ego- cells resulting in continued TORC1 inactivation and prolonged G0 arrest, 
even when the drug is removed from the extracellular medium.  Very little is 
currently known about how rapamycin is detoxified in yeast cells.  The only 
known detoxification mechanism for rapamycin occurs primarily in the human 
liver and involves the cytochrome P450 CYP3A4 (Anzenbacher & Anzenbacherova 
2001; Guengerich 1999; Li et al. 1995). 
In this chapter we set out to test the above models. 
 Results 3.2
 Establishing the ego- phenotype under our laboratory 3.2.1
conditions 
The phenotype of mutants lacking any of the four components of the EGO 
complex in response to rapamycin treatment was tested.  This was carried out to 
establish the phenotype of ego- mutants in response to rapamycin treatment in 
our strain background and under our laboratory conditions. 
Heterozygous diploids were purchased from the Yeast Deletion Collection (in 
which every non-essential gene has been replaced with a KanMX4 cassette 
(Giaever et al. 2002)) and sporulated.  The resulting tetrads were dissected to 
produce fresh haploids.  A number of fresh haploids were created for each null 
mutant to reduce the potential for second site mutations within the strains and 
therefore ensure that the phenotype observed is a result of loss of the particular 
gene of interest only.  Dissected tetrads resulted in viable robust colonies for all 
spores with a 2:2 segregation of G418 sensitive and resistant colonies (data not 
shown); G418 resistance identified cells that were null mutants for the gene of 
interest. 
At least two tetrads were dissected per ego- mutant and of these at least three 
independent mutant haploids were tested for their ability to recover from 
rapamycin treatment.  Exponentially growing cultures were treated (or not) with 
rapamycin (200 ng/mL) for two hours after which cells were washed three times 
in fresh media and spotted onto a YPD plate.  We found that all mutant 
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segregants behaved identically and representatives of each ego- mutant can be 
seen in Figure 3.1.   
We found that wild-type cells were able to recover from a two-hour rapamycin 
treatment (Figure 3.1).  However, cells lacking any one of the four subunits of 
the EGO complex (Ego1p, Ego3p, Gtr1p or Gtr2p) failed to resume proliferation 
within two days following removal of the drug (Figure 3.1).  The recovery defect 
is profound.  We have confirmed that mutant cells in our background strain 
lacking the gene of any one member of the EGO complex fail to recover from 
rapamycin treatment under our laboratory conditions. 
 Methylene blue staining 3.2.2
Loss of viability of ego- mutants when treated with rapamycin could explain why 
we fail to observe recovery of ego- cells following removal of the drug from the 
media.  We employed the metabolic viability stain methylene blue to test 
whether cells remain alive both in the constant presence of rapamycin or 
following rapamycin washout.  Methylene blue is able to cross the plasma 
membrane of both live and dead cells.  In live yeast cells, methylene blue can 
be reduced resulting in loss of the blue colour whilst dead cells are unable to 
metabolise the dye and stain blue (Painting & Kirsop 1990).  
Due to the similarity in phenotype observed for all four ego- knockout strains we 
tested ego1Δ and gtr2Δ cells as representatives of ego- mutants and examined 
the viability of cells treated with rapamycin.  Exponentially growing cultures in 
YPD were treated with rapamycin (200 ng/mL) for 24 hours; at various time 
points samples were taken, exposed to methylene blue and cell staining 
observed by microscopy.  Cultures were also treated with rapamycin for two 
hours after which cells were washed three times with fresh media and 
inoculated into YPD for 24 hours after which cells were stained with methylene 
blue. 
As can be seen in Table 3.1 wild-type cells did not stain with methylene blue up 
to and at 24 hours after the introduction of rapamycin and at 24 hours after 
washout of rapamycin following a two-hour treatment.   
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Figure 3.1 Loss of any subunit of the EGO complex results in a rapamycin 
recovery defect phenotype 
Exponentially growing cultures of wild-type, ego1∆, ego3∆, gtr1∆ and gtr2∆ cells 
were treated (or not) at an OD600nm of ~0.1 for two hours with rapamycin (200 
ng/mL) in YPD at room temperature with agitation.  Cells were collected and 
washed three times in fresh YPD after which ten-fold serial dilutions were 
created and spotted (5 µL) onto a YPD plate which was incubated at 28°C for 
two days prior to scanning. 
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We also found that neither ego1Δ nor gtr2Δ cells stained blue up to 24 hours in 
the constant presence of rapamycin, nor at 24 hours after the removal of the 
drug following a two-hour rapamycin treatment.  We did not observe the 
presence of any significant number of ‘ghost’ cells for any treatment or at any 
time point measured.  Ghost cells appear flat and white as a result of loss of 
integrity, usually a result of lysis, which prevents retention of methylene blue 
within the cell. 
To ensure that dead cells indeed stain positive with methylene blue, control 
samples of heat killed cells were stained with methylene blue.  Samples of wild-
type, ego1Δ and gtr2Δ cultures that had been treated with rapamycin for four 
hours (to ensure the viability stain was effective in the presence of the drug) 
were heated to 85˚C for 10 minutes before being exposed to methylene blue.   
As seen in Table 3.1 we found that over 99% of heat treated wild-type, ego1Δ 
and gtr2Δ cells showed strong staining with methylene blue.  We conclude that 
methylene blue is effective in our wild-type, ego1Δ and gtr2Δ cells and that the 
presence of rapamycin does not interfere with the staining of dead cells. 
We conclude that the rapamycin recovery defect seen in ego- mutants is unlikely 
to result from cell death, at least as measured by methylene blue staining. 
 Uptake of amino acids 3.2.3
It would appear that cell death in the presence of rapamycin is unlikely to 
explain the recovery defect seen in ego- mutants.  Testing the ability of ego- 
mutant cells to actively import amino acids will provide a second independent 
test of viability. 
If loss of the EGO complex results in cell death following rapamycin treatment 
we would expect to see little or no uptake of amino acids into ego- cells 
following treatment with the drug.  Measuring the ability of ego- cells to import 
amino acids would also begin to test the permease switch model, which predicts 
that ego- mutants are unable to import amino acids following rapamycin 
treatment.   
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Table 3.1 Methylene blue staining of cells treated with rapamycin 
Exponentially growing wild-type, ego1Δ and gtr2Δ cultures were treated (or not) 
with rapamycin (200 ng/mL) in YPD and incubated at room temperature with 
agitation.  Treated cultures were either maintained in the presence of the drug 
or following two hours after the introduction of rapamycin cells were washed 
three times in fresh media after which they were incubated at room 
temperature with agitation to recover.  All cultures were maintained in an 
exponential growth phase for the duration of the experiment.  Samples of wild-
type, ego1Δ and gtr2Δ cells that had been exposed to rapamycin for four hours 
were killed by heating to 85°C for 10 min.  Cells were exposed to methylene 
blue and staining observed by microscopy.  A minimum of 200 cells were counted 
for each of 3 replicates.  
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If ego- mutants fail to express active general amino acid permeases at the cell 
surface following rapamycin treatment, we would also expect to see no uptake 
of amino acids into rapamycin treated ego- cells.  If neither the loss of viability 
nor permease switch model applies to ego- mutants, then we would expect to 
see no difference in amino acid uptake between rapamycin treated wild-type 
and ego- mutant cells. 
We measured the uptake of a mix of 35S-labelled methionine and 35S-labelled 
cysteine into exponentially growing cells in YPD that were either untreated or 
continuously treated with rapamycin (200 ng/mL) for two, six or 24 hours at 
room temperature with agitation.  Cultures were maintained in the exponential 
growth phase for the duration of the experiment by dilution into the appropriate 
medium. 
As seen in Figure 3.2 there was no difference in the uptake of amino acids 
between untreated wild-type and untreated ego1Δ mutant cells.  However, a 
subtle but significant (p=0.02) defect in the ability of untreated gtr2Δ cells to 
import amino acids was observed relative to untreated wild-type cells (Figure 
3.2). 
It would appear that loss of Ego1p does not affect amino acid import under our 
standard laboratory conditions (Figure 3.2).  On the other hand, the lower 
uptake of amino acids by untreated gtr2Δ cells compared to that of wild-type 
cells suggests that amino acid permeases are not expressed correctly or are not 
fully active under normal conditions in a gtr2Δ mutant (Figure 3.2).  This could 
be because Gtr2p is specifically required for trafficking, or activity, of amino 
acid permeases to the cell surface under normal conditions.  Alternatively it is 
possible that Gtr2p is required for all cellular trafficking, which includes amino 
acid permeases to the plasma membrane. 
Treatment of all cultures with rapamycin resulted in a decrease in the import of 
radiolabelled amino acids compared to that of untreated cultures (Figure 3.2).  
We found that the uptake of radiolabelled amino acids into ego1Δ cells at both 
two and six hours following rapamycin treatment was not significantly different 
to radiolabelled amino acid uptake into the equivalently treated wild-type cells 
(p=0.63 and 0.20 respectively) (Figure 3.2). 
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Figure 3.2 Uptake of amino acids following rapamycin treatment  
The OD600nm of exponentially growing wild-type, ego1∆ and gtr2∆ cultures was 
normalised to an OD600nm of ~0.1 in YPD, cultures were treated (or not) with 
rapamycin (200 ng/mL) and incubated at room temperature with agitation.  All 
cultures were maintained in an exponential growth phase for the duration of the 
experiment by dilution into appropriate medium.  At two, six and 24 hours after 
the introduction of rapamycin or 24 hours following rapamycin washout (washout 
occurred two hours after the introduction of the drug) cell pellets, normalised to 
an OD600nm of ~0.25, were resuspended in YPD containing a mix of 
35S-labelled 
methionine and 35S-labelled cysteine (0.4 MBq) and incubated for five minutes at 
room temperature.  Cells were washed six times with ice-cold methionine (75 
mM) and cysteine (75 mM); retained radiation was measured using a scintillation 
counter and expressed as counts per minute (CPM) relative to that for the 
average untreated wild-type cells (39,398 CPM).  Control readings of media with 
radiation ranged from 1,042 to 4,748 CPM.  N=6 independent cultures; error bars 
denote S.E.M.; * p<0.05 relative to equivalently treated wild-type cells. 
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The uptake of radiolabelled amino acids into gtr2Δ cells was significantly lower 
following a two hour rapamycin treatment compared to that of wild-type cells 
after two hours in rapamycin (p=0.16) (Figure 3.2).  After six hours in the 
presence of rapamycin the uptake of radiolabelled amino acids into gtr2Δ cells 
was not significantly different to radiolabelled amino acid uptake into 
equivalently treated wild-type cells (p=0.32) (Figure 3.2).  
It is possible that gtr2Δ cells may respond normally to rapamycin treatment but 
have a general defect in amino acid uptake under all conditions.  We asked 
whether the fold decrease in amino acid import differed between wild-type and 
gtr2Δ cells up to six hours in the presence of rapamycin.  We normalised the 
uptake of radiolabelled amino acids into two and six hour rapamycin treated 
gtr2Δ cells to that of untreated gtr2Δ cells.  We found that the fold decrease in 
radiolabelled amino acid uptake into gtr2Δ cells in the presence of rapamycin 
was not significantly different to that of wild-type cells for either a two hour or 
six hour treatment (p=0.3 and 0.9 respectively) (Figure 3.3). 
We have observed that the trend in amino acid uptake by ego1Δ and gtr2Δ 
mutants occurred as wild-type cells up to and at six hours following the 
introduction of rapamycin.  The ability of ego1Δ and gtr2Δ mutants to import 
amino acids in the presence of rapamycin suggests that ego- cells are indeed 
viable in the presence of the drug.  The ability of ego- cells to import amino 
acids following rapamycin treatment and the lack of methylene blue staining in 
the presence of the drug leads us to conclude that loss of cell viability is unlikely 
to explain the inability of ego- mutants to recover from rapamycin treatment. 
We have observed a difference in the ability of ego1Δ and gtr2Δ to import amino 
acids, both into untreated cells and cells that have been exposed to rapamycin 
for two hours.  The significant decrease in uptake of amino acids by two hour 
rapamycin treated gtr2Δ cells, compared to equivalently treated wild-type cells, 
suggests that we cannot rule out the possibility that the general amino acid 
permeases are being incorrectly expressed in rapamycin-treated gtr2Δ cells and 
that this could explain the inability of at least a subset of ego- mutants to 
recover from rapamycin treatment.   
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Figure 3.3 Uptake of amino acids into wild-type and gtr2Δ cells relative to 
their own uptake of untreated cells 
The wild-type and gtr2Δ mutant amino acid uptake results from Figure 3.2 with 
the counts per minute (CPM) of rapamycin treated cells expressed relative to 
their own untreated CPM (36,753 CPM for WT and 25,630 CPM for gtr2Δ).  N=6 
independent cultures; error bars denote S.E.M. 
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However, the inability of ego- mutants to recover from rapamycin treatment is 
shared between all four ego- null mutants (Figure 3.1).  We also measured the 
uptake of amino acids into ego1Δ cells and find that there is no significant 
difference in the uptake of amino acids into rapamycin-treated ego1Δ cells 
compared to equivalently treated wild-type cells (Figure 3.2).  We can therefore 
conclude that whilst there appears to be a difference in the requirement of 
different subunits of the EGO complex for permease trafficking, the ability of 
rapamycin treated ego1Δ cells to import amino acids in a manner similar to 
rapamycin treated wild-type cells suggests that the permease switch model is 
unlikely to explain the shared ego- mutant phenotype with regards to rapamycin 
recovery. 
Amino acid uptake was also measured in recovering cells; exponentially growing 
wild-type, ego1Δ and gtr2Δ cultures were treated with rapamycin (200 ng/mL) 
for two hours at room temperature with agitation after which cells were washed 
three times in fresh media and incubated at room temperature with agitation to 
recover.  Radiolabelled amino acid uptake was measured 24 hours after the 
transferral of rapamycin-treated cells into fresh media.  All cultures were 
maintained in an exponential growth phase for the duration of the experiment 
by dilution into fresh media.   
Consistent with wild-type cells being able to recover from rapamycin treatment, 
we found that the uptake of the radiolabelled amino acids into recovering wild-
type cells was not significantly different to that of untreated wild-type cells 24 
hours after the removal of rapamycin (p=0.16) (Figure 3.2). 
Following washout of rapamycin (“recovery”), uptake of radiolabelled amino 
acids into cells lacking either Ego1p or Gtr2p did not resemble that of untreated 
cells (Figure 3.2); again, these results are consistent with the inability of ego- 
mutants to recover following rapamycin treatment (as seen in Figure 3.1).  Not 
only did the uptake of radiolabelled amino acids into ego1Δ and gtr2Δ cells after 
a “recovery period” not resemble that of untreated cells, we also found that the 
uptake of radiolabelled amino acids into cells following a “recovery period” was 
lower than the radiolabelled amino-acid uptake measured following a six hour 
rapamycin treatment (Figure 3.2).  It would appear that, with regards to amino 
acid uptake, ego1Δ and gtr2Δ cells recovering from rapamycin behave 
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differently to those that are in the constant presence of rapamycin for up to six 
hours. 
We have observed that the uptake of radiolabelled amino acids into ego1Δ and 
gtr2Δ cells after a “recovery period” is lower than that of cells in the constant 
presence of rapamycin (for up to six hours) (Figure 3.2).  The uptake of amino 
acids into wild-type, ego1Δ and gtr2Δ cells that had been maintained in the 
continuous presence of rapamycin for 24 hours was also measured to compare 
the uptake of recovering cells and those exposed to rapamycin for a long time.  
We found that all cultures were able to import the radiolabelled amino acid mix 
following 24 hours in the presence of rapamycin, however ego1Δ and gtr2Δ 
mutants imported significantly less compared to wild-type cells (p=0.006 or 
p=0.01 respectively) (Figure 3.2).  These results could be a result of loss of 
viability in the continuous presence of rapamycin for an extended period of 
time; however, the methylene blue viability stain data would suggest that this is 
not the case (Table 3.1).  Alternatively, in the continued presence of rapamycin 
ego1Δ and gtr2Δ mutants could be overreacting or responding aberrantly to the 
effects of the drug. 
In conclusion, we have found that loss of the EGO complex does not appear to 
impinge on the ability of ego- cells to import amino acids following rapamycin 
treatment.  It is doubtful that lack of amino acid permeases at the cell surface 
following rapamycin treatment explains the inability of all ego- mutants to 
recover from rapamycin treatment.  However, we have made two unexpected 
observations.  Firstly we show that there appears to be a difference between 
Ego1p and Gtr2p with regards to their role in permease trafficking.  Second, it 
would appear that ego- mutants overreact, compared to wild-type cells, to the 
continued presence of rapamycin for 24 hours.  It is noteworthy that the 
overreaction to the continued presence of the drug is also shared with ego- cells 
recovering for 24 hours from a two hour treatment with rapamycin.  It is possible 
that the altered states (as observed by amino acid uptake) of ego- cells in the 
continued presence of rapamycin for 24 hours and of ego- cells recovering from 
rapamycin treatment for 24 hours could hint at why ego- mutants fail to recover 
from rapamycin treatment. 
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 Testing gap1∆ null mutants for recovery from rapamycin 3.2.4
TORC1 activity is controlled by nutrient sensing; therefore it is possible that 
there is a threshold of intracellular nutrient availability below which TORC1 
remains inactive.  If there is a modest decrease in the availability of amino acids 
detected in ego- mutants and the sensed availability lies just under this 
threshold it could result in ego- mutants with constitutively inactive TORC1 
following rapamycin treatment.  This situation may apply to gtr2∆ mutants in 
particular. 
If a modest decrease in sensed amino acids explains the inability of ego- mutant 
cells to recover from rapamycin treatment we would expect that a severe 
reduction in amino acid uptake would be sufficient to result in an inability of 
cells to recover from rapamycin.  As described earlier, Gap1p is the predominant 
general amino acid permease presented at the cell surface following TORC1 
inactivation (Beck et al. 1999).  We would therefore predict that loss of Gap1p 
would result in a dramatic reduction in the uptake, and therefore intracellular 
availability, of amino acids following rapamycin treatment.  If amino acid 
availability needs to be above a certain threshold, at which the ego- mutants are 
on the edge, we would predict that a gap1∆ null mutant should fail to recover 
from rapamycin treatment. 
We tested the ability of a gap1∆ null mutant, in the same strain background as 
our wild-type and the ego- mutants, to recover from rapamycin treatment.  
Wild-type, ego1∆ and gap1Δ cells were treated with rapamycin for two hours 
after which cells were washed three times in fresh YPD and spotted to a plain 
YPD plate to recover.  As seen in Figure 3.4 wild-type cells were able to recover 
from rapamycin treatment as seen previously (Figure 3.1).  As expected, loss of 
Ego1p resulted in cells that were unable to recover from rapamycin treatment 
(Figure 3.4).  We found that gap1Δ cells were able to recover from rapamycin 
treatment in a manner indistinguishable from that of wild-type cells (Figure 
3.4).  These results suggest that the presence of Gap1p in the plasma membrane 
is not required for yeast to recover from rapamycin treatment.  The results also 
imply that a threshold of amino acid uptake does not explain why ego- mutants 
fail to recover from rapamycin. 
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Figure 3.4 Loss of Gap1p does not result in a rapamycin recovery defect 
Exponentially growing wild-type, ego1Δ and gap1Δ cultures at an OD of ~0.1 
were treated (or not) with rapamycin (200 ng/mL) in YPD at room temperature 
with agitation for two hours.  Cells were washed three times in fresh media; ten-
fold serial dilutions were created and spotted (5 µL) onto a YPD plate which was 
incubated at 30°C for two days. 
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 Testing recovery of ego- mutants from various TORC1 3.2.5
inactivating treatments 
If the TORC1 reactivation model explains the inability of ego- mutants to recover 
from rapamycin, we would predict that ego- mutants should fail to recover from 
any treatment that results in inactivation of TORC1; for example using nutrient 
starvation or caffeine treatment (Beck et al. 1999; Reinke et al. 2006; Wanke et 
al. 2008).  We wished to test the ability of ego1Δ and gtr2Δ to recover from a 
concentration of caffeine that is inhibitory for ego- mutants as well as from a 
period of carbon or nitrogen starvation. 
To determine what concentration caffeine is inhibitory to ego- mutant cells we 
first tested the ability of an ego1Δ mutant to form colonies in the presence of 
various concentrations of caffeine.  Exponentially growing wild-type and ego1Δ 
cultures were normalised to an OD600nm of ~0.1 in YPD from which ten-fold serial 
dilutions were created and spotted to YPD plates containing various 
concentrations of caffeine (0-9 mM).  Plates were incubated at 30˚C for two 
days.  As seen in Figure 3.5 wild-type cells were able proliferate in the presence 
of all concentrations of caffeine tested.  We found that ego1Δ mutants were 
able to proliferate as effectively as wild-type on plain YPD plates and were able 
to proliferate in the presence of 3 mM caffeine, albeit ego1Δ cells appeared 
more sensitive to the effects of 3 mM caffeine than wild-type cells (Figure 3.5).  
A small amount of growth was observed for the most concentrated ego1Δ culture 
in the presence of 6 mM caffeine and no growth was observed for ego1Δ cells in 
the presence of 9 mM caffeine (Figure 3.5).  We conclude that 9 mM caffeine is 
sufficient to fully inhibit proliferation, and thus to fully inactivate TORC1 in ego- 
mutants.  
To test whether ego- mutants were able to recover from caffeine treatment, 
exponentially growing wild-type, ego1Δ and gtr2Δ cultures were treated with 
rapamycin (200 ng/mL) or caffeine (9 mM) for two hours after which cells were 
washed three times in YPD and spotted to a YPD plate which was incubated at 
30˚C to recover.  As seen previously (Figure 3.1) we found that wild-type cells 
were able to recover from rapamycin treatment whereas ego1Δ and gtr2Δ 
mutants were unable to do so (Figure 3.6). 
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Figure 3.5 Testing sensitivity of yeast to caffeine 
Exponentially growing wild-type and ego1Δ cultures were normalised to an 
OD600nm of ~0.1 in YPD.  Ten-fold serial dilutions were created in YPD and 
spotted (5 µL) onto either a plain YPD plate or plates containing caffeine (3, 6 or 
9 mM) which were incubated at 30˚C for two days. 
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However, we found that wild-type, ego1Δ and gtr2Δ mutants were all able to 
recover from a two hour treatment with caffeine (Figure 3.6).   
We also tested the ability of ego- mutants to recover from physiological 
conditions known to inhibit TORC1 activity.  Exponentially growing cultures of 
wild-type, ego1Δ and gtr2Δ cells in YPD were washed three times in either SD-AA 
(for nitrogen starvation) or YP (for carbon starvation) media and subsequently 
inoculated into their respective drop-out media and incubated at room 
temperature with agitation for two hours.  After the two hour incubation, ten-
fold serial dilutions were created in YPD and spotted on to a YPD plate to 
recover at 30˚C for two days.  As seen in Figure 3.6 we found that ego1Δ and 
gtr2Δ cells were able to recover, as wild-type, from a period of either carbon or 
nitrogen starvation.   
The ability of ego- mutants to resume proliferation following alternative TORC1 
inhibiting treatments suggests that a general loss of the EGO complex does not 
compromise TORC1 reactivation under the conditions tested above.  These 
results suggest that the TORC1 reactivation model is unlikely to explain the 
rapamycin recovery defect of ego- mutants.  It is possible that the EGO complex 
is selectively required for recovery of rapamycin via some other drug selective 
mechanism, for example detoxification of rapamycin itself or removal of the 
rapamycin-Fpr1p complex from TORC1. 
 Do known multidrug detoxification pathways have a role 3.2.6
in recovery from rapamycin? 
Could the EGO complex be required for rapamycin detoxification?  If rapamycin 
is cleared from yeast by known drug detoxification mechanisms, which may 
depend on the EGO complex, we would predict that loss of the mechanism 
involved in rapamycin detoxification, for example cytochrome P450s or the 
pleiotropic drug resistance (PDR) pathway, would phenocopy the loss of ego- 
mutants. 
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Figure 3.6 Recovery of ego- from TORC1 inactivating treatments  
Exponentially growing wild-type, ego1Δ and gtr2Δ cultures at an OD600nm of ~0.1 
were untreated, treated with rapamycin (200 ng/mL) or caffeine (9 mM) in YPD 
and incubated at room temperature for two hours with agitation.  Cells were 
washed three times into fresh YPD and ten-fold serial dilutions were spotted (5 
µL) onto a plain YPD plate.  Alternatively, cultures at an OD600nm of ~0.1 were 
pelleted and cells resuspended in media lacking either carbon or nitrogen.  This 
was repeated twice more before cells were inoculated into the relevant drop-
out media and incubated at room temperature for two hours with agitation.  
Ten-fold serial dilutions were created in YPD and spotted (5 µL) onto a plain YPD 
plate. Plates were incubated at 30°C for 2 days. 
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Little is known about how rapamycin is detoxified in cells.  Some evidence from 
mammalian systems suggests that rapamycin can be detoxified in liver by the 
cytochrome P450 CYP3A4 (Anzenbacher & Anzenbacherova 2001; Guengerich 
1999; Li et al. 1995).  Yeast contain two cytochrome P450’s: Erg5p (which is non-
essential) and Erg11p (which is essential).  DAP1 encodes an accessory protein 
that is required for the function of Erg11p (Mallory et al. 2005).  We tested 
whether loss of ERG5 or DAP1, which should also compromise Erg11p function, 
affects recovery from rapamycin. 
A number of large-scale genome-wide genetic screens have been carried out 
using rapamycin.  Studies carried out by Butcher et al. (2006) found that 
overexpression of three pleiotropic resistance genes (PDR16, PDR17, and PDR3)  
resulted in a potential reduction in sensitivity to rapamycin.  Hillenmeyer et al. 
(2008) also performed a large-scale screen and found that loss of 252 genes, out 
of 510 genes they classed as being involved in multidrug resistance, resulted in 
hypersensitivity to rapamycin.  Whilst Hillenmeyer et al. (2008) did not specify 
which null ‘multidrug resistance’ mutants resulted in rapamycin sensitivity, they 
alluded that PDR1 and PDR5 were included in their ‘multidrug resistance’ set.  It 
is possible therefore that pleitropic drug resistance (PDR) pathways have a role 
in rapamycin detoxification.  Therefore, we also tested the ability of pdr1Δ, 
pdr3Δ and pdr5Δ mutants to recover from rapamycin treatment.  Pdr1p and 
Pdr3p are transcription factors that regulate the ABC transporter proteins, an 
example of which is Pdr5p (Moye-Rowley 2003). 
Exponentially growing cultures of wild-type, ego1Δ, erg5Δ, dap1Δ, pdr1Δ, pdr3Δ 
and pdr5Δ cells in the BY4743 strain background were treated with rapamycin 
(200 ng/mL) in YPD for two hours at 28˚C with agitation.  Cells were washed 
three times in fresh YPD and ten-fold serial dilutions were spotted onto a YPD 
plate which was incubated at 28˚ for two days. 
We found that wild-type cells were able to recover from a two-hour rapamycin 
treatment whereas ego1Δ mutants failed to recover (Figure 3.7).  It would 
appear that loss of either Erg5p or Dap1p does not compromise recovery from 
rapamycin and cells behaved as wild-type (Figure 3.7).  Furthermore, loss of any 
one of Pdr1p, Pdr3p or Pdr5p did not compromise recovery from rapamycin 
treatment; the PDR null mutants tested all behaved as wild-type (Figure 3.7). 
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Figure 3.7 Recovery from rapamycin of null mutants involved in multidrug 
resistance 
Exponentially growing cultures of wild-type, ego1Δ, pdr1Δ, pdr3Δ, pdr5Δ, erg5Δ 
and dap1Δ cells at an OD600nm of ~0.1 were treated (or not) with rapamycin (200 
ng/mL) in YPD at 28˚C for two hours with agitation.  Cells were washed three 
times with fresh media after which ten-fold serial dilutions were created and 
spotted (5 µL) onto a YPD plate which was incubated at 28°C for 2 days.  
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The lack of a rapamycin recovery defect phenotype for any mutant involved in 
known drug detoxification pathways tested suggests it is unlikely that classical 
multidrug resistance pathways have a role in detoxification of rapamycin in 
yeast.  It is worth noting that only a small subset of proteins involved in 
multidrug resistance have been tested here.  If the EGO complex is required for 
detoxification of rapamycin it may do so via proteins not tested here, require 
the involvement of more than one detoxification method, do so via a novel 
detoxification method or some combination thereof.  We cannot therefore 
exclude the rapamycin detoxification model to explain why ego- mutants fail to 
recover from rapamycin treatment, but it would appear that rapamycin 
detoxification is unlikely to involve the cytochrome P450’s or the pleiotropic 
drug resistance mechanisms alone. 
 Conclusion 3.3
The work carried out in this chapter was undertaken to test the four models we 
proposed that could explain the rapamycin recovery defect observed in mutants 
lacking the EGO complex.   
Loss of Viability Model  
Initially we proposed that loss of viability of ego- mutants in response to 
rapamycin could explain the inability of ego- cells to recover from rapamycin 
treatment.  It would appear that this model is incorrect.  The use of the 
methylene blue viability stain showed that ego- cells did not stain up to and at 
24 hours after the introduction of rapamycin nor at 24 hours after washout of 
the drug.  We also found that amino acid uptake by ego- mutants was no 
different to that of wild-type cells six hours after the introduction of rapamycin.  
Due to the profound nature of the recovery defect, if cells died in the presence 
of rapamycin we would have expected to see some evidence of this in either the 
methylene blue staining or amino acid uptake. 
We therefore conclude that loss of the EGO complex does not result in cell death 
following exposure to rapamycin. 
Permease Switch Model  
Our second model speculated that the amino acid permease switch from specific 
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permeases to general permeases upon TORC1 inactivation is not completed in 
ego- mutants, resulting in cells in a permanent state of starvation and thus G0 
arrest.  We find that ego1Δ cells are able to import amino acids in a manner 
similar to that of wild-type cells up to and at six hours after the introduction of 
rapamycin.  Whilst we find that the overall import of amino acids is lower into 
two-hour rapamycin-treated gtr2Δ mutants, compared to wild-type, the fold 
decrease in uptake is not statistically significant between the two strains.  It is 
likely that the low uptake of amino acids into gtr2Δ cells following a two hour 
rapamycin treatment is a result of a general defect in uptake of amino acids into 
gtr2Δ cells.  The trend in amino acid uptake into ego- mutants does not appear 
to be different to that for wild-type cells up to six hours after the addition of 
rapamycin.  This would suggest that amino acid permeases are present at the 
cell surface of ego- cells treated with rapamycin and it is unlikely that ego- 
mutants are starving in the presence of the drug. 
It is worth noting that, whilst it would appear that amino acids are imported into 
rapamycin treated ego- cells, we did not confirm that the permease switch took 
place in these cells.  It would be worth confirming in rapamycin-treated ego- 
mutants that the specific amino acid permeases were degraded and that general 
amino acid permeases were expressed at the cell surface.  Two complimentary 
assays could be carried to confirm the switch had in fact occurred.  Firstly, the 
abundance of the specific amino acid permease Tat2p could be monitored over 
time, following the addition of rapamycin, by western blot analysis (Beck et al. 
1999).  This would test if all Tat2p permease protein had been degraded and 
therefore none should be present at the cell surface.  To test if Gap1p, a 
general amino acid permease, is transported to the cell surface following 
rapamycin treatment, the localisation of GFP tagged Gap1p could be monitored 
by fluorescent microscopy.  Furthermore, AZC is a toxic proline analogue that is 
imported by the Gap1p permease (Andréasson et al. 2004).  Sensitivity to AZC of 
cells that had been treated with rapamycin could be tested; if rapamycin 
treated cells failed to grow in the presence of AZC it would indicate that Gap1p 
is indeed present and active at the cell surface. 
It is possible that six hours in rapamycin is not long enough for the permease 
switch to have occurred.  Evidence from Beck et al. (1999) would suggest that 
this is not the case.  Beck et al. (1999) found that the specific amino acid 
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permease Tat2p was almost completely degraded following a one hour 
rapamycin treatment.  We would therefore expect the amino acid permease 
turnover to have occurred by our two hour time measurement and certainly by 
six hours. 
To ensure the levels of amino acids being sensed in ego- mutants were not near 
a limiting threshold required for TORC1 activity we tested the ability of a gap1Δ 
null mutant to recover from rapamycin treatment.  If the intracellular 
concentration of amino acids detected is crucial for recovery of yeast from 
rapamycin treatment we would have expected a gap1Δ null mutant (in which 
amino acid import should be severely compromised upon rapamycin treatment) 
to have a recovery defect as seen in ego- mutants.  We did not find this to be 
the case.  Loss of Gap1p did not affect the ability of cells to recover from 
rapamycin treatment.  The wild-type phenotype of gap1Δ mutants suggests that 
merely lowering the intracellular amino acid concentration does not impact the 
ability of yeast cells to recover from rapamycin treatment.   
By measuring the uptake of amino acids following rapamycin treatment, we 
would conclude that the permease switch model does not explain the rapamycin 
recovery defect of ego- mutants. 
TORC1 Reactivation Model  
If the EGO complex is required for TORC1 reactivation following any condition 
which inactivated the complex, we would expect to see the same recovery 
defect in ego- mutants following any TORC1 inactivating treatment.  We find 
that ego- mutants are in fact able to recover from all chemical and conditional 
TORC1 inactivating treatments tested, with the exception of rapamycin.  These 
results suggest that loss of the EGO complex does not result in a complete 
inability to reactivate TORC1 and that the recovery defect observed in ego- 
mutants is a rapamycin-selective phenotype.  
An alternative physiological method of inactivating TORC1 is to grow cultures to 
saturation, resulting in nutrient limitation.  A genome-wide study by Powers et 
al. (2006) investigated the chronological life span of ~4800 null mutants by 
growing cells to saturation in complete synthetic media and at various time 
points transferring aliquots to fresh media and observing the ability of cells to 
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resume proliferation as measured by OD600nm.  All four null mutants of the EGO 
complex were included in this screen and Powers et al. (2006) found that all four 
null mutants were able to resume proliferation as efficiently as wild-type 
cultures, even after five weeks in stationary phase (Table 3.2).  These results 
support our conclusion that loss of the EGO complex does not result in an 
inability of ego- cells to reactivate TORC1 per se in order to resume 
proliferation. 
Rapamycin Detoxification Model  
Yeast have a number of mechanisms for detoxifying xenobiotics, these include 
the pleiotropic drug resistance pathway and cytochrome P450s.  We speculated 
that the EGO complex could be required to detoxify rapamycin.  Loss of proteins 
from the PDR or cytochrome P450 drug resistance mechanisms did not 
compromise recovery from rapamycin treatment.  However, both mechanisms 
involve a large number of proteins and it is likely that redundancy occurs within 
each system.  Large-scale studies have hinted that overexpression or loss of 
multidrug resistance genes affects sensitivity of yeast to rapamycin; however, to 
our knowledge, no specific study to date has investigated the method by which 
rapamycin is detoxified in yeast.  We therefore cannot rule out the possibility 
that the EGO complex is required for detoxification of rapamycin; however, if it 
does, it is likely to be via a mechanism not tested here. 
Summary 
Four models were presented that could explain the inability of ego- mutants to 
resume proliferation following treatment with rapamycin.  We find that the ego- 
rapamycin recovery defect phenotype cannot be explained by loss of viability, 
loss of general amino acid permeases at the cell surface nor an inability of ego- 
mutants to reactivate TORC1 from an inactive state. 
We have, however, discovered that the inability of ego- cells to recover from 
rapamycin treatment is a rapamycin-selective phenotype.  The rapamycin 
recovery defect phenotype of ego- mutants could therefore be a result of 
inadequate rapamycin detoxification by an unknown mechanism in ego- cells.   
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Gene 1 week 2 weeks 5 weeks 
EGO1 1.082 1.231 0.980 
EGO3 0.901 2.996 3.745 
GTR1 1.145 2.472 0.974 
GTR2 1.099 1.073 1.292 
    
Table 3.2 Chronological lifespan of ego- mutants from Powers et al. (2006) 
Data taken from Powers et al. (2006) in which cultures were grown to saturation 
phase in complete synthetic liquid media.  An aliquot of cells was transferred 
into fresh media at 1, 2 and 5 weeks after saturation and the ability to resume 
proliferation was assessed by spectrometry measuring OD600nm.  Viability was 
determined relative to the mean viability for the deletion collection at each 
time point. 
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Alternatively, it is possible that the EGO complex is selectively required for the 
uncoupling of the rapamycin-Fpr1p intermediate complex from the TOR1 
complex.  Loss of the EGO complex would therefore result in rapamycin 
irreversibly bound to TORC1. 
Whilst the majority of published studies on the EGO complex have been carried 
out using rapamycin treatments for up to six hours (Binda et al. 2009; Dubouloz 
et al. 2005) we have measured amino acid uptake following 24 hours in the 
constant presence of rapamycin into wild-type and ego- mutants.  To our 
surprise, we found that the uptake of amino acids into 24 hour treated ego- 
mutants was significantly lower than that of wild-type cells treated for 24 hours 
with rapamycin.  It was interesting to observe that ego- cells that had undergone 
a period of “recovery” (from a two hour treatment of rapamycin) also had a 
lower amino acid uptake that was not significantly different to the uptake of 
amino acids into cells that had been exposed to rapamycin for 24 hours.  The 
similarity between the amino acid uptake of ego- mutants following a 24 hour 
rapamycin treatment and those that were in a “recovery period” for 24 hours 
could hold clues as to why null mutants of the EGO complex fail to recover from 
rapamycin treatment. 
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4 Rapamycin-insensitive TORC1 activity 
 Introduction 4.1
In the previous chapter, we showed that the rapamycin recovery defect 
observed in ego- mutants is a rapamycin selective phenotype.  We tested four 
hypotheses that could explain the inability of ego- mutants to recover from 
rapamycin; two were discounted: the loss of viability model and the permease 
switch model.  It is possible however that the EGO complex is selectively 
required for TORC1 reactivation following rapamycin treatment or for 
detoxification of rapamycin or both. 
Inactivation of TORC1 results in a number of physiological changes within a yeast 
cell including: the down-regulation of translation, the induction of autophagy, 
the phosphorylation of Sch9p and the switch from specific to general amino acid 
permeases at the cell surface (De Virgilio & Loewith 2006b).  Null ego- mutants 
appear to behave as wild-type cells following exposure to rapamycin for up to six 
hours; as assayed by the down regulation of translation, the induction of 
autophagy (Dubouloz et al. 2005) and the phosphorylation of Sch9p (Binda et al. 
2009).  So why do ego- mutants fail to recover from rapamycin treatment?  We 
found that following a longer exposure to rapamycin (24 hours), the ego- 
mutants showed a lower rate of amino acid uptake compared to that of wild-
type cells.  This altered amino acid uptake rate following a longer exposure to 
the drug was also evident when the ego- mutants had been treated with 
rapamycin for a short time (two hours), washed into fresh media and incubated 
for 24 hours, i.e. while attempting to recover.  This observation hints that ego- 
mutant cells may indeed respond differently to rapamycin compared to wild-
type cells. 
During the course of our studies we observed that wild-type cells were able to 
proliferate, albeit slowly, in the continuous presence of a high concentration of 
rapamycin (200 ng/mL) i.e. a concentration far exceeding the minimum 
inhibitory concentration of ~3-5 ng/mL that fully induces phenotypes associated 
with inactivated TORC1 (Neklesa & Davis 2008).  It is generally thought that 
rapamycin is a complete inhibitor of proliferation in yeast.  Barbet et al. (1996) 
and Heitman, et al. (1991) concluded that high concentrations of rapamycin 
95 
 
inhibit the proliferation of cells in the JK9-3d strain background.  Upon closer 
inspection of the literature we found that some groups have in fact observed 
residual proliferation of cells in the presence of high concentrations of 
rapamycin (in the BY4743 background as is used here), but have not commented 
on it (for example Dubouloz et al. (2005) and Neklesa & Davis (2008)).  Is it 
possible that rapamycin does not fully inhibit proliferation of yeast cells, at least 
in the BY4743 background? 
Note; throughout the rest of this thesis, unless otherwise stated, the term ‘high 
concentration’ of rapamycin is indicative of a concentration at or above 20 
ng/mL, i.e. at least four times the minimum inhibitory concentration of the drug 
in wild-type cells. 
 Results 4.2
 Wild-type cells proliferate in the presence of a high 4.2.1
concentration of rapamycin (200 ng/mL) 
To begin to characterise the proliferation of wild-type cells in the presence of 
high concentrations of rapamycin we monitored the culture density in a 
population of wild-type cells over a period of 12 hours following the addition of 
rapamycin (200 ng/mL).  We used a Coulter particle counter to measure cell 
number; a Coulter counter is able to detect the absolute number of cells in a 
given volume of sample regardless of changes in cell size or shape that can occur 
following rapamycin treatment (Loewith & Hall 2011). 
Exponentially growing wild-type cultures in YPD were treated (or not) with 
rapamycin (200 ng/mL) at time 0 in YPD and incubated at room temperature 
with agitation.  At two hour intervals, starting at time 0, the culture density was 
measured by Coulter counter for up to 12 hours after the addition of rapamycin.  
Cultures were maintained in an exponential growth phase for the duration of the 
experiment by dilution into the appropriate medium if necessary; the culture 
density was subsequently adjusted by the appropriate dilution factor.  The 
results are expressed as semi-Log2 plots of relative culture density with time 
after the addition of rapamycin.  The steady-state growth rate is also shown and 
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was calculated as a reciprocal of the doubling time between two and 12 hours 
after the introduction of rapamycin. 
As seen in Figure 4.1A untreated wild-type cultures maintained a logarithmic 
growth rate over the 12 hour time-course.  Within the first two hours of 
rapamycin treatment we found that the growth rate of wild-type cultures slowed 
compared to the growth rate of untreated wild-type cultures (Figure 4.1A).   
Following the two hour transition period, rapamycin treated wild-type cultures 
maintained a steady growth rate for the remaining 10 hours monitored, a growth 
rate that was slower than that of untreated wild-type cultures; we call this the 
‘rapamycin-insensitive growth rate’ (Figure 4.1A).  Due to the stable nature of 
the rapamycin-insensitive growth rate between two and 12 hours after the 
introduction of the drug we were able to calculate the growth rates of untreated 
and rapamycin treated wild-type cultures.  As seen in Figure 4.1B we found that 
treatment of wild-type cultures with rapamycin resulted in a decrease in growth 
rate to ~34% that of untreated wild-type cultures.  It would appear that under 
our laboratory conditions wild-type cells are able to maintain proliferation in the 
presence of 200 ng/mL rapamycin, albeit at a slower residual rate compared to 
that of untreated wild-type cells. 
It is possible that the growth rate of wild-type cultures in the continued 
presence of rapamycin is due to a mixed population of cells – those that are 
completely inhibited by rapamycin and those that are resistant to the drug.  The 
results seen in Figure 4.1A however would argue against this possibility.  The 
growth rate of rapamycin treated wild-type cultures is constant between two 
and 12 hours after the introduction of rapamycin, and within each time point 
interval.  If a mixed population of rapamycin sensitive and resistant cells were 
present we would expect the growth rate of the rapamycin treated culture to 
increase over time due to an increasing proportion of rapamycin resistant cells, 
with time, within the population.  We do not see this trend within the data 
(Figure 4.1A). 
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Figure 4.1 Proliferation of wild-type cells in the constant presence of 
rapamycin (200 ng/mL) 
A: Exponentially growing wild-type cultures in YPD were normalised to an 
OD600nm of ~0.025, treated (or not) with rapamycin (200 ng/mL) at time 0 and 
incubated at room temperature with agitation.  The culture density was 
measured by Coulter counter every two hours up to 12 hours after the addition 
of rapamycin.  The Log2 of the relative cell number compared to the average 
number of cells at time 0 was calculated and plotted.  A polynomial line of best 
fit with an order of 5 is shown for wild-type cells in the presence of rapamycin.  
Error bars denote S.E.M.    
B: The growth rate of wild-type cultures was calculated between two and 12 
hours (between which the rapamycin-insensitive growth rate was stable) and 
calculated relative to the average growth rate of untreated wild-type cultures 
(0.5 hr-1).  N=4 independent cultures; error bars denote S.E.M.; * p=0.0004 
relative to untreated wild-type. 
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To test for any changes in cell population, we examined the growth rate of wild-
type cultures in the presence of rapamycin that had previously been exposed to 
the drug and allowed to recover.  We predict that if a subset of rapamycin 
resistant cells are present in the population, the rapamycin sensitivity of the 
wild-type culture as a whole would decrease following a number of cycles of 
rapamycin treatment and recovery. 
Wild-type cultures were treated with rapamycin (200 ng/mL) for 24 hours in YPD 
at 28˚C with agitation.  Cells were washed three times in fresh YPD and spotted 
onto a plain YPD plate to recover at 28˚C.  Cells that had recovered from the 
first rapamycin treatment were retreated with rapamycin (200 ng/mL) for a 
further 24 hours at 28˚C with agitation and cells were again washed and plated 
for recovery and incubated at 28˚C.  Exponentially growing cultures of naïve 
(never been treated with rapamycin), once recovered and twice recovered wild-
type cells were treated (or not) with rapamycin (200 ng/mL) in YPD at 28˚C with 
agitation.  The culture density was measured at three and six hours after the 
introduction of rapamycin by spectrometry at OD600nm and the growth rate 
calculated.  We chose to measure culture density at three and six hours after 
the introduction of rapamycin due to the stability of the rapamycin-insensitive 
growth rate between these times (Figure 4.1A).  The growth rates of rapamycin-
treated cultures were calculated relative to the growth rate of the equivalent 
untreated culture. 
As seen in Figure 4.2 we found that the residual growth rates, in the presence of 
a high concentration of rapamycin, of wild-type cultures that had previously 
been exposed to rapamycin, either once or twice, was not significantly different 
to that of naïve wild-type cultures treated with rapamycin for the first time 
(p=0.20 and 0.69).  It would appear that exposure to rapamycin does not result 
in selection for rapamycin-resistant cells under the conditions of our 
experiment.  The slow residual growth rate of wild-type cultures in the presence 
of a high concentration of rapamycin is therefore likely to reflect slow residual 
proliferation of all the cells in the culture. 
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Figure 4.2 The rapamycin-insensitive growth rate of wild-type cells is not 
altered by previous exposure to rapamycin  
Exponentially growing wild-type cultures were normalised to an OD600nm of ~0.05 
and treated with rapamycin (200 ng/mL) for 24 hours at 28˚C with agitation.  
Cells were washed three times using fresh YPD and the cultures plated onto a 
YPD plate to recover at 30°C.  These recovered cells were inoculated into YPD 
and when in exponential growth phase normalised to an OD600nm of ~0.05 and re-
treated for a further 24 hours with rapamycin (200 ng/mL) in YPD at 28˚C with 
agitation.  Cells were washed three times using fresh YPD and plated onto a YPD 
plate to recover at 30°C.  Untreated (naïve) cells, those that had been 
previously treated once or twice with rapamycin were then grown to exponential 
growth phase and normalised to an OD600nm of ~0.04 and treated (or not) with 
rapamycin (200 ng/mL).  The culture density was measured by spectrometry at 
OD600nm at three and six hours after the introduction of rapamycin and the 
growth rate calculated.  The growth rates are expressed relative to their 
equivalent untreated culture (0.7 hr-1, 0.8 hr-1 and 0.8 hr-1 for naïve, recovered 
once and recovered twice).  N=3 independent cultures; error bars denote the 
S.E.M. 
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Finally, we tested if the minimum inhibitory concentration of rapamycin is 
altered in wild-type cells that had recovered from a previous rapamycin 
treatment (200 ng/mL).  Exponentially growing wild-type cultures were treated 
with rapamycin (200 ng/mL) in YPD at 28˚C with agitation for 24 hours after 
which cells were washed three times in fresh YPD, spotted onto a YPD plate and 
incubated at 30˚C.  Naïve and recovered wild-type cells in an exponential 
growth phase were treated (or not) with rapamycin (5, 7.5 or 10 ng/mL) in YPD 
and incubated at 28˚C with agitation for six hours.  An end-point assay was used 
to test rapamycin sensitivity by measuring the change in culture density by 
spectrometry at OD600nm following the six hour incubation period.  Each endpoint 
OD600nm measurement is expressed relative to the average OD600nm of the 
respective untreated culture. 
As seen in Figure 4.3 we found that there was no significant difference between 
the sensitivity to rapamycin of naïve wild-type cells and those that had 
recovered from previous treatment with the drug (p=0.96 in 5 ng/mL, 0.70 in 7.5 
ng/mL and 0.55 in 10 ng/mL rapamycin).  These results suggest that recovery 
from rapamycin does not select for rapamycin-resistant mutants under the 
conditions of our experiment. 
We have identified that wild-type yeast cells are able to maintain some 
significant proliferation in the presence of a high concentration of rapamycin 
(200 ng/mL), albeit at a slower rate than that of untreated cells.  It is unlikely 
that the residual proliferation observed is a result of ineffective rapamycin; we 
observed a decrease in the proliferation rate of wild-type cells treated with 7.5-
10 ng/mL rapamycin (compared to that of untreated cells), a concentration at 
least 20 times lower than the concentration used to measure the growth rate of 
cultures.  The residual proliferation of wild-type cells therefore appears to be a 
robust, inherent behaviour of wild-type cells and is not a result of ineffective 
rapamycin or, that we see, of rapamycin-resistant cells.  We use the term 
‘rapamycin-insensitive growth rate’ to describe the residual growth of cultures 
in the presence of rapamycin. 
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Figure 4.3 Sensitivity of naïve or recovered wild-type cultures to various 
concentrations of rapamycin 
Exponentially growing wild-type cultures were normalised to an OD600nm of ~0.05 
and treated with rapamycin (200 ng/mL) for 24 hours in YPD at 28˚C with 
agitation.  After 24 hours in the presence of the drug, cells were washed three 
times in fresh YPD and spotted onto a YPD plate which was incubated at 28˚C for 
two days.  Exponentially growing naïve wild-type cells (those that had not been 
previously exposed to rapamycin) and wild-type cells that had recovered from a 
24 hour treatment were normalised to an OD600nm of ~0.1 to which rapamycin 
was added (5, 7.5 or 10 ng/mL), untreated control cultures were also included.  
Cultures were incubated at 28˚C with agitation for six hours after which the 
OD600nm was measured and expressed relative to the average OD600nm of 
untreated cultures (0.34 OD600nm for naïve and 0.16 OD600nm for recovered 
cultures).  N=3 independent cultures; error bars denote S.E.M. 
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 Rapamycin treatment induces autophagy in wild-type and 4.2.2
in ego1∆ cells 
It is possible that we see continued, albeit slow, proliferation of wild-type cells 
in the presence of 200 ng/mL rapamycin due to an abnormal response to the 
drug, and therefore ineffective TORC1 inactivation.  We measured the induction 
of autophagy, a hallmark of inactive TORC1, to ensure that our drug treatment 
was effective at inactivating TORC1 in wild-type cells.  We used a plasmid borne 
Pgk1-GFP construct (Welter et al. 2010) to assay autophagy.  Pgk1p is a 
housekeeping protein that is expressed throughout the cytosol under normal 
conditions; upon the induction of autophagy Pgk1-GFP is transported to the 
vacuole.  The Pgk1 component of the fusion is degraded in the vacuole whilst 
the GFP fragment is resistant to vacuolar proteases (Welter et al. 2010).  By 
probing for the presence of free GFP on a western blot we can determine 
whether or not autophagy has occurred.   
Cultures of wild-type and ego1Δ cells expressing a plasmid borne Pgk1-GFP 
construct were grown overnight in selective media.  Once in an exponential 
growth phase the cultures were treated (or not) with rapamycin (20, 50, 100 or 
200 ng/mL) in YPD at 28˚C with agitation for six hours.  Normalised cell pellets 
were collected, lysed using NaOH with 2-Mercaptoethanol on ice and proteins 
from whole cell lysates were separated by SDS PAGE.  Separated proteins were 
transferred to a membrane and probed with an anti-GFP antibody followed by a 
secondary antibody conjugated to horseradish peroxidase. 
As seen in Figure 4.4 we found that we were able to detect the full Pgk1-GFP 
construct, but no free GFP, in untreated wild-type cells, consistent with no 
autophagy occurring under these conditions (Figure 4.4A).  We found that 
autophagy was induced in wild-type cells treated with rapamycin (200 ng/mL) 
(Figure 4.4A) suggesting that treatment of wild-type cells with 200 ng/mL 
rapamycin results in inactive TORC1.  We also tested whether lower 
concentrations of rapamycin were able to induce autophagy in wild-type cells.   
As seen in Figure 4.4A, the presence of free GFP was detected in wild-type cells 
following treatment with any high concentration of rapamycin tested (i.e. a 
concentration of rapamycin 20 ng/mL or above).  The extent of free GFP also 
appears comparable regardless of the high concentration tested (Figure 4.4A). 
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Figure 4.4 Autophagy is induced upon treatment of yeast cells with high 
concentrations of rapamycin  
A: Wild-type cells expressing a plasmid borne Pgk1-GFP construct were grown 
overnight in selective media.  The following day, cultures in an exponential 
growth phase were normalised to an OD600nm of ~0.25 which were pelleted and 
washed once in water before being resuspended in YPD.  Cultures were treated 
(or not) with rapamycin (20, 50, 100 or 200 ng/mL) and incubated at 28˚C with 
agitation for six hours.  Cells were lysed and proteins separated from whole cell 
lysates by SDS PAGE, transferred to a membrane and probed with an anti-GFP 
antibody.  Detection was carried out using a secondary antibody conjugated to 
horseradish peroxidase and an ECL detection kit.  
B: Null ego1Δ mutant cells expressing a plasmid borne Pgk1-GFP construct were 
grown overnight in selective media.  The following day cultures in an 
exponential growth phase were normalised to an OD600nm of ~0.2 which were 
pelleted and resuspended in YPD.  Cultures were treated (or not) with rapamycin 
(20, 50, 100 or 200 ng/mL) and incubated at 28˚C with agitation for six hours.  
Cells were lysed and proteins separated from whole cell lysates by SDS PAGE, 
transferred to a membrane and probed with an anti-GFP antibody.  Detection 
was carried out using a secondary antibody conjugated to horseradish peroxidase 
and an ECL detection kit. 
Note: These experiments were carried out independently on separate days; 
therefore results between each strain should not be compared, only those 
results from treatments within the same strain are comparable.  
 
104 
 
 
The induction of autophagy in wild-type cells following treatment with 20-200 
ng/mL rapamycin suggests that TORC1 is being inactivated in these cultures.  
The residual rapamycin-insensitive growth rate is therefore unlikely to be a 
result of ineffective TORC1 inhibition either because of altered drug or altered 
response to the drug.  The similarity between the free GFP signals observed in 
wild-type cells when treated with rapamycin within a range of 20 ng/mL to 200 
ng/mL suggests that TORC1 is inactivated to a similar extent within this 
rapamycin concentration range.  Concentrations of rapamycin above at least 20 
ng/mL completely induce autophagy, a hallmark of low TORC1 activity. 
We also tested whether a rapamycin treatment range of 20-200 ng/mL was 
sufficient to fully induce autophagy in ego1Δ cells.  As seen in Figure 4.4B we 
only observed the full Pgk1-GFP construct in untreated ego1Δ cells, suggesting 
that TORC1 is sufficiently active in untreated ego1Δ cells to fully inhibit 
autophagy, despite loss of the EGO complex.  We found that autophagy was 
induced in rapamycin treated ego1Δ cells and that the presence of free GFP was 
comparable between all concentrations tested (Figure 4.4B).  These results 
suggest that a concentration of 20 ng/mL is enough to inactivate TORC1 in ego1Δ 
cells.  We therefore conclude that concentrations of rapamycin above 20 ng/mL 
are sufficient for TORC1 inactivation in both wild-type and ego1Δ cells. 
 Proliferation of wild-type cells in various high 4.2.3
concentrations of rapamycin 
We have demonstrated that wild-type cells are able to proliferate slowly in the 
presence of 200 ng/mL rapamycin, a high concentration at which TORC1 is 
inhibited, as measured by the induction of autophagy (Figure 4.4A).  We found 
that treatment with 20 ng/mL rapamycin was sufficient to induce autophagy in 
wild-type cells to an apparently similar extent as treatment with 200 ng/mL 
rapamycin.  It is possible that the slow rapamycin-insensitive growth rate 
observed in wild-type cultures at 200 ng/mL of drug is a result of rapamycin-
inhibited TORC1, or is a result peculiar to that particular concentration of the 
drug, e.g. potential off-target effects.  In the former case, we expect the same, 
measurable residual growth at all high concentrations of rapamycin; in the latter 
case, residual growth would vary with concentration of the drug, even when 
present at high levels. 
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Exponentially growing wild-type cultures were treated (or not) with rapamycin 
(20, 50, 100 or 200 ng/mL) in YPD and incubated at room temperature with 
agitation.  The culture density was measured by Coulter counter at two hour 
intervals, from time 0 (the addition of rapamycin) to 12 hours after the 
introduction of rapamycin.  Cultures were maintained in an exponential growth 
phase for the duration of the experiment by dilution into the appropriate 
medium where necessary and the culture density measured was adjusted by the 
appropriate dilution factor.  The growth rate was calculated between two and 
12 hours after the introduction of rapamycin, i.e. when the rapamycin-
insensitive growth rate is stable, and expressed relative to the average 
untreated growth rate. 
As seen in Figure 4.5 the growth rate of wild-type cultures treated with 200 
ng/mL rapamycin is approximately 34% of that seen in untreated cultures.  
Treatment with lower concentrations of rapamycin, between 20 and 100 ng/mL, 
did not result in a growth rate different to that of cultures in 200 ng/mL 
rapamycin (Figure 4.5).  It would appear that all high concentrations of 
rapamycin tested result in the same residual rapamycin-insensitive growth rate. 
We conclude that rapamycin treatment of 20 ng/mL and above is sufficient to 
induce the rapamycin-insensitive growth rate of wild-type cultures.  These 
results are consistent with concentrations of rapamycin above 20 ng/mL being 
sufficient for the induction of autophagy.  The consistency of the rapamycin-
insensitive growth rate of wild-type cultures treated with any high concentration 
of the drug suggests that the rapamycin-insensitive growth rate is a true 
phenotype of wild-type cultures treated with high concentrations of rapamycin. 
 Can ego- mutant cells proliferate in the presence of high 4.2.4
concentrations of rapamycin? 
Published data suggests that hallmarks of inactive TORC1 do not appear to differ 
in ego- mutants compared to wild-type cells following short treatments with 
rapamycin (Binda et al. 2009; Dubouloz et al. 2005).  We have identified a new 
phenotype of yeast in response to rapamycin: the rapamycin-insensitive 
proliferation rate.  Is the EGO complex required to maintain this rapamycin-
insensitive proliferation? 
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Figure 4.5 Growth rate of wild-type cultures in various high concentrations 
of rapamycin 
Exponentially growing cultures of wild-type cells at an OD600nm of ~0.025 were 
treated (or not) with rapamycin (20-200 ng/mL) in YPD and incubated at room 
temperature with agitation.  The culture density was measured by Coulter 
counter every two hours from time 0 (the introduction of rapamycin) to 12 hours 
after the addition of rapamycin.  The growth rate was calculated for each 
culture between two and 12 hours after the introduction of rapamycin and 
expressed relative to the untreated wild-type growth rate (0.5 hr-1).  N=4 
independent cultures; error bars denote S.E.M.; * p<0.05 relative to the 
untreated growth rate. 
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Exponentially growing ego1Δ mutant cultures were treated (or not) with 
rapamycin (200 ng/mL) in YPD and incubated at room temperature with 
agitation.  The culture density was measured by Coulter counter at two-hour 
intervals, from time 0 (the addition of rapamycin) to 12 hours after the 
introduction of rapamycin.  Results are expressed as a semi-Log2 plot of the 
relative culture density with time.  The steady state growth rate of untreated 
and rapamycin treated ego1Δ cultures, calculated between two and 12 hours 
after the introduction of rapamycin, is also shown relative to that of untreated 
wild-type cultures from Figure 4.1B which were measured in parallel. 
We found that the growth rate of untreated ego1Δ cultures was not significantly 
different to that of untreated wild-type cultures (p=0.95) (Figure 4.6B), 
suggesting that the EGO complex is not limiting for proliferation under normal 
conditions.  The ego1Δ mutant cultures took approximately two hours to slow 
their growth rate in response to rapamycin after which a slow steady growth 
rate was observed for the remainder of the experiment (Figure 4.6A).  We found 
that the stable growth rate of ego1Δ cultures in the presence of rapamycin was 
significantly slower than that of wild-type cultures growing in the continued 
presence of the drug (p=1.61E-07) (Figure 4.6B).  We conclude that cells lacking 
Ego1p respond differently to the presence of rapamycin than do wild-type cells 
and that Ego1p is required to support residual rapamycin-insensitive 
proliferation. We have therefore identified a novel phenotype in which ego1Δ 
cells behave differently to wild-type cells when treated with rapamycin and one 
that is evident within two hours after the introduction of the drug. 
 Does the proliferation rate of ego1Δ mutants vary with 4.2.5
the concentration of rapamycin, when present at high 
concentrations? 
We have shown that the rapamycin-insensitive growth rate of ego1Δ mutants is 
significantly slower than that of wild-type cultures when treated with 200 ng/mL 
rapamycin.  We have also shown that the rapamycin-insensitive growth rate of 
wild-type cells is independent of the external concentration of rapamycin.  Is 
the same also true for ego1Δ cells? 
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Figure 4.6 Proliferation of ego1Δ cells in the constant presence of 
rapamycin (200 ng/mL) 
A: Exponentially growing ego1Δ cultures in YPD were normalised to an OD600nm of 
~0.025, treated (or not) with rapamycin (200 ng/mL) at time 0 and incubated at 
room temperature with agitation.  The culture density was measured by Coulter 
counter every two hours from time 0 (the introduction of rapamycin) to 12 hours 
after the addition of rapamycin.  The Log2 of culture density between two and 
12 hours was calculated relative to the average culture density at time 0 and 
plotted.  A polynomial line of best fit with an order of 5 is shown for ego1Δ cells 
in the presence of rapamycin.  Error bars denote S.E.M.    
B: The growth rates of ego1Δ cultures were calculated between two and 12 
hours (when the rapamycin-insensitive growth rate was stable) and calculated 
relative to the average growth rate of untreated wild-type cultures (0.5 hr-1) 
from Figure 4.1B (indicated by a dashed border) which were measured in 
parallel.  N=4 independent cultures; error bars denote S.E.M.; * p=1.6x10-7 
relative to rapamycin treated wild-type cultures. 
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Exponentially growing ego1Δ cultures were treated (or not) with rapamycin (20, 
50, 100 or 200 ng/mL) in YPD and incubated at room temperature with agitation.  
The culture density was measured by Coulter counter every two hours from time 
0 (the addition of rapamycin) to 12 hours after the introduction of rapamycin.  
Cultures were maintained in an exponential growth phase for the duration of the 
experiment by dilution into the appropriate medium when necessary and the 
culture density measured was adjusted by the appropriate dilution factor.  The 
growth rate was calculated between two and 12 hours after the introduction of 
rapamycin (when the rapamycin-insensitive growth rate is stable) and expressed 
relative to the average untreated growth rate of wild-type cultures measured in 
4.2.3 (these experiments were carried out in parallel). 
As seen in Figure 4.7 we found that the rapamycin-insensitive growth rate of 
ego1Δ cultures was extremely low for all concentrations of rapamycin tested, 
and did not appear to vary with an increasing concentration of the drug in the 
medium.  The growth rate of rapamycin treated ego1Δ cultures was significantly 
slower than that for the equivalently treated wild-type cultures at each 
concentration of rapamycin tested (p=0.005 for 20 ng/mL, 0.02 for 50 ng/mL, 
0.009 for 100 ng/mL and 0.006 for 200 ng/mL) (Figure 4.7). 
The similarity in growth rate of ego1Δ cultures treated with various 
concentrations of rapamycin, as observed for wild-type cultures, again suggests 
that the lowest concentration of the drug tested is enough to maximally inhibit 
TORC1. 
 Are all subunits of the EGO complex required to support 4.2.6
rapamycin-insensitive proliferation? 
We have identified that cells lacking Ego1p have a significantly slower 
proliferation rate in the presence of rapamycin than that of rapamycin treated 
wild-type cells.  Loss of any one of the four components of the EGO complex 
results in a failure to recover from rapamycin treatment (Figure 3.1).  Are all 
members of the EGO complex also required to support rapamycin-insensitive 
proliferation?  We measured the growth rate of rapamycin treated cultures of 
ego3Δ, gtr1Δ and gtr2Δ mutants to test whether they too show a growth rate 
defect in the presence of the drug. 
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Figure 4.7 Growth rate of wild-type and ego1Δ cultures in various high 
concentrations of rapamycin 
Exponentially growing ego1Δ cultures at an OD600nm of ~0.025 were treated (or 
not) with rapamycin (20-200 ng/mL) in YPD and incubated at room temperature 
with agitation.  The culture density was measured by Coulter counter every two 
hours from time 0 (the introduction of rapamycin) to 12 hours after the addition 
of rapamycin.  The growth rate was calculated for each culture between two 
and 12 hours after the introduction of rapamycin and expressed relative to the 
untreated wild-type growth rate from Figure 4.5 (0.5 hr-1), which were measured 
in parallel.  The growth rate of wild-type cells in various concentrations of 
rapamycin, and carried out in parallel, from Figure 4.5 (indicated by a dashed 
border) is included as a comparison.  N=4 independent cultures; error bars 
denote S.E.M.; * p<0.05 relative to equivalently treated wild-type. 
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Exponentially growing cultures of wild-type, ego3Δ, gtr1Δ and gtr2Δ cells were 
treated (or not) with rapamycin (200 ng/mL) for 12 hours in YPD at room 
temperature with agitation.  The culture density was measured by Coulter 
counter every two hours, from time 0 (the introduction of rapamycin) to 12 
hours after the introduction of the drug.  The growth rate of each culture was 
calculated between two and 12 hours after the introduction of rapamycin.  
Growth rates are expressed relative to the average growth rate of untreated 
wild-type cultures. 
We found that the growth rate of any untreated ego- mutant was no different to 
the growth rate of untreated wild-type cultures (p=0.39 for ego3Δ, 0.56 for 
gtr1Δ and 0.61 for gtr2Δ compared to untreated wild-type) (Figure 4.8).  These 
results are consistent with loss of the EGO complex not limiting growth in 
nutrient rich conditions.  In the presence of rapamycin, we found that loss of 
any one of the EGO complex components resulted in a significantly slower 
growth rate compared to wild-type cultures in the constant presence of 
rapamycin (p=0.045 for ego3Δ, 0.048 for gtr1Δ and 0.03 for gtr2Δ) (Figure 4.8).  
We conclude that a slow rapamycin-insensitive growth rate, compared to that of 
wild-type cultures, is shared with all null mutants of the EGO complex. 
We also measured the growth rate of gtr2Δ cultures treated with 20 ng/mL and 
200 ng/mL rapamycin to determine whether the rapamycin-insensitive growth 
rate in these mutants is independent of the concentration of rapamycin tested, 
as was seen for ego1Δ mutants.  Exponentially growing wild-type, ego1Δ and 
gtr2Δ cultures were treated (or not) with rapamycin (20 or 200 ng/mL) in YPD 
and incubated at 28˚C with agitation for six hours.  The culture density was 
measured by spectrometry (at OD600nm) at three and six hours after the 
introduction of rapamycin; the growth rate was calculated between these time 
points and expressed relative to the average growth rate of untreated wild-type 
cultures. 
As seen in Figure 4.9 we found that the rapamycin-insensitive growth rate of 
gtr2Δ cultures was the same at both concentrations of rapamycin tested (20 and 
200 ng/mL) (p=0.23). 
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Figure 4.8 The growth rate of ego- mutants in the presence of a high 
concentration rapamycin 
Exponentially growing WT, ego3Δ, gtr1Δ and gtr2Δ cultures were normalised to 
an OD600nm of ~0.02 and treated (or not) with rapamycin (200 ng/mL) in YPD and 
incubated at room temperature.  The culture density was measured every two 
hours from time 0 (the introduction of rapamycin) during the course of 12 hours 
by Coulter counter.  The growth rates were calculated between two and 12 
hours after the introduction of rapamycin and expressed relative to the average 
untreated wild-type (0.3 hr-1).  N=3 independent cultures for WT and 4 for all 
remaining cultures; error bars denote S.E.M.; * p<0.05 relative to rapamycin 
treated wild-type cells. 
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Figure 4.9 Growth rate of wild-type, ego1Δ and gtr2Δ cultures in 20 and 
200 ng/mL rapamycin 
Exponentially growing wild-type, ego1Δ and gtr2Δ cultures were normalised to 
an OD600nm of ~0.05 for untreated cultures or ~0.1 for treated cultures.  
Normalised cultures were treated (or not) with rapamycin (20 or 200 ng/mL) in 
YPD and incubated at 28˚C with agitation for six hours.  The OD600nm was 
measured at three and six hours after the introduction of rapamycin and the 
growth rate calculated.  Growth rates are expressed relative to the average 
growth rate of untreated wild-type cultures (0.6 hr-1).  N=4 independent cultures 
for ego1Δ, 3 for wild-type and gtr2Δ; error bars denote S.E.M.; * p<0.05 relative 
to equivalently treated wild-type cultures. 
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The similarity in the reduced rapamycin-insensitive growth rates of ego1Δ and 
gtr2Δ cultures (compared to that of wild-type cultures) in concentrations of 
rapamycin above 20 ng/mL suggests that the reduced rapamycin-insensitive 
growth rate of ego1Δ and gtr2Δ cultures in any high concentration of rapamycin 
is likely to apply for all ego- null mutants. 
 Are Tor1p and Tco89p required for rapamycin-insensitive 4.2.7
proliferation? 
We have found that the EGO complex is important for full rapamycin-insensitive 
proliferation.  The EGO complex is a known activator of TORC1 and TORC1 
activity is partly compromised in cells lacking the EGO complex (Binda et al. 
2009; Dubouloz et al. 2005).  Could rapamycin only partly inhibit yeast TORC1?  
It is now known that rapamycin is an incomplete inhibitor of mammalian 
mTORC1 (Feldman et al. 2009; Thoreen et al. 2009).  What if rapamycin-
insensitive TORC1 activity drives the rapamycin-insensitive proliferation of yeast 
cells?  If this is the case we would predict that any condition that compromises 
TORC1 activity, either genetically or chemically, would also result in a slow 
rapamycin-insensitive growth rate phenotype.  TORC1 contains two specific and 
non-essential subunits, Tor1p and Tco89p; are these TORC1 specific proteins 
required for rapamycin-insensitive proliferation? 
Exponentially growing wild-type, tor1Δ, and tco89Δ cultures were treated (or 
not) with rapamycin (200 ng/mL) for 12 hours in YPD at room temperature with 
agitation.  The culture density was measured by Coulter counting every two 
hours and the growth rate determined between two and 12 hours after the 
introduction of the drug.  Growth rates were calculated relative to the average 
untreated wild-type growth rate. 
As seen in Figure 4.10 we found no significant difference in the growth rate of 
untreated cultures for either tor1Δ or tco89Δ mutants compared to that of wild-
type cultures (p=0.41 for tor1Δ and 0.69 for tco89Δ).  When treated with 
rapamycin we observed a statistically significant reduction in the proliferation 
rate of cells lacking either Tor1p or Tco89p compared to rapamycin treated 
wild-type cells (p=0.04 and 0.02 respectfully) (Figure 4.10).   
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Figure 4.10 Proliferation of tor1Δ and tco89Δ cells in the constant presence 
of rapamycin (200 ng/mL) 
Exponentially growing tor1Δ and tco89Δ cultures were normalised to an OD600nm 
of ~0.02 and treated (or not) with rapamycin (200 ng/mL) in YPD at room 
temperature.  A Coulter counter was used to measure the culture density every 
two hours and the growth rate was calculated between two and 12 hours after 
the introduction of rapamycin.  Growth rates were calculated relative to the 
average untreated wild-type (0.3 hr-1) from Figure 4.8 (indicated by a dashed 
border), which were measured in parallel.  N=3 independent cultures for wild-
type and 4 for all remaining cultures; error bars denote S.E.M.; * p<0.05 relative 
to the rapamycin-insensitive growth rate of wild-type cultures. 
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These results suggest that in the presence of rapamycin Tor1p and Tco89p are 
required to maintain residual proliferation.  These results are consistent with 
rapamycin failing to fully inactivate TORC1 and residual TORC1 activity driving 
at least part of the residual proliferation. 
We also measured the growth rate of tco89Δ cultures treated with 20 and 200 
ng/mL rapamycin to determine whether the rapamycin-insensitive growth rate is 
independent of the high concentration of rapamycin used.  Exponentially 
growing tco89Δ cultures were treated (or not) with rapamycin (20 and 200 
ng/mL) in YPD at 28˚C with agitation.  The culture density was measured by 
spectrometry at OD600nm at three and six hours after the introduction of 
rapamycin and the growth rate was determined between these time points.  The 
growth rate was calculated relative to the growth rate of untreated wild-type 
cultures from Figure 4.9 which were measured in parallel.  The growth rate of 
untreated and rapamycin treated (20 and 200 ng/mL) ego1Δ mutants from Figure 
4.9 were also measured in parallel and are included as controls.   
We found that the rapamycin-insensitive growth rate of tco89Δ mutants was not 
significantly different (p=0.60) when tco89Δ cultures were treated with either 20 
or 200 ng/mL rapamycin (Figure 4.11).  These results show that for tco89Δ 
mutants, as for ego- mutants, the rapamycin-insensitive growth rate is 
consistent regardless of the concentration of rapamycin tested. 
 Growth rate of kog1ts in the presence of a high 4.2.8
concentration of rapamycin 
Kog1p is the only specific and essential subunit of TORC1 (Loewith et al. 2002).  
Due to the essential nature of KOG1 we used a plasmid borne temperature 
sensitive allele of kog1ts (Nakashima et al. 2008) to reduce basal TORC1 activity 
at the non-permissive temperature.  Heterozygous diploid kog1Δ/KOG1 cells 
were transformed with pkog1ts, sporulated and dissected on YPD plates to 
produce kog1Δ haploid cells containing pkog1ts (termed kog1ts).  The 
temperature sensitive kog1ts allele was introduced into a kog1Δ null mutant to 
ensure all TORC1 complexes contained the mutated Kog1p protein. 
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Figure 4.11 The growth rate of tco89Δ cells in 20 and 200 ng/mL rapamycin 
Exponentially growing tco89Δ mutant cultures were normalised to an OD600nm of 
~0.05 for untreated cultures or ~0.1 for treated cultures.  Normalised cultures 
were treated (or not) with rapamycin (20 or 200 ng/mL) in YPD and incubated at 
28˚C with agitation for six hours.  The OD600nm was measured at three and six 
hours after the introduction of rapamycin and the growth rate calculated.  
Growth rates are expressed relative to the average untreated wild-type (0.6 hr-1) 
from Figure 4.9 which were measured in parallel.  The untreated and rapamycin-
induced growth rates of wild-type and ego1Δ from Figure 4.9 are included as a 
comparison and were measured in parallel.  Data already shown in Figure 4.9 is 
indicated by a dashed border.  N=3 independent cultures for wild-type and 4 for 
ego1Δ and tco89Δ; error bars denote S.E.M.; * p<0.05 relative to equivalently 
treated wild-type culture.   
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Wild-type and kog1ts cultures were grown in YPD at both the permissive (22˚C) 
and non-permissive (37˚C) temperature with agitation for 24 hours.  Cultures 
were maintained in an exponential growth phase by dilution, as required, into 
fresh YPD.  Exponentially growing cultures were treated (or not) with rapamycin 
(200 ng/mL) in YPD and incubated at the respective temperature for a further 12 
hours.  The culture density was measured by Coulter counter and the growth 
rate of each culture calculated between two and 12 hours after the addition of 
rapamycin.  Growth rates were calculated relative to the average untreated 
wild-type growth rate of cultures at 22˚C. 
As seen in Figure 4.12 there was no significant difference (p=0.11) between the 
growth rate of untreated wild-type and kog1ts cultures at the permissive 
temperature.  These results suggest that the temperature-sensitive kog1ts allele 
is functional at the permissive temperature.  We found that at the non-
permissive temperature there was a significant difference (p=0.02) in the growth 
rate of untreated kog1ts cultures compared to untreated wild-type cultures 
suggesting that Kog1p activity, and by inference TORC1 activity, is lower in 
kog1ts cells at 37˚C (Figure 4.12). 
At both the permissive and non-permissive temperature we observed a 
significantly slower growth rate for kog1ts cultures treated with rapamycin 
compared to rapamycin treated wild-type cultures (p=0.02 at 22˚C and 0.004 at 
37˚C) (Figure 4.12).  These results suggest that Kog1p, and thus TORC1 activity, 
is required to maintain proliferation in the presence of rapamycin. 
We also determined the growth rate of kog1ts cultures in the presence of 20 
ng/mL and 200 ng/mL rapamycin.  Exponentially growing kog1ts cultures were 
treated (or not) with rapamycin (20 or 200 ng/mL) in YPD and incubated at 28˚C 
with agitation.  The OD600nm of each culture was measured at three and six hours 
following the introduction of rapamycin and the growth rate calculated.  The 
growth rates of untreated and rapamycin treated wild-type cultures, shown in 
Figure 4.9, were measured in parallel and all growth rates were calculated 
relative to that of the average untreated wild-type cultures.  A modest but 
significant (p=0.02) growth defect was observed for untreated kog1ts cultures 
incubated at 28˚C compared to that of untreated wild-type cultures (Figure 
4.13).   
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Figure 4.12 Growth rate of kog1ts in the constant presence of rapamycin 
(200 ng/mL) 
Wild-type and kog1Δ-pkog1ts (kog1ts) cultures were grown at both the permissive 
(22˚C) and non-permissive (37˚C) temperature for 24 hours in YPD; cultures 
were diluted with fresh media to maintain an exponential growth phase when 
necessary.  Following a 24 hour pre-treatment at the respective temperature, 
cultures were normalised to an OD600nm of ~0.025, treated (or not) with 
rapamycin (200 ng/mL) in YPD and maintained at their respective temperatures 
with agitation.  The culture density was measured by Coulter counter every two 
hours from time 0 to 12 hours after the addition of rapamycin.  The growth rate 
was calculated between two and 12 hours following the introduction of 
rapamycin and calculated relative to the average untreated wild-type growth 
rate at 22°C (0.39 hr-1).  N=3 independent cultures; error bars denote S.E.M.; * 
p<0.05 
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Figure 4.13 Growth rate of kog1ts in 20 and 200 ng/mL rapamycin 
Exponentially growing wild-type, ego1Δ and kog1ts mutant cultures were 
normalised to an OD600nm of ~0.05 for untreated cultures or ~0.1 for treated 
cultures.  Normalised cultures were treated (or not) with rapamycin (20 or 200 
ng/mL) for six hours in YPD and incubated at 28˚C with agitation.  The OD600nm 
was measured at three and six hours after the introduction of rapamycin and the 
growth rate calculated.  Growth rates are expressed relative to the average 
untreated wild-type (0.6 hr-1).  Note: The untreated and rapamycin-insensitive 
growth rates of wild-type and ego1Δ have previously been shown in Figure 4.9, 
as indicated by dashed borders.  N=3 independent cultures for wild-type and 
kog1ts and 4 for ego1Δ; error bars denote S.E.M.; * p<0.05 relative to 
equivalently treated wild-type cultures.   
121 
 
 
The growth rates of kog1ts cultures in the presence of either 20 ng/mL or 200 
ng/mL rapamycin were not significantly different from each other (p=0.60) 
(Figure 4.13).  Consistent will all strains tested so far, we find that the 
rapamycin-insensitive growth rate of kog1ts is the same regardless of the 
concentration of rapamycin tested. 
 Can yeast cells proliferate in the complete absence of 4.2.9
Kog1p? 
It has been proposed that TORC1 activity is absolutely required for yeast to 
proliferate.  A study carried out by Loewith et al. (2002) demonstrated that cells 
expressing KOG1 under a galactose promoter slowed proliferation following the 
addition of glucose to the medium (within 12-15 hours after initiating the GAL 
shut-off).  If TORC1 activity is absolutely required for yeast proliferation it 
would provide strong evidence that rapamycin is not a complete inhibitor of 
TORC1.  To determine whether cell proliferation is absolutely dependent on 
TORC1 activity we assayed, by microscopy, the ability of kog1∆ null mutant cells 
to proliferate following dissection from heterozygous diploids. 
Heterozygous kog1Δ/KOG1 diploids were sporulated and the resulting tetrads 
dissected onto both plain YPD plates and YPD plates containing a high 
concentration of rapamycin (200 ng/mL).  The ability of each spore to 
proliferate was monitored by microscopy over three days.  One day after 
dissection, we found that 50% of the spores had formed small colonies on the 
plain YPD plate (Table 4.1).  These colonies were subsequently confirmed as 
being wild-type cells by their sensitivity to G418 (data not shown).  We found 
that 10% of dissected cells (all kog1Δ by inference) had undergone 1-3 doublings 
within the first day but did not proliferate further after that (Table 4.1).  The 
remaining 40% of dissected spores (all kog1Δ by inference) failed to divide even 
once during the three days monitored (Table 4.1).  These results suggest that 
Kog1p, and thus the TOR1 complex, may be absolutely required for proliferation 
of yeast cells. 
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Days 
after 
dissection 
YPD YPD & rapamycin (200 ng/mL) 
0 
doublings 
1-3 
doublings 
colony 
formation 
0 
doublings 
1-3 
doublings 
colony 
formation 
1 
40% 
(16/40) 
10% 
(4/40) 
50% 
(20/40) 
53% 
(19/36) 
25% 
(9/36) 
22% 
(8/36) 
2 
40% 
(16/40) 
10% 
(4/40) 
50% 
(20/40) 
50% 
(18/36) 
3%  
(1/36) 
47% 
(17/36) 
3 
40% 
(16/40) 
10% 
(4/40) 
50% 
(20/40) 
50% 
(18/36) 
0%  
(0/36) 
50% 
(18/36) 
       
Table 4.1 Germination and proliferation of kog1Δ/WT diploids in the 
absence and presence of rapamycin (200 ng/mL) 
Heterozygous kog1Δ/KOG1 diploid cells were inoculated into liquid sporulation 
media and incubated at room temperature with agitation.  Digested tetrads 
were dissected onto either plain YPD plates or YPD plates containing rapamycin 
(200 ng/mL) which were incubated at 30˚C.  The ability of cells to divide was 
observed by microscopy every day for three days and the number of doublings 
scored.  The percentage of cells per score is recorded, with the fraction of the 
total spores recorded underneath. 
123 
 
 
We found that 20% of kog1Δ mutant spores were able to divide a few times on 
YPD within the first day following dissection.  To test whether this short, limited 
burst of proliferation was a result of inherited Kog1p, and thus potentially active 
TORC1, via meiosis we also dissected kog1Δ/KOG1 tetrads in the presence of 
rapamycin (200 ng/mL) to reduce any potential remaining TORC1 activity.  Three 
days after dissection, we found that 50% of spores were able to produce 
colonies, albeit more slowly than those dissected onto a plain YPD plate (these 
colonies were all subsequently confirmed as wild-type cells by their inability to 
grow in the presence of G418 (data not shown)).  The remaining 50% of spores 
(all kog1Δ by inference) completely failed to proliferate during the three days 
monitored (Table 4.1).  It is therefore likely that any initial proliferation of 
kog1Δ cells on the plain YPD plate was due to inherited Kog1p protein (and thus 
active TORC1) following meiosis of the heterozygous diploid. 
We conclude that Kog1p, and thus TORC1 activity, is absolutely essential for 
yeast to proliferate.  Furthermore, we find that all 18 independent wild-type 
spores tested were slowly able to form colonies when germinated in the 
presence of a high concentration of rapamycin.  This observation further 
supports our conclusion that rapamycin is not a complete inhibitor of yeast 
TORC1 activity. 
 Rapamycin-insensitive TORC1 activity is inhibited by 4.2.10
caffeine 
It appears from our analysis of mutants with reduced TORC1 activity that the 
rapamycin-insensitive growth rate of yeast cultures is a result of residual TORC1 
activity.  Caffeine has been shown to preferentially inhibit TORC1 in yeast in a 
manner different to that of rapamycin (Reinke et al. 2006; Wanke et al. 2008).  
We therefore utilised a sub-inhibitory concentration of caffeine to reduce TORC1 
activity in wild-type cells and observed the consequence on the proliferation 
rate in the presence and absence of rapamycin. 
Exponentially growing cultures of wild-type and ego1∆ cells were treated (or 
not) with rapamycin (200 ng/mL), caffeine (3 mM) or both in YPD and incubated 
at room temperature with agitation.  The culture density was measured by 
Coulter counter every two hours up to 12 hours after the introduction of the 
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drugs.  The growth rate of each culture was calculated between two and 12 
hours after the introduction of the drugs and expressed relative to the average 
growth rate of untreated wild-type cultures. 
As seen in Figure 4.14 the growth rate of wild-type cultures treated with a sub-
inhibitory concentration of caffeine was no different to that of untreated 
cultures (p=0.70).  We found that treatment with a high concentration of 
rapamycin alone resulted in a reduced growth rate in wild-type cells consistent 
with our previous results (Figure 4.1B).  When treated with both a sub-inhibitory 
concentration of caffeine and a high concentration of rapamycin we observed a 
significantly slower growth rate of wild-type cultures compared to that of 
cultures treated with rapamycin alone (p=4x10-6) (Figure 4.14).  These results 
further support our view that the rapamycin-insensitive growth rate is 
dependent on TORC1 activity and that rapamycin does not fully inhibit TORC1. 
The growth rate of cultures of ego1∆ mutants in the presence of rapamycin, 
caffeine or both was also measured.  We found that the growth rate of ego1∆ 
cultures in the presence of a sub-inhibitory concentration of caffeine alone was 
significantly slower than that of untreated ego1∆ cultures (p=0.02) and was not 
significantly different to the growth rate of wild-type cultures treated with 
rapamycin (p=0.50) (Figure 4.14).  The treatment of ego1∆ cultures with 
combined caffeine and rapamycin almost completely abolished the rapamycin-
insensitive growth rate of ego1∆ cultures (p=0.01 compared to rapamycin 
treated ego1∆ cultures).  These results are consistent with our model that the 
rapamycin-insensitive growth rate is at least partially or wholly dependent on 
TORC1 activity.  These results also suggest that the slow rapamycin-insensitive 
growth rate of ego1∆ cultures is a result of lower basal TORC1 activity, as 
demonstrated by their hypersensitivity to caffeine. 
Overall, we have found that yeast cells maintain slow proliferation in the 
presence of high concentrations of rapamycin.  Loss of the EGO complex results 
in a slow rapamycin-insensitive proliferation rate, which is likely due to reduced 
basal TORC1 activity in these cells.  The ability of cells to maintain proliferation 
in the presence of rapamycin suggests that the drug is not a complete inhibitor 
of TORC1 activity; cells lacking TORC1 activity (as assayed in kog1∆ null 
mutants) are unable to proliferate.   
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Figure 4.14 Growth rate of wild-type and ego1∆ cultures treated with a high 
concentration of rapamycin and sub-inhibitory concentration of caffeine 
Exponentially growing wild-type and ego1Δ cultures, normalised to an OD600nm of 
~0.025, were untreated or treated with rapamycin (200 ng/mL), caffeine (3 mM) 
or both in YPD.  All cultures were incubated at room temperature with agitation 
for 12 hours.  The culture density was measured by Coulter counter every two 
hours from time 0 (the addition of the drugs).  The growth rate was calculated 
between two and 12 hours after the introduction of the drugs and calculated 
relative to the average growth rate of untreated wild-type cultures (0.4 hr-1).  
N=4 independent cultures; error bars denote S.E.M.; * p<0.05. 
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For the remainder of this chapter, we will explore the potential origin of the 
slow rapamycin-insensitive growth rate of ego- mutants in more detail. 
 Ego1p is required for rapamycin-insensitive translation 4.2.11
What could cause the slow rapamycin-insensitive growth rate in ego- mutants?  
Results published by Binda et al. (2009) and Dubouloz et al. (2005) have found 
that rapamycin appears to induce most TORC1-related physiological changes 
normally in mutants lacking the EGO complex.  A key downstream function of 
TORC1 activity in supporting proliferation is the promotion and maintenance of 
protein synthesis (Barbet et al. 1996).  It is possible that the reduced rapamycin-
insensitive proliferation rate of ego1∆ mutants is a consequence of reduced 
translation rates within these cells.  To test this possibility we measured the 
translation rate in wild-type and ego1∆ cells treated (or not) with rapamycin. 
Exponentially growing wild-type and ego1Δ cultures were untreated, treated 
with rapamycin (200 ng/mL) or cycloheximide (25 μg/mL) in YPD at room 
temperature with agitation for six hours.  Treatment of yeast with 
cycloheximide inhibits translation initiation (Obrig & Culp 1971) and therefore 
was included as a negative control for translation rates.  After six hours, cultures 
were normalised for OD600nm, pelleted and resuspended in SD-methionine which 
was supplemented with a mix of 35S-labelled methionine and 35S-labelled 
cysteine (0.4 MBq) (hereafter referred to as radiolabelled amino acids).  Cultures 
were incubated in the presence of the radiolabelled amino acid mix at room 
temperature with agitation for 10 minutes.  Cells were subsequently chemically 
lysed on ice, TCA was added to precipitate peptides and peptide samples washed 
three times with ice-cold acetone.  Radiation retained within precipitated 
peptides was measured by scintillation counter. 
We found that the rate of incorporation of radiolabelled amino acids into 
peptides from untreated wild-type and untreated ego1Δ cells was not 
significantly different (p=0.61) (Figure 4.15) suggesting that translation rates are 
similar in these untreated cells.  Treatment with cycloheximide, which abolishes 
translation in yeast, was included as a negative control.  Treatment of both 
wild-type and ego1Δ mutants with cycloheximide resulted in a barely detectable 
level of precipitated radiolabel (Figure 4.15).   
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Figure 4.15 Translation rates of rapamycin and cycloheximide treated wild-
type and ego1Δ mutant cells 
Exponentially growing wild-type and ego1Δ cultures were untreated (at an 
OD600nm of ~0.05), treated with rapamycin (200 ng/mL) (at an OD600nm of ~0.2) or 
cycloheximide (25 μg/mL) (at an OD600nm of ~0.4) in YPD at room temperature 
with agitation for six hours.  After the six hour treatment period cultures were 
normalised to an OD600nm of ~0.4 and resuspended in SD-methionine containing a 
mix of 35S-labelled methionine and 35S-labelled cysteine (0.4 MBq) and incubated 
for 10 min at room temperature with agitation.  Cells were chemically lysed on 
ice and peptides precipitated using TCA on ice.  Retained radiation in TCA 
precipitable material was measured by Scintillation counter and calculated 
relative to that of the average untreated wild-type (143,545 CPM).  Control 
readings of media with radiation ranged from 249 to 600 CPM.  N=6, three 
technical repeats of three independent cultures; error bars denote S.E.M.; * 
p<0.05 
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Treatment of wild-type cells with rapamycin resulted in a decrease in the 
detection of peptide-associated radiolabelled amino acids (Figure 4.15).  The 
reduction of 35S-radiolabel detection from wild-type cells suggests that the 
translation rate is decreased in rapamycin treated cells, consistent with reduced 
TORC1 activity.  We found that rapamycin treated ego1Δ cells had a significantly 
lower incorporation of radiolabelled amino acids into peptides compared to that 
of rapamycin treated wild-type cells (p=0.04).  Indeed, the incorporation of 
radiolabel into peptides from rapamycin treated ego1Δ cells was not significantly 
different to that of cycloheximide treated ego1Δ cells (p=0.12) (Figure 4.15).  
These results suggest that the translation rate of rapamycin treated ego1Δ 
mutants is reduced to basal levels in the presence of the drug.  It appears that 
residual TORC1 activity in rapamycin treated cells is required to maintain 
translation that in turn is likely to support rapamycin-insensitive proliferation. 
 Growth rate of caf20∆ and eap1∆ in the presence of a 4.2.12
high concentration of rapamycin 
Rapamycin is an incomplete inhibitor of mTORC1 (Feldman et al. 2009; Thoreen 
et al. 2009), our results suggest that yeast TORC1 is not completely inhibited by 
rapamycin either.  The regulation of the translation inhibitor 4E-BP1 (eIF4E 
Binding Protein) is one known rapamycin insensitive function of mTORC1 
(Feldman et al. 2009; Thoreen et al. 2009).  Caf20p and Eap1p are thought to 
perform the function of 4E-BP1 in yeast, which do not appear to have direct 
homologs of 4E-BP1 (Altmann et al. 1997; Cosentino et al. 2000; Thomas & Hall 
1997).  We measured the rapamycin-insensitive growth rate of null mutants 
lacking either Eap1p or Caf20p to test whether loss of either of these two 
proteins affects the rapamycin-insensitive growth rate. 
Exponentially growing cultures of wild-type, ego1Δ, caf20∆ and eap1∆ cells were 
treated (or not) with rapamycin (200 ng/mL) in YPD and incubated at 28˚C with 
agitation.  At three and six hours following the introduction of rapamycin the 
density of each culture was measured by spectrometry at OD600nm and the growth 
rate determined between these two time points.  The growth rate of all cultures 
were calculated relative to the average untreated growth rate of wild-type 
cultures.   
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As seen in Figure 4.16 we found no significant difference between the growth 
rates of untreated ego1Δ, caf20∆ or eap1∆ mutants compared to that of 
untreated wild-type cultures (p=0.55 for ego1Δ, 0.054 for caf20∆ and 0.16 for 
eap1∆).  We found that the growth rate of caf20∆ mutants treated with 
rapamycin was not significantly different (p=0.43) to that of wild-type cultures 
(Figure 4.16).  However, we found that the growth rate of rapamycin treated 
eap1∆ was significantly slower (p=0.008) compared to that of wild-type cultures.  
The slow rapamycin-insensitive growth rate of eap1∆ cultures was not 
significantly different to that of rapamycin treated ego1∆ cultures (p=0.15) 
(Figure 4.16).  These results suggest that Eap1p is required to maintain the wild-
type rapamycin-insensitive growth rate.  These results are also consistent with 
Eap1p supporting a rapamycin-insensitive function.  It is possible that Eap1p 
functions downstream of TORC1 via a currently unknown mechanism that is 
insensitive to rapamycin treatment. 
 Do wild-type cultures of various genetic backgrounds 4.2.13
have a rapamycin-insensitive growth rate? 
So far all the yeast strains we have examined have been in the BY4743 genetic 
background.  However, it is possible that the discovery of a rapamycin-
insensitive growth rate is a phenomenon of the BY4743 genetic background.  We 
measured the rapamycin-insensitive growth rate of wild-type strains in two 
alternative genetic backgrounds, W303 and EG123. 
Exponentially growing cultures of wild-type (BY4743, W303 or EG123 genetic 
background) and ego1∆ (BY4743 genetic background) cells were treated (or not) 
with rapamycin (200 ng/mL) in YPD at 28˚C with agitation.  The culture density 
was measured by spectrometry at OD600nm at three and six hours after the 
introduction of rapamycin and the growth rate calculated.   
As seen in Figure 4.17 we found that wild-type cultures in both the W303 and 
EG123 genetic backgrounds were able to maintain some proliferation in the 
presence of rapamycin.  It would appear that the W303 wild-type cultures were 
hypersensitive to rapamycin and had a significantly slower rapamycin-insensitive 
growth rate in the presence of 10 ng/mL of the drug compared to that of 
equivalently treated BY4743 wild-type cultures (p=0.002) (Figure 4.17). 
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Figure 4.16 The rapamycin-insensitive growth rates of caf20∆ and eap1∆ 
cultures in the presence of rapamycin (200 ng/mL) 
Exponentially growing cultures of wild-type, ego1∆, caf20∆ and eap1∆ cells were 
normalised to an OD600nm of ~0.05 and untreated or normalised to an OD600nm of 
~0.1 and treated with rapamycin (200 ng/ml) in YPD and incubated at 28˚C with 
agitation.  The culture density was measured at three and six hours after the 
introduction of rapamycin by spectrometry at OD600nm and the growth rate 
calculated between these time points.  The growth rate of each culture was 
calculated relative to the average untreated wild-type growth rate (0.6 hr-1).  
N=10 independent cultures for wild-type cultures, 8 for ego1∆ cultures and 3 for 
caf20∆ and eap1∆ cultures. Error bars denote S.E.M.; * p<0.05 compared to 
equivalently treated wild-type culture. 
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Figure 4.17 The rapamycin-insensitive growth rate of wild-type strains of 
various genetic backgrounds 
Exponentially growing cultures of wild-type (BY4743, W303 or EG123 genetic 
backgrounds) and ego1∆ (BY4743 background) cells were normalised to an 
OD600nm of ~0.1.  Normalised cultures were treated (or not) with rapamycin (10, 
50, 100 or 200 ng/mL) and incubated at 28˚C with agitation for six hours.  The 
culture density was measured by spectrometer at OD600nm three and six hours 
after the introduction of rapamycin and the growth rate calculated between 
these time points.  N=3 independent cultures.  Error bars denote S.E.M.; * 
p<0.05 relative to the equivalently treated wild-type BY4743 strain. 
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However at concentrations above 50 ng/mL rapamycin, the rapamycin-
insensitive growth rate of W303 wild-type cultures was not significantly different 
to those of the BY4743 wild-type cultures (p=0.06 in 50 ng/mL, 0.15 in 100 
ng/mL and 0.10 in 200 ng/mL rapamycin) (Figure 4.17).  We found that the 
rapamycin-insensitive growth rate of the EG123 wild-type cultures was not 
significantly different to that of BY4743 wild-type cultures in the presence of 10 
or 50 ng/mL rapamycin (p=0.68 in 10 ng/mL and 0.1 in 50 ng/mL rapamycin) 
(Figure 4.17).  However, in concentrations of rapamycin greater than 50 ng/mL, 
the rapamycin-insensitive growth rate of EG123 wild-type cultures appears 
slower than those of equivalently treated BY4743 wild-type cultures (p=0.01 in 
100 ng/mL and 0.02 in 200 ng/mL rapamycin) (Figure 4.17).  We therefore 
conclude that all wild-type strains tested are able to maintain proliferation in 
the constant presence of high concentrations of rapamycin, albeit at a slower 
rate compared to untreated cultures.  It would appear that sensitivity to low 
concentrations of rapamycin is different with regards to the strain background.  
The growth rate of cultures in the presence of high concentrations of rapamycin 
(in this case concentrations of 50 ng/mL and above) also appears to be slower in 
the EG123 wild-type cultures compared to those of the BY4743 or W303 wild-
type cultures. 
 Conclusion 4.3
In this chapter, we have identified a novel phenotype of yeast in response to 
rapamycin; the rapamycin-insensitive proliferation.  The ability of yeast to 
maintain proliferation in the constant presence of rapamycin suggests that 
rapamycin is not a complete inhibitor of TORC1 in yeast.  The use of alternative 
mTORC1 inhibitors (which, unfortunately, are not effective in yeast (Liu et al. 
2012)) has shown that mTORC1 is not completely inhibited by rapamycin 
treatment; rapamycin-treated mammalian cells exhibit a milder phenotype than 
those treated with alternative inhibitors (Feldman et al. 2009; Thoreen et al. 
2009).  The results presented here suggest that yeast TORC1 more closely 
resembles mTORC1 than previously thought.   
We find that the rapamycin-insensitive growth rate of yeast cultures is 
observable when growth rates are calculated from the culture density, as 
measured by Coulter counter or as measured by optical spectrometry.  We also 
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find that a slow rapamycin-insensitive growth rate is observed when cultures are 
incubated at room temperature, 28˚C or 37˚C.  The observation of a rapamycin-
insensitive growth rate is not specific to the BY4743 genetic background; we 
have also observed residual growth of wild-type cultures in the W303 and EG123 
strain backgrounds in the presence of high concentrations of rapamycin. 
To confirm that TORC1 is not fully inactivated in rapamycin-treated yeast cells 
we established the phenotype of cells that lacked the essential TORC1 
component Kog1p.  We found that freshly dissected kog1∆ mutant cells failed to 
proliferate one day after dissection.  A short burst of proliferation was seen for 
20% of kog1∆ mutants within the first day; however, this was rapamycin 
inhibitable and is thus likely to be due to intact TORC1 being inherited by 
meiosis and sustaining limited proliferation.  No proliferation was observed for 
kog1∆ mutants that were dissected onto plates containing a high concentration 
of rapamycin.  The phenotype of cells lacking Kog1p demonstrates that yeast 
cells are unable to proliferate in the complete absence of Kog1p and by 
inference, TORC1 activity.  That we see proliferation occurring in both wild-type 
and ego- mutants in the presence of rapamycin strongly suggests that some 
residual TORC1 activity remains following treatment with high concentrations of 
the drug. 
We find that there is a significant difference in the rapamycin-insensitive growth 
rates of wild-type and ego- mutant cultures; ego- mutants proliferate much 
slower in the presence of rapamycin.  This slow rapamycin-insensitive growth 
rate of ego- mutants appears to be the first phenotype identified in which ego- 
mutants differ to wild-type cultures in response to short rapamycin treatment 
times – a clear growth rate defect can be observed within six hours after the 
addition of rapamycin.   
Reduction of TORC1 activity by means of either genetic or chemical 
manipulation has shown that the ability of yeast to proliferate in the presence of 
rapamycin does indeed require TORC1 activity.  The measurement of rapamycin-
insensitive growth rate in tor1∆, tco89∆ and kog1ts mutants or a combined 
rapamycin/caffeine treatment of wild-type cultures has shown that reduction of 
TORC1 activity in addition to rapamycin treatment results in a slower rapamycin-
insensitive growth rate.  The slow rapamycin-insensitive growth rate of ego- 
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mutants is therefore likely to be due to low TORC1 activity in these cells, 
perhaps as a result of loss of signalling to TORC1 by the EGO complex. 
TORC1 is a regulator of translation initiation (Barbet et al. 1996; Urban et al. 
2007), we therefore measured the translation rate of wild-type and ego1∆ 
mutants treated with rapamycin as a measure of TORC1 activity.  We found that 
translation rates were indeed lower in ego1∆ rapamycin treated cells compared 
to that of rapamycin treated wild-type cells.  These results suggest that TORC1 
activity is more severely reduced in ego- mutants in the presence of rapamycin 
compared to that of wild-type cells.  It would be worth considering in the future 
to perform a time-course assay to monitor how long after the addition of 
rapamycin translation is inhibited and at what time after the addition of 
rapamycin the ego1∆ mutants have a slower translation rate compared to that of 
wild-type cells.  It is possible that the slow translation rate of ego1∆ mutants 
treated with rapamycin is influencing the proliferation rate of these mutants.  
We find that there is an approximate 5.9 (+/- 3.5, SD) fold decrease in the 
translation rate of rapamycin treated ego1∆ cells compared to that of wild-type 
cells.  We also find that the slow rapamycin-insensitive growth rate of ego1∆ 
cultures is approximately 4.9 (+/- 1.0, SD) times slower than that of wild-type 
cultures.  Indeed, in the previous chapter (3.2.3), we found that ego1∆ cells 
treated with rapamycin for 24 hours resulted in a 4.7 (+/- 2.1, SD) fold decrease 
in amino acid uptake compared to that of ego1∆ cells treated with rapamycin for 
two hours.  The similarity in the fold decrease in these three variables in ego1∆ 
cells suggests that these processes could be a result of a common denominator, 
one possibility being low TORC1 activity. 
We propose that rapamycin treatment inactivates TORC1 activity which quickly 
results in a decrease in the translation rate.  This decreased translation rate 
then has an almost immediate effect (within two hours) on slowing the 
proliferation rate.  The defect in amino acid uptake of ego1∆ cells responds 
more slowly to reduced TORC1 activity as a result of rapamycin treatment, but 
eventually reaches a similar fold decrease as that seen for the translation rate 
and proliferation rate.  The response of amino acid uptake to low TORC1 activity 
is not necessarily a result of the continued presence of rapamycin in the 
external media, we found that the uptake of amino acids into ego1∆ cells 24 
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hours after a “recovery period” was similar to that of cells following a 24 hour 
exposure to the drug.  This observation suggests that TORC1 activity is 
maintained at a lower activity state in ego1∆ cells during a “recovery period” 
either as a result of persistence of the drug or an inability to reactivate TORC1.  
Either of these possibilities could impact the ability of ego1∆ cultures to recover 
from rapamycin treatment. 
It is possible that the ability to proliferate in the presence of rapamycin impacts 
the ability of yeast cells to recover from rapamycin treatment.  Our data imply 
that TORC1 activity is excessively reduced in ego- mutants, possibly with an  
approximately 5-fold decrease, compared to that of wild-type cells treated with 
the drug.  The identification of a rapamycin-insensitive growth defect in ego- 
mutants and that the slow growth rate is potentially a result of decreased TORC1 
activity could be used to further explore the inability of ego- mutants to recover 
from rapamycin treatment. 
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5 Rapamycin-insensitive proliferation 
underpins recovery from rapamycin 
 Introduction 5.1
We have identified a novel rapamycin-insensitive growth rate that is absolutely 
dependent on rapamycin-insensitive activity of TORC1.  Mutants lacking a 
functional EGO complex are compromised in both rapamycin-insensitive TORC1 
activity and in the ability to recover from the drug.  Is it possible that the slow 
rapamycin-insensitive growth rate of ego- mutants in the presence of rapamycin 
somehow compromises their ability to recover following drug washout? 
 Results 5.2
 Can we invoke a rapamycin recovery defect in wild-type 5.2.1
cells? 
In the previous chapter we found that treatment of wild-type cultures with a 
sub-inhibitory concentration of caffeine selectively compromised rapamycin-
insensitive growth.  Caffeine treatment thus mimics ego- mutations in this 
regard.  If the slow rapamycin-insensitive growth rate of ego- mutants 
compromises their ability to recover from the drug, then maintaining wild-type 
cells in the presence of a sub-inhibitory concentration of caffeine should be 
sufficient to invoke a rapamycin recovery defect.  
Exponentially growing wild-type cultures were treated (or not) with rapamycin 
(200 ng/mL), caffeine (3 mM) or both in YPD at room temperature with agitation 
for two hours.  Cells were washed three times in either plain YPD or YPD 
containing caffeine (3 mM) as appropriate before ten-fold serial dilutions were 
created in the appropriate media and spotted onto both a plain YPD plate and a 
YPD plate containing caffeine (3 mM).  The plates were incubated at 30˚C for 
two days. 
The period in which cultures were exposed to the drug(s) we term the 
‘treatment’ phase.  Following the treatment phase, cells were washed, referred 
to as ‘drug washout’, to remove any external drug from the media, plated onto 
YPD plates and incubated; this incubation time is referred to as the ‘recovery’ 
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phase, i.e. the incubation period following washout of drugs from the media.  
We found that wild-type cells treated with both rapamycin and caffeine during 
the treatment phase were able to recover in the absence of any drug during the 
recovery phase (Figure 5.1).  These results suggest that a slow rapamycin-
insensitive growth rate during the treatment phase alone does not prevent 
recovery from rapamycin.  To maintain low TORC1 activity during the recovery 
phase, i.e. mimicking the state of an ego- mutant, wild-type cells were 
maintained in the presence of caffeine (3 mM) for the duration of the recovery 
phase.  Following a combined rapamycin and caffeine treatment phase and 
incubation in the constant presence of caffeine for the recovery phase, we found 
that wild-type cells were unable to recover (Figure 5.1).  These results show 
that maintaining low TORC1 activity, due to the presence of a sub-inhibitory 
concentration of caffeine, during the treatment phase and recovery phase is 
sufficient to mimic the phenotype of ego- mutants in wild-type cells with 
regards to rapamycin recovery. 
When is TORC1 activity required to permit recovery from rapamycin?  The 
presence of caffeine during both the treatment and recovery phase prevents 
wild-type cells recovering from rapamycin.  We tested the ability of cells to 
recover following treatment with rapamycin alone and the subsequent recovery 
phase occurring in the presence of caffeine.  We found that wild-type cells were 
unable to recover from this treatment (Figure 5.1).  These results suggest that 
TORC1 activity is specifically required during the recovery phase to enable cells 
to recover from rapamycin.   
The ability of cells to recover from both a rapamycin and caffeine treatment 
suggests that it is not the slow growth rate of cultures in the drugs per se that 
prevents recovery, but rather insufficient TORC1 activity during the recovery 
phase.  It is therefore possible that the inability of ego- mutants to recover from 
rapamycin treatment is a result of low TORC1 activity during the recovery phase. 
Whilst it has been shown that TORC1 is the predominant target of caffeine in 
yeast (Reinke et al. 2006; Wanke et al. 2008) it is possible that off-target effects 
of the drug hinder the recovery of wild-type cells in the presence of both 
rapamycin and caffeine. 
138 
 
 
Figure 5.1 Recovery of wild-type cells from rapamycin treatment in the 
presence of caffeine 
Exponentially growing wild-type cells at an OD600nm of ~0.1 were treated (or not) 
with rapamycin (200 ng/mL), caffeine (3 mM) or both in YPD at room 
temperature with agitation for two hours for the treatment phase.  Cells were 
washed three times in fresh media or media containing caffeine (3 mM) as 
appropriate and ten-fold serial dilutions were plated (5 µL) onto plain YPD or 
YPD plates containing caffeine (3 mM).  Plates were incubated at 30°C for two 
days for the recovery phase. 
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To ensure that off-target effects of caffeine do not prevent the recovery of wild-
type cells from rapamycin, we repeated the rapamycin recovery assay using 
wild-type cells expressing a caffeine resistant allele of tor1 (tor1I1954V (Reinke et 
al. 2006)). 
Wild-type cells expressing either the wild-type TOR1 gene or the caffeine 
resistant tor1I1954V allele were grown overnight in selective media.  Once in an 
exponential growth phase, cultures were treated (or not) with rapamycin (200 
ng/mL), caffeine (3 mM) or both in YPD at 28˚C with agitation for a two hour 
treatment phase.  Cells were washed three times in YPD and ten-fold dilutions 
were spotted to either a plain YPD plate or a YPD plate containing caffeine (3 
mM).  Plates were incubated at 28˚ for two days for a recovery phase. 
As seen in Figure 5.2 wild-type cells expressing either pTOR1 or ptor1I1954V were 
able to recover from all treatments tested when plated onto plain YPD.  We 
found that wild-type cells expressing the caffeine resistant tor1I1954V, but not the 
wild-type TOR1 allele, recovered from rapamycin treatment when the recovery 
phase was carried out in the continuous presence of caffeine (Figure 5.2).  We 
therefore conclude that caffeine is inhibiting the ability of wild-type cells to 
recover from rapamycin due to specifically targeting, and reducing, TORC1 
activity. 
 The rapamycin-insensitive growth rate persists following 5.2.2
washout of the drug 
TORC1 activity is somehow required during the recovery phase for cells to 
recover from rapamycin.  Is it possible that the effects of rapamycin (or 
rapamycin itself) are maintained following washout of rapamycin from the 
medium?  Does the slow rapamycin-insensitive growth rate persist following 
washout of the drug? 
Exponentially growing cultures of wild-type and ego1∆ cells were treated (or 
not) with a high concentration of rapamycin (40 ng/mL) in YPD and incubated at 
room temperature with agitation.   
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Figure 5.2 Recovery of wild-type cells from rapamycin when expressing a 
caffeine resistant tor1I1954V allele in the presence of caffeine 
Wild-type cells containing either pTOR1, ptor1I1954V were grown overnight in 
selective media.  Whilst in an exponential growth phase the cells were 
normalised to an OD600nm of ~0.1 and transferred into YPD.  Normalised cultures 
were treated (or not) with rapamycin (200 ng/mL), caffeine (3 mM) or both and 
incubated at 28˚C with agitation for a two hour treatment phase.  Cells were 
washed three times in fresh YPD and ten-fold serial dilutions were plated (5 µL) 
onto plain YPD or YPD plates containing caffeine (3 mM).  Plates were incubated 
at 30°C for two days for the recovery phase. 
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Two hours after the introduction of rapamycin, cells were washed three times 
with fresh drug-free media, inoculated into fresh YPD and incubated at room 
temperature with agitation for a 12 hour ‘recovery phase’.  Control cultures of 
untreated exponentially growing cultures in YPD, incubated at room 
temperature with agitation were included.  The culture density was measured by 
Coulter counter and the Log2 of the relative culture density to the average at 
the time of rapamycin washout is shown. 
As seen in Figure 5.3A we found that over the course of 12 hours after washout 
of rapamycin, the growth rate of wild-type cultures remained slow and stable.  
Indeed the growth rate of wild-type cultures observed during this recovery 
period looked remarkably similar to that of the rapamycin-insensitive growth 
rate of wild-type cultures seen in the constant presence of a high concentration 
of rapamycin (Figure 4.1).  We also found that the growth rate of ego1∆ cultures 
during the recovery period remained slow and stable for the 12 hours monitored 
(Figure 5.3B).  The growth rate of ego1∆ cultures following a two hour 
rapamycin treatment again resembled that of ego1∆ cultures in the constant 
presence of a high concentration of rapamycin (Figure 4.6).  These observations 
suggest that the effects of rapamycin can persist for many hours following 
washout of the drug from the medium.  Neither the growth rate of wild-type nor 
ego1∆ cultures appears to change over the 12 hours monitored. 
 Monitoring rapamycin in cells using mass spectrometry 5.2.3
Does rapamycin persist in cells following washout of the drug from the medium?  
We can use a mass spectrometry approach to monitor the cell-associated 
rapamycin pool (for example see Taylor & Johnson (1998)).  Here, we measured 
the unmodified parent ion of cell-associated rapamycin extracted from yeast 
cultures, i.e. the chemically and metabolically unmodified drug. 
During optimisation of the mass spectrometry experiment, we initially 
attempted to detect the presence of cell-associated rapamycin in yeast cells 
treated for two hours with rapamycin (200 ng/mL), our standard conditions.  
However, to maximise the detectable signal we chose to treat cells with a higher 
concentration of rapamycin (400 ng/mL) for four hours. 
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Figure 5.3 The rapamycin-insensitive growth rate of cultures maintains 
after washout of the drug 
Exponentially growing cultures of wild-type and ego1∆ cells were normalised to 
an OD600nm of ~0.1 in YPD.  Normalised cultures were treated (or not) with 
rapamycin (40 ng/mL) in YPD and incubated at room temperature with agitation 
for two hours.  Rapamycin treated cells were subsequently washed three times 
in fresh YPD and inoculated into fresh media to ‘recover’ at room temperature 
with agitation (time of rapamycin washout: t=0).  Untreated cultures were 
maintained at room temperature with agitation as a control.  Cultures were 
diluted as necessary with fresh media to maintain exponential growth.  The 
culture density was measured by Coulter counter with time and the Log2 of the 
relative culture density (to the average at the time of rapamycin washout) is 
shown with a line of best fit plotted.  N=3 independent cultures; error bars 
denote S.E.M. 
143 
 
 
It is possible that altering the rapamycin concentration and treatment time 
affects the behaviour of cultures with regards to rapamycin recovery.  A 
rapamycin recovery assay was carried out on wild-type and ego1∆ cultures 
following a four hour rapamycin (400 ng/mL) treatment: exponentially growing 
wild-type and ego1∆ cultures were treated (or not) with rapamycin (200 or 400 
ng/mL) in YPD and incubated at 28˚C with agitation for four hours.  Cells were 
washed three times with fresh YPD before being spotted onto a YPD plate which 
was incubated at 28˚C for two days.  As seen in Figure 5.4 we found that wild-
type cells were able to recover from a four hour rapamycin treatment (either 
200 ng/mL or 400 ng/mL) whereas the ego1∆ mutant cells were unable to do so.  
Treatment of cells with a higher concentration of rapamycin for four hours does 
not therefore affect the ability of yeast cells to recover.  
Detection of extracted cell-associated rapamycin was carried out in 
collaboration with Dr. Karl Burgess of the University of Glasgow Polyomics 
Facility.  I ran many of the samples through the mass spectrometer myself 
(having been taught the procedure by Dr. Burgess) whilst others were run by Dr. 
Burgess.  Optimisation of the conditions required to detect rapamycin by mass 
spectrometry were carried out by Dr. Burgess and myself.  The identification of 
rapamycin peaks and determination of signal intensities was carried out by Dr. 
Burgess or Dr. Stephan Weidt (also of the University of Glasgow Polyomics 
Facility).  Further analysis of the identified rapamycin signal peaks was carried 
out by myself. 
To monitor the cell-associated pool of rapamycin, exponentially growing wild-
type and ego1Δ cultures were treated with rapamycin (400 ng/mL) in YPD for 
four hours at room temperature with agitation.  After four hours, cells were 
washed three times with fresh YPD, inoculated into fresh media and incubated 
at room temperature with agitation for the ‘recovery phase’.  Cell pellets 
equivalent to ~10 OD600nm units were collected at time 0 (the time of rapamycin 
washout), seven hours and 20 hours after drug washout.  The pellets were 
washed three times in ice-cold water and cells lysed by vortexing in ice-cold 
water and an equal volume of glass beads.  Rapamycin was extracted from the 
cell lysate into ethyl acetate.  Detection of rapamycin by mass spectrometry was 
carried out in negative ionisation mode following retention on a C18 column.   
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Figure 5.4 Recovery of wild-type and ego1∆ from 400 ng/mL rapamycin 
Exponentially growing WT and ego1Δ cultures at an OD600nm of ~0.1 were treated 
(or not) with rapamycin (200 ng/mL or 400 ng/mL) in YPD at 28˚C with agitation 
for four hours.  Cells were washed three times in fresh YPD after which ten-fold 
serial dilutions were created and spotted (5 µL) onto a YPD plate to recover.  
Plates were incubated at 28˚C for two days. 
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The identity of rapamycin signal peaks was confirmed by retention time, mass 
and fragment pattern compared to an authentic standard. 
It is possible that loss of the EGO complex results in an increased uptake of 
rapamycin into these mutant cells compared to that of wild-type cells.  The 
total cell-associated pool of rapamycin was measured for both wild-type and 
ego1∆ mutant cells at t=0, i.e. the time of washout of rapamycin following the 
treatment period.  As seen in Figure 5.5 we found no significant difference 
(p=0.36) in the cell-associated pool of rapamycin between wild-type and ego1Δ 
cells. 
We found that the cell-associated pool of rapamycin in wild-type cells decreased 
slowly during the recovery period (Figure 5.6).  Indeed, we found that 20 hours 
after washout of the drug the cell-associated pool of rapamycin in wild-type 
cells had only decreased to approximately a third of that at the time of washout 
(p=0.002 at 20 hours compared to time 0) (Figure 5.6).  We found that the cell-
associated pool of rapamycin also decreased slowly, possibly more slowly, in 
ego1Δ mutants recovering from rapamycin treatment (Figure 5.6).  We therefore 
conclude that rapamycin itself remains associated with cells for a long time 
following washout of the drug from the media, and to a significant extent in 
both wild-type and ego1Δ mutants.  It is therefore likely that the persistence of 
the rapamycin-insensitive growth rate into the recovery phase is a result of the 
persistence of the drug in the cell. 
The cell-associated pool of rapamycin decreased slowly during the recovery 
period.  Is it possible that rapamycin is not actively detoxified in yeast, but is 
instead diluted among progeny cells due to continued, slow proliferation?  The 
culture density of both wild-type and ego1Δ cultures was monitored during the 
above recovery experiment (Figure 5.7).  The total amount of cell-associated 
rapamycin present in the culture during recovery was estimated by normalising 
the cell-associated pool of rapamycin for the culture density at each time point 
(Figure 5.8).  We found that the density of wild-type cultures doubled 
approximately one and a half times during the 20 hour recovery phase (Figure 
5.7), consistent with these cells proliferating very slowly.   
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Figure 5.5 Uptake of rapamycin into wild-type and ego1Δ cells 
Exponentially growing wild-type and ego1∆ cultures at an OD600nm of ~0.6 were 
treated with rapamycin (400 ng/mL) in YPD at room temperature with agitation 
for four hours after which cells were washed three times in YPD.  Cell pellets 
equivalent to ~10 OD600nm units were washed three times with ice-cold water 
before being physically lysed in an equal volume of glass beads and ice-cold 
water by vortexing.  Rapamycin was extracted from the lysate into ethyl acetate 
and measured by mass spectrometry.  Signal intensities were calculated relative 
to the average wild-type signal (1,124,479 a.u.). N=3 independent cultures, 
error bars denote S.E.M.  
 
Mass spectrometry was carried out in collaboration with Dr. Burgess and Dr. 
Weidt of the University of Glasgow Polyomics Facility. 
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Figure 5.6 Cell associated rapamycin during a ‘recovery phase’ from 
rapamycin treatment 
Exponentially growing wild-type and ego1∆ cultures at an OD600nm of ~0.6 were 
treated with rapamycin (400 ng/mL) in YPD and incubated at room temperature 
for four hours.  Cells were then washed three times with YPD and inoculated into 
fresh media (time 0) and incubated at room temperature with agitation for the 
‘recovery phase’.  At time 0, 7 and 20 hours following the washout of rapamycin 
cell pellets equivalent to ~10 OD600nm units were pelleted and washed three 
times in ice-cold water.  Cells were lysed by vortexing in an equal volume of ice-
cold water and glass beads.  Rapamycin was extracted into ethyl acetate, a 
sample of which was passed through a mass spectrometer.  The rapamycin mass 
spectrometry signal was calculated relative to that at time 0 (values ranged 
from 62,264 to 1,551,834 a.u.).  N=5 independent cultures; error bars denote 
S.E.M.; * p<0.05 relative to time 0.  
 
Mass spectrometry was carried out in collaboration with Dr. Burgess and Dr. 
Weidt of the University of Glasgow Polyomics Facility. 
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Figure 5.7 Increase in culture density during recovery from rapamycin 
Exponentially growing wild-type and ego1∆ cultures at an OD600nm of ~0.6 were 
treated with rapamycin (400 ng/mL) in YPD and incubated at room temperature 
for four hours.  Cells were then washed three times with fresh YPD and 
inoculated into fresh media (time 0) and incubated at room temperature with 
agitation for the ‘recovery phase’.  At time 0, 7 and 20 hours following the 
removal of rapamycin the density of each culture was measured by spectrometry 
at OD600nm and calculated relative to that at time 0 which ranged from 0.6-1.23 
OD600nm.  N=5 independent cultures; error bars denote S.E.M.; * p<0.05 relative 
to time 0.  
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When the total amount of cell-associated rapamycin in wild-type cells was 
calculated we found that there was no significant change in the amount of cell-
associated rapamycin during the 20 hours monitored (p=0.68 at seven and 0.8 at 
20 hours compared to time 0) (Figure 5.8).  As the mass spectrometer is only 
able to detect the unmodified parent ion, these results imply that rapamycin is 
not metabolised in, nor exported from, wild-type cells during recovery.  The 
growth rate of ego1Δ cultures was also monitored during the recovery phase and 
the cultures barely doubled during the recovery phase (Figure 5.7).  The total 
amount of cell-associated rapamycin again did not appear to change significantly 
over the 20 hours monitored (p=0.41 at seven and 0.16 at 20 hours compared to 
that at time 0) (Figure 5.8).  The observable cell-associated pool of rapamycin is 
remarkably stable in both wild-type and ego1Δ cells, strongly suggesting that 
rapamycin is not actively detoxified in yeast cells.  
We conclude that the observable pool of rapamycin is not significantly 
metabolised by yeast cells, but is slowly diluted between an increasing number 
of progeny cells.  The lack of any apparently active detoxification within cells 
suggests that yeast may recover from the drug by a ‘dilution-by-proliferation’ 
mechanism.  Such a ‘dilution-by-proliferation’ mechanism would rely on the 
ability of cells to maintain proliferation in the presence of the drug.  Therefore 
the slow rapamycin-insensitive growth rate observed for ego1Δ mutants could 
help explain their inability to recover from rapamycin treatment. 
 Can ego- mutants recover from rapamycin? 5.2.4
If rapamycin is detoxified by a dilution-by-proliferation mechanism, then the 
ability of cells to recover is dependent on both the size of the intracellular drug 
pool and on the rapamycin-insensitive growth rate.  Cells lacking the EGO 
complex are still able to proliferate in the presence of high concentrations of 
the drug, albeit more slowly.  Therefore, we predict that ego- mutants should be 
able to recover from lower concentrations of rapamycin, but concentrations that 
still induce hallmarks of inactive TORC1.  The ability of ego1Δ and gtr2Δ mutants 
to recover from various high concentrations of rapamycin was tested. 
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Figure 5.8 The total intracellular concentration of rapamycin present 
during the ‘recovery phase’ 
The total cell-associated concentration of rapamycin was calculated by 
normalising the relative cell-associated rapamycin signal from Figure 5.6 to the 
increase in culture density from Figure 5.7 for each time point measured.  The 
total concentration of cell associated rapamycin was calculated relative to that 
present at time 0 (values ranged from 62,264 to 1,551,834 a.u).  N=5 
independent cultures; error bars denote S.E.M.  
 
Mass spectrometry was carried out in collaboration with Dr. Burgess and Dr. 
Weidt of the University of Glasgow Polyomics Facility. 
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Exponentially growing cultures of wild-type, ego1Δ and gtr2Δ cells were treated 
(or not) with rapamycin (20, 50, 100 and 200 ng/mL) in YPD at room 
temperature with agitation for two hours.  Cells were washed three times with 
fresh YPD and ten-fold serial dilutions were spotted to a YPD plate.  Plates were 
incubated at 30˚C and colony formation was determined after two days.  As seen 
in Figure 5.9 wild-type cells were able to recover from all concentrations of 
rapamycin tested consistent with our previous results.  We found that cells 
lacking either Ego1p or Gtr2p failed to recover from concentrations of rapamycin 
greater than 50 ng/mL (Figure 5.9).  However, we found that ego1Δ and gtr2Δ 
mutants were in fact able to recover from a 20 ng/mL rapamycin treatment.  
These results suggest that the ability of ego- mutants to recover from rapamycin 
is not an absolute property of the mutants but is potentially dependent on the 
size of the intracellular pool of the drug. 
If, as it appears, the ability of ego- mutants to recover from rapamycin is 
dependent on the size of the intracellular pool of the drug, an alternative 
method to vary this pool would be to vary the treatment time.  A rapamycin 
recovery spot assay was carried out as above using high concentrations of 
rapamycin (20-200 ng/mL) and treatment times of 15-240 minutes.  The ability 
to recover was scored as full growth (+++) to no growth (-) and the results are 
shown in Table 5.1.  Wild-type cells were able to recover from all treatments 
tested (Table 5.1).  We found that ego1Δ and gtr2Δ cells could also recover from 
treatment with high (greater than 20 ng/mL) concentrations of rapamycin, but 
only if such treatments were for shorter amounts of time (Table 5.1).  As the 
concentration of rapamycin increased in the media, the exposure time required 
to induce a recovery defect of ego1Δ and gtr2Δ cells decreased (Table 5.1).  The 
discovery that the ability of ego- mutants to recover from rapamycin is 
dependent on both the treatment time and the drug concentration strongly 
implies that the size of the intracellular pool of rapamycin is crucial for 
recovery.  These results also suggest that the ego- mutant recovery defect is a 
quantitative defect (i.e. varies by degree and as a function of the size of the 
cell-associated drug pool), rather than being a qualitative defect (i.e. yes or no). 
152 
 
 
Figure 5.9 Recovery of wild-type and ego- mutants from various 
concentrations of rapamycin 
Exponentially growing wild-type, ego1Δ and gtr2Δ cultures at an OD600nm of ~0.1 
were treated (or not) with rapamycin (20–200 ng/mL) in YPD at room 
temperature with agitation for two hours.  Cells were washed three times in 
fresh YPD, ten-fold serial dilutions were created and spotted (5 µL) onto a YPD 
plate that was incubated at 30˚C for two days. 
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[rap] 
ng/mL 
Time (min) 
  0 15 30 60 120 240 
WT 
20 +++ +++ +++ +++ +++ +++ 
50 +++ +++ +++ +++ +++ +++ 
100 +++ +++ +++ +++ +++ +++ 
200 +++ +++ +++ +++ +++ +++ 
        
ego1Δ 
or 
gtr2Δ 
20 +++ +++ +++ +++ +++ +++ 
50 +++ +++ ++ + - - 
100 +++ ++ +/- - - - 
200 +++ +/- - - - - 
 
Table 5.1 Recovery from various concentrations of rapamycin with varying 
treatment times 
Exponentially growing wild-type, ego1Δ and gtr2Δ cultures at an OD600nm of ~0.1 
were treated with rapamycin (20, 50, 100 or 200 ng/mL) in YPD at room 
temperature for 0, 15, 30, 60, 120 or 240 minutes.  Cells were washed three 
times with fresh YPD, ten-fold serial dilutions were created and spotted to a YPD 
plate which was incubated for two days at 30˚C.  Colony formation was scored 
as full growth (+++) to no growth (-). 
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 Can we quantify the recovery time? 5.2.5
We have found that the ability of ego- mutants to recover from rapamycin is 
concentration dependent (within a range of high concentrations of the drug).  Is 
it possible to quantify the time at which cells, both wild-type and ego- mutants, 
recover from rapamycin treatment?  Understanding the kinetics of recovery from 
rapamycin could help determine the underlying ‘detoxification’ mechanism. 
Exponentially growing cultures of wild-type and ego1Δ cells were treated with 
various concentrations of rapamycin (20-200 ng/mL for wild-type cultures, 20-40 
ng/mL for ego1Δ cultures) in YPD and incubated at room temperature with 
agitation for two hours.  Cells were washed three times with fresh media, 
inoculated into fresh YPD and incubated at room temperature with agitation for 
a ‘recovery phase’.  The culture density of each strain was measured by Coulter 
counter over a recovery period of 48 hours.  The density of untreated cultures 
and those in the continuous presence of rapamycin (20 or 50 ng/mL) in YPD at 
room temperature with agitation were also measured for at least 14 hours after 
the introduction of rapamycin.  Results are expressed as semi-Log2 plots of the 
culture density with time, relative to the average culture density at the time of 
rapamycin washout. 
Representative plots for both wild-type and ego1Δ cultures during a 48-hour 
recovery period are shown in Figure 5.10; in these particular examples, wild-
type cultures were recovering from 100 ng/mL rapamycin whilst ego1Δ cultures 
were recovering from 30 ng/mL rapamycin.  A line of best fit has been fitted to 
the control cultures (untreated and continuously rapamycin treated) and 
extrapolated where necessary.  Each succeeding pair of data points for the 
relative culture density of recovering cultures were joined by a straight line 
(Figure 5.10).  For the wild-type culture, the growth rate of the recovering 
culture initially resembled that of the culture in the continuous presence of the 
drug for up to 18-20 hours following washout of rapamycin (Figure 5.10).  
Between 18-20 hours, the growth rate of the wild-type culture appeared to 
switch from that resembling the culture in the continuous presence of the drug 
to that resembling the untreated culture (Figure 5.10).   
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Figure 5.10 Observing cultures recovering from rapamycin treatment 
Control cultures of exponentially growing wild-type and ego1Δ cultures at an 
OD600nm of ~0.1 were untreated or treated with rapamycin (50 ng/mL for wild-
type, 20 ng/mL for ego1Δ) in YPD at room temperature with agitation.  Cultures 
were maintained in an exponential growth phase for the duration of the 
experiment by dilution into the appropriate media, and the culture density 
adjusted by the appropriate dilution factor.  The Log2 of the culture density, as 
measured by Coulter counter, was calculated relative to the culture density at 
two hours after the addition of rapamycin i.e. the time after which the 
rapamycin-insensitive growth rate is steady (Coulter counter values ranged from 
19,901 to 34,927 a.u.).  The culture density was measured up to at least 14 
hours after the addition of the drug and a line of best fit for each plot is shown.  
For monitoring the recovery time, exponentially growing wild-type and ego1Δ 
cultures at an OD600nm of ~0.1 were treated with rapamycin (100 ng/mL for wild-
type, 30 ng/mL for ego1Δ) in YPD at room temperature with agitation for two 
hours.  Cells were subsequently washed three times with fresh media, inoculated 
into fresh YPD and incubated at room temperature with agitation for a ‘recovery 
phase’.  Cultures were maintained in an exponential growth phase for the 
duration of the experiment by dilution into the appropriate media and the 
culture density adjusted by the appropriate dilution factor.  The Log2 of the 
culture density, as measured by Coulter counter for up to 48 hours after drug 
washout, was calculated relative the culture density at the time of rapamycin 
washout (Coulter counter values ranged from 10,953 to 24,656 a.u.) and each 
data-point is connected by a straight line. 
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The identification of a clear point of switching in growth rate of the recovering 
wild-type culture, that appears to occur within one culture doubling, suggests 
that most of the cells in the culture synchronously recover from the drug 
treatment, i.e. return to full, active proliferation at approximately the same 
time: the “recovery time”.    
The ego1Δ cultures, in this case recovering from a lower concentration of the 
drug, behaved similarly to the recovering wild-type culture in switching from 
one growth rate to the other within a defined time window corresponding to 
approximately one cell doubling (Figure 5.10).  The mutant culture also behaved 
as recovering at a particular point: the “recovery time”. 
In subsequent systematic analysis, we estimated the recovery time by 
quantifying the observed lag time between a recovering culture and an 
equivalent untreated culture (measured in parallel) returning to, or remaining 
in, rapid exponential growth, see Figure 5.11.  Note, in estimating the recovery 
time, we took into consideration the fact that recovering cells continued to 
proliferate slowly following washout of rapamycin, therefore we determined the 
lag time along the slope of the growth rate of continuously treated cultures, as 
illustrated in Figure 5.11.  The lag time to recovery for each individual culture 
was estimated as the average of three measurements of the lag time on the 
same dataset, as shown in Figure 5.11.  Three such measurements of lag time 
were made using three independent cultures (experimental replicates) which 
were averaged to arrive at the final recovery time for each strain. 
 How does the recovery time vary with concentration of 5.2.6
rapamycin? 
We can estimate the time at which cultures behave as though recovering from 
rapamycin.  How does this recovery time vary with the concentration of 
rapamycin treatment?  Does a ‘dilution-by-proliferation’ model explain the 
kinetics of recovery? 
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Figure 5.11 Demonstrating how the lag time to recovery was determined 
The recovering wild-type culture from Figure 5.10 is used to illustrate how the 
recovery time was determined.  The growth rate of the untreated and the 
continuously treated culture are plotted with a line of best fit for each, whilst 
each data point for the recovering culture is shown: each sequential pair of data 
points are joined by a straight line.  Three estimates of lag time were measured 
in a region where the growth rate of the recovering culture clearly matches that 
of the untreated culture.  The slope of the growth rate of the continuously 
rapamycin treated culture (grown in parallel) was used to estimate lag time: i.e. 
the time delay between points at which the untreated culture and the 
recovering culture intercept the dashed lines (at the slope of a culture growing 
in the continuous presence of a high concentration of rapamycin).  The lag time 
was estimated three times and the average calculated to determine the 
recovery time for each individual culture.  
Note that these three cultures: untreated, continuously treated and recovering, 
were grown in parallel for this experiment and originated from the same 
overnight culture.  Washout of rapamycin occurred at t=0. 
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The recovery times of wild-type cultures were measured as described in the 
previous section (Figure 5.11) in cultures recovering from 20 to 200 ng/mL 
rapamycin, all high concentrations.  As seen in Figure 5.12, the recovery times 
of wild-type cultures from concentrations of 20-50 ng/mL rapamycin increased 
with an increasing concentration of the drug in the media.  The rate of increase 
of recovery time with concentration slows at 100 ng/mL rapamycin (Figure 
5.12).  It took wild-type cells ~20 hours to recover from the highest 
concentration of rapamycin tested (200 ng/mL) at which point the response 
seems to saturate (Figure 5.12).  It would appear that the recovery time of wild-
type cultures is dependent on the concentration of rapamycin present in the 
media during the (two hour) treatment phase but begins to saturate above 
approximately 100 ng/mL rapamycin.  The discovery that wild-type cultures take 
approximately 20 hours to recover from rapamycin suggests that the mechanism 
of reducing the biologically active pool of the drug is incredibly slow, consistent 
with our model of dilution-by-proliferation. 
The recovery times for ego1Δ cultures also increased with an increase in 
rapamycin concentration; however, the rate of increase in recovery time with 
increasing concentration of drug was much more dramatic compared to that of 
wild-type cultures (Figure 5.12).  We found that ego1Δ cultures took much 
longer to recover from rapamycin than comparably treated wild-type cultures.  
Indeed, at the highest concentration of rapamycin used to treat ego1Δ cultures 
(40 ng/mL), recovery occurred ~35 hours after washout of the drug, whereas 
wild-type cultures recovered after ~15 hours from this concentration of 
rapamycin (40 ng/mL) (Figure 5.12).  Due to the length of time it took for ego1Δ 
cultures to recover from 40 ng/mL rapamycin, we did not measure the recovery 
times from concentrations of rapamycin higher than this.  We did not detect any 
sign of saturation within the concentration range measured for ego1Δ cultures 
(Figure 5.12) but have observed that ego1Δ cultures take much longer to recover 
from rapamycin than wild-type cultures. 
Is rapamycin-inhibited TORC1 inherently difficult to reactivate, particularly in 
the absence of the EGO complex?  Is there evidence in Figure 5.12 for an 
inherent, slow reactivation of TORC1 from rapamycin treatment?   
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Figure 5.12 The time at which wild-type and ego1Δ cells recover from 
various concentrations of rapamycin 
The recovery times for wild-type and ego1Δ cultures from various high 
concentrations of rapamycin (between 20-200 ng/mL).  The recovery times were 
measured as explained in section 5.2.5 and Figure 5.11.  N=3 independent 
cultures; error bars denote S.E.M. 
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We linearly extrapolated the recovery time plots for both wild-type and ego1Δ 
mutants to the axes.  If a lag in TORC1 reactivation exists, then we would expect 
each plot to extrapolate to the y-axis, i.e. a time needed to recover from 
rapamycin inhibited TORC1 at a theoretical but ‘inhibitory’ rapamycin 
concentration of 0 ng/mL.  However, if no lag in TORC1 reactivation occurs we 
would expect the plots to extrapolate to the x-axis.  We found that 
extrapolation of the recovery time plots for both wild-type and ego1Δ mutants 
extrapolated to the x-axis (Figure 5.13), consistent with there being no inherent 
lag time for TORC1 reactivation in the presence or absence of the EGO complex.  
Instead it is more likely that the slow recovery times from rapamycin, observed 
for both wild-type and ego1Δ cultures, are a result of the kinetics of reducing 
the biologically active rapamycin pool rather than in reactivating TORC1 itself.  
 Does the rapamycin-insensitive growth rate explain the 5.2.7
recovery time? 
It would appear that rapamycin is not actively detoxified in yeast and that there 
is no inherent lag for TORC1 reactivation following rapamycin treatment.  We 
can test whether a model of dilution-by-proliferation explains the kinetics of 
recovery observed for both wild-type and ego1Δ cultures.  A mechanism of 
dilution-by-proliferation is dependent on the ability of cells to maintain 
proliferation in the constant presence of rapamycin; i.e. the rapamycin-
insensitive growth rate.  This model predicts that doubling the size of the 
intracellular pool of rapamycin would extend the recovery time of a culture by 
one doubling time, at the rapamycin-insensitive growth rate.  By knowing the 
doubling times for both the wild-type and ego1Δ cultures in the presence of 
rapamycin we can calculate a predicted recovery time from any concentration of 
rapamycin by the mechanism of dilution-by-proliferation. 
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Figure 5.13 Extrapolating recovery time to the origin 
The recovery time plots of Figure 5.12 for wild-type and ego1Δ mutants linearly 
extrapolated to intercept the axis. 
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To calculate the predicted recovery time, we used the following formula: 
tR = tDT x log2 [rap]treatment + a 
 where: tR   predicted recovery time (hrs) 
   tDT   observed doubling time in the constant   
     presence of a high concentration   
     of rapamycin (far in excess of the minimum  
     inhibitory concentration) (hrs)  
   [rap]treatment the concentration of rapamycin in the media  
     during the treatment phase (ng/mL) 
   a  constant (hrs), a “fudge-factor” derived from  
     the best fit of the initial trajectory of tR to the 
     experimentally observed recovery times 
Note, this calculation assumes that the extracellular concentration of rapamycin 
is proportional to the intracellular concentration of the drug, i.e. that doubling 
the extracellular concentration of rapamycin in the media will double the 
intracellular rapamycin pool. 
The predicted recovery times for wild-type and ego1Δ cultures were calculated 
and plotted in Figure 5.14 (grey lines).  The strain specific rapamycin-insensitive 
doubling times used in the calculation were measured in the constant presence 
of 20 ng/mL rapamycin (in parallel to cultures from which the experimentally 
observed recovery times were measured).  As seen in Figure 5.14 the predicted 
recovery times for wild-type cultures appear very similar to the recovery times 
measured experimentally, particularly at concentrations of rapamycin up to 50 
ng/mL rapamycin.  We found that the predicted recovery times for ego1Δ 
mutants were indistinguishable from the experimentally observed recovery times 
(Figure 5.14). 
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Figure 5.14 The predicted and experimentally observed recovery times for 
wild-type and ego1Δ cultures from various high concentrations of rapamycin 
treatment 
The recovery times for wild-type and ego1Δ cells were predicted using the 
following formula:  
   tR = tDT x log2 [rap]treatment + a  
For wild-type cultures:  
 tDT = 5.32 (hrs)  
 [rap] = 20-200 ng/mL  
 a = -14.5 (hrs)  
For ego1Δ mutants:  
 tDT = 23.79 (hrs)  
 [rap] = 20-40 ng/mL  
 a = -93 (hrs)  
The predicted recovery times are shown in grey whilst the experimentally 
observed recovery times, from Figure 5.12, are plotted in black.  Error bars 
denote S.E.M. 
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We conclude that a dilution-by-proliferation model is sufficient to explain: 
1) The kinetics of recovery of wild-type cultures from 
rapamycin treatment. 
2) The kinetics of recovery of ego1Δ cultures from rapamycin 
treatment. 
3) The extent of the ego1Δ mutant, and by inference ego- 
mutant, recovery defect. 
We can calculate the theoretical doubling time of cultures that would best 
explain the experimentally observed recovery time plots (Figure 5.12) if the 
dilution-by-proliferation model applies.  The theoretical doubling times, for 
wild-type and ego1∆ cultures, were calculated as the initial slopes of the plots 
of recovery time versus the log2 of the rapamycin concentration.  As seen in 
Table 5.2 we found that the theoretical and observed doubling times for both 
wild-type and ego1∆ cultures were indistinguishable, within error, from the 
respective doubling times measured in the constant presence of rapamycin.  The 
dilution-by-proliferation model indeed fits the experimentally observed data 
extremely closely. 
 Does a rapamycin-insensitive growth rate correlate with 5.2.8
recovery? 
It would appear that the inability of ego- mutants to recover from rapamycin 
treatment is a result of their slow rapamycin-insensitive growth rate.  In the 
previous chapter we identified null mutants, in addition to those of the EGO 
complex, that exhibit a significantly slower rapamycin-insensitive growth rate 
compared to that of wild-type cultures.  Does a slow rapamycin-insensitive 
growth rate impact the ability to recover from the drug for these null mutants?  
We tested the ability of tor1Δ, tco89Δ and eap1Δ null mutants, which we have 
shown to have a rapamycin-insensitive growth defect, to recover from rapamycin 
treatment (Figure 4.10 and Figure 4.16).    
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Initial slope of recovery 
time vs Log2 of rapamycin 
concentration (hrs) 
Observed doubling time in 
the constant presence of 
rapamycin (20 ng/mL) (hrs) 
WT 5.27 +/- 0.65 5.32 +/- 0.17 
ego1∆ 24.52 +/- 0.97 23.79 +/- 5.51 
   
Table 5.2 Comparison of the calculated slope of the recovery time to the 
observed rapamycin-insensitive doubling time 
The slope for the initial region of the observed recovery times (between 20-50 
ng/mL for wild-type cultures and 20-40 ng/mL for ego1Δ cultures) was 
calculated using the observed recovery times verses the Log2 of rapamycin 
concentration.  To compare, the doubling time of wild-type and ego1Δ cultures 
in the constant presence of rapamycin (20 ng/mL), as measured in parallel to 
cultures from which the recovery times were determined, is included.  Results 
are shown +/- standard deviation. 
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A slow rapamycin-insensitive growth rate was also observed for wild-type strains 
in the EG123 genetic background (Figure 4.17).  Testing the ability of these 
cultures to recover from rapamycin will give an indication as to whether our 
dilution-by-proliferation model also applies to all yeast strains and is not specific 
to cells in the BY4743 genetic background. 
Exponentially growing cultures of wild-type (BY4743, W303 and EG123 genetic 
backgrounds), ego1Δ, tor1Δ, tco89Δ and eap1Δ cells (all mutant haploids were in 
a BY4743 genetic background) were treated (or not) with rapamycin (200 ng/mL) 
in YPD at 28˚C with agitation for two hours.  Cells were washed three times in 
fresh YPD from which ten-fold serial dilutions were created and spotted onto a 
YPD plate that was incubated at 28˚C for two days. 
We found that all strains with a slower rapamycin-insensitive growth rate in the 
presence of 200 ng/mL rapamycin, compared to that of wild-type (BY4743) 
cultures, struggled to recover from rapamycin treatment.  As seen in Figure 5.15 
tor1Δ, tco89Δ or eap1Δ null mutants and the wild-type (EG123) culture failed to 
efficiently recover from rapamycin treatment.  These results are consistent with 
a slow rapamycin-insensitive growth rate impacting the ability of cultures to 
recover from the drug and appears independent of genetic background.  By 
comparison the rapamycin-insensitive growth rate of wild-type (W303) was not 
significantly different to that of the wild-type (BY4743) culture in the constant 
presence of 200 ng/mL rapamycin (Figure 4.17).  As seen in Figure 5.15 the wild-
type (W303) culture could efficiently recover from rapamycin treatment.  These 
results support our hypothesis that the ability to recover from rapamycin is 
primarily, but not exclusively, dependent on the growth rate of cultures in the 
presence of the drug. 
 Conclusion 5.3
In this chapter we have proposed a model to explain rapamycin detoxification in 
yeast cells; that is, rapamycin is not actively detoxified but instead the 
intracellular rapamycin pool is diluted by proliferation.   
167 
 
 
Figure 5.15 Recovery of tor1Δ, eap1Δ wild-type (W303, EG123), and tco89Δ 
from rapamycin treatment 
Exponentially growing cultures of wild-type (By4743, W303 and EG123 genetic 
backgrounds), ego1Δ, tor1Δ, eap1Δ and tco89Δ cultures at an OD600nm of ~0.1 
(0.05 for tco89Δ mutants) were treated (or not) with rapamycin (200 ng/mL) in 
YPD at 28˚C with agitation for two hours.  Cells were washed three times in 
fresh YPD before ten-fold serial dilutions were created and spotted (5 µL) onto a 
YPD plate which was incubated at 28°C for two days.  The rapamycin-insensitive 
growth rates, as a percentage of that of BY4743 wild-type cultures, are also 
shown and were calculated from Figure 4.10, Figure 4.16 and Figure 4.17. 
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The dilution-by-proliferation model also explains why loss of the EGO complex 
results in a rapamycin recovery defect; ego- mutants are unable to proliferate 
quickly enough in the presence of rapamycin to reduce the drug to a sub-
inhibitory concentration within the timings of our experiments. 
Through the use of mass spectrometry analysis we have shown that the 
observable pool of rapamycin is not degraded in, nor exported from yeast cells: 
it would appear that rapamycin is not actively metabolised in yeast.  Initially we 
found that the cell-associated pool of rapamycin decreased during a ‘recovery 
phase’.  However, these results were based on culture samples that had been 
normalised for OD600nm and therefore did not take into account the increase in 
culture density during the ‘recovery phase’.  When the cell-associated pool of 
rapamycin, as measured by mass spectrometry, was normalised for the increase 
in culture density we found that the total cell-associated concentration of 
rapamycin present during the ‘recovery phase’ did not change over the 20 hours 
monitored.  The decrease in cell-associated rapamycin per volume of culture, 
but stability over the whole culture, led us to conclude that the observable cell-
associated pool of rapamycin is reduced by the slow mechanism of dilution-by-
proliferation.  The ability of yeast cells to maintain proliferation in the constant 
presence of rapamycin thus allows the drug to be diluted among an increasing 
number of progeny cells; the intracellular concentration eventually reaching a 
threshold concentration below that required to inactivate TORC1. 
In the previous chapter we showed that ego- mutants were unable to recover 
from rapamycin (200 ng/mL).  In this chapter, we found that the ability of ego- 
cells to recover from rapamycin was in fact concentration dependent: ego- 
cultures were in fact able to recover from treatments with lower, yet still 
TORC1 inhibiting, concentrations of rapamycin or from higher concentrations 
treated for a short time, consistent with the biologically-active pool of the drug 
also being diluted by proliferation.  The knowledge that ego- cells were able to 
recover from lower, yet still inhibitory, concentrations of rapamycin allowed us 
to monitor the culture density, for both wild-type and ego1∆ mutants, during a 
‘recovery phase’ from various concentrations of the drug.  We discovered that 
the recovery time for both wild-type and ego1∆ cells increased with an 
increasing concentration of rapamycin and eventually saturated in wild-type 
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cultures.  The length of time it took for wild-type cultures to recover from our 
standard two hour treatment with 200 ng/mL rapamycin was extremely long – 
approximately 20 hours and suggests that rapamycin is not easily ‘detoxified’ 
even in wild-type cells.  Null ego1∆ mutants demonstrated a severe and slow 
defect in recovery times from rapamycin treatment, consistent with their over-
reaction to the presence of rapamycin, other examples being: their slow 
rapamycin-insensitive growth rate, decreased translation rate and the eventual 
amino acid uptake rate compared to those of wild-type cultures. 
To test our model that the biologically-active pool of rapamycin is ‘detoxified’ in 
a dilution-by-proliferation manner, we predicted the recovery times for both 
wild-type and ego1∆ cultures from various concentrations of rapamycin based on 
their individual rapamycin-insensitive growth rates.  We found that the 
predicted and experimentally observed recovery times closely resembled each 
other, suggesting that dilution-by-proliferation is likely to be the mechanism by 
which rapamycin is ‘detoxified’.  We observed some divergence between the 
predicted and observed recovery times for wild-type cultures treated with 
higher concentrations of rapamycin.  It is possible that this is due to saturation 
of the drug importer in vivo.  We note however that the trend of the predicted 
recovery times closely matched that observed experimentally, suggesting that 
the observed saturation curve is an inherent property of the dilution-by-
proliferation mechanism.  We conclude that the inability of ego1∆ cultures, and 
by inference ego- mutants, to recover from rapamycin treatment is due to their 
slow rapamycin-insensitive growth rate, which is most likely a result of reduced 
TORC1 activity in these mutant strains.  Indeed, we predict that it would take 
ego1∆ cultures ~90 hours to commence normal proliferation from a two hour 
treatment with 200 ng/mL rapamycin. 
Having identified that a slow rapamycin-insensitive growth rate of ego1∆ 
cultures, and by inference ego- mutants, inhibits recovery from rapamycin we 
tested the ability of other null mutants (tor1Δ, tco89Δ and eap1Δ), that have a 
slow rapamycin-insensitive growth rate, to recover from rapamycin.  We found 
that a slow rapamycin-insensitive growth rate, compared to that of wild-type 
cultures, correlated with the ability of cultures to recover from rapamycin 
treatment.  Mutants lacking Tco89p have a rapamycin-insensitive growth rate 
similar to that of ego1∆ cultures and completely failed to recover from 
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rapamycin treatment.  Null mutant cultures (or wild-type EG123) in which the 
rapamycin-insensitive growth rate is compromised, but not to the extent of that 
of ego1∆ mutants, struggled to recover from rapamycin treatment and only very 
small colonies were observed.  These results imply that there is likely to be a 
rapamycin-insensitive growth rate threshold with regards to the ability to 
recover from rapamycin under our experimental conditions.  Cultures with a 
rapamycin-induced growth rate slower than this threshold are perceived as being 
completely unable to recover from the drug.  We therefore conclude that the 
rapamycin-insensitive proliferation rate, discovered in the previous chapter, 
underlies the ability of cells to recover. 
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6 Identifying other potential regulators of 
TORC1 
 Introduction 6.1
The focus of this project so far has been to understand how yeast cells recover 
from rapamycin and why TORC1, and its known activators, are required for this 
process.  The EGO complex was identified by the De Virgilio group as an 
activator of TORC1.  A number of additional upstream regulators of TORC1 that 
appear to respond to nutrient availability have also been identified: for 
example, the SEA complex (Panchaud et al. 2013b); Vam6p (Binda et al. 2009) 
and the leucyl-tRNA synthetase (Bonfils et al. 2012).  It would appear that these 
regulators all act via the EGO complex to moderate TORC1 activity.  However, 
the EGO complex is not essential: cells devoid of the complex are fully viable 
and are able to recover from periods of environmental and nutritional stress 
(Figure 3.6).  It is therefore highly likely that additional, as yet unknown, 
regulators of TORC1 remain to be identified. 
Prior to the start of this project, a large-scale, primary genetic screen was 
carried out by the Gray laboratory in collaboration with the Johnston laboratory 
(Dalhousie University, Canada) to identify null mutants that failed to recover 
from a long exposure time to high concentrations of rapamycin.  Here, the 
results of the primary screen will be analysed and extended in an attempt to 
identify novel regulators of TORC1. 
 Results 6.2
 Summary of the primary screen 6.2.1
To identify null mutants that fail to recover from rapamycin treatment, the 
Johnston laboratory (Dr. Pak Poon, Dr. Richard Singer and Dr. Gerry Johnston) at 
Dalhousie University performed a large-scale genetic screen, testing ~4,700 null 
mutant haploids, each lacking a single non-essential gene, for their ability to 
recover from rapamycin treatment. 
Although this portion of the work was not carried out by myself, here I will 
summarise how the primary screen was performed.  This will provide background 
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information for my subsequent analysis of the primary data provided by the 
screen.  Three independent robotic runs of the primary screen were performed 
on the arrayed BY4742 haploid deletion collection, which were freshly defrosted 
and grown prior to screening.  The arrayed collection was pinned onto YPD 
plates containing 100 or 200 ng/mL rapamycin and incubated at 30˚C for three 
or seven days.  Following incubation, the arrayed collection was re-pinned (by 
robot) onto plain YPD plates which were incubated at 30˚C for up to three days.  
The ability of each colony to resume proliferation on the plain YPD plates was 
then scored, by image analysis, as either unable to form colonies or formed 
small, mid-sized or full-sized colonies compared to that of the wild-type strain.  
Table 6.1 shows the number of null mutants identified with a colony size smaller 
than that of wild-type cultures following recovery from rapamycin treatment. 
 Analysis of the results of the primary screen 6.2.2
The following work is my analysis of the results of the primary screen.  Of the 
~4,700 null mutants tested, 172 were found in at least one of the three runs 
performed.  Table 6.2 shows the number of null mutants identified in either one, 
two or all three runs.  The average number of null mutants identified per run of 
the primary screen was 98, as calculated from Table 6.1, a small fraction of the 
collection screened.  We can predict the frequency of null mutants expected to 
be found by chance in any two or all three runs of the screen.  We predict that 
six null mutants would be identified by chance in any two runs of the screen 
(Table 6.2).  As seen in Table 6.2, 39 null mutants were in fact identied in any 
two runs of the primary screen, which is an approximate 6.5-fold enrichment 
over the number expected by chance.  If the primary screen only identified null 
mutants by chance then we would predict that no null mutant would be 
identified in all three runs of the screen (Table 6.2).  We find that this is not the 
case and 49 null mutants were identified in all three runs, an approximate 
1,200-fold enrichment over the number expected by chance (Table 6.2).  Due to 
the fold enrichment of the null mutants identified in any two or all three runs of 
the primary screen, these null mutants shall be analysed further and are classed 
as the ‘primary null mutant set’.   
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Run 
Concentration of 
rapamycin (ng/mL) 
Treatment 
time (days) 
Number of null mutants 
identified with a colony 
formation defect 
1 100 3 118 
2 100 7 73 
3 200 7 103 
    
Table 6.1 Null mutants identified from each run of the primary screen with 
a colony formation defect 
Three runs of the primary screen were carried out by Dr. Poon.  The ability of 
each strain to form a colony was scored by image analysis and the number of null 
mutants identified, per run, with a colony size smaller than that of wild-type 
cultures is shown.  
 
Note: All runs of the screen and identification of mutants with a recovery 
defect were carried out by Dr. Poon in the Johnston Laboratory at Dalhousie 
University, Canada. 
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 Identified only 
in any one run 
Identified only 
in any two runs 
Identified in 
all three runs 
Total 
Experimentally 
observed 
84 39 49 172 
Mathematically 
predicted 
~282 
~6 
(6.2) 
<1 
(0.044) 
 
Fold enrichment - ~6.5 ~1,200  
     
Table 6.2 The number of null mutants identified across the three runs that 
were scored as having at least a mild rapamycin recovery defect 
The number of null mutants experimentally observed as having a recovery defect 
(i.e. a colony size smaller than that of wild-type cultures following the recovery 
phase) in one run, any two runs or in all three runs is shown.  The predicted 
number of null mutants that would be identified by chance is also included and 
was calculated as follows: The frequency of observing 98 null mutants (the 
average identified in one run of the screen) by chance in 4,700 genes tested is 
0.021 (98/4,700).  The frequency of observing a null mutant by chance in any 
pair of three runs is therefore calculated as 6.2 mutants  
(3 X ((0.021 X 0.021) X 4,700)).  The frequency of identifying a null mutant by 
chance in all three runs of the screen is 9.3x10-6 (3 X 0.021); in a deletion 
collection of 4,700 mutants this equates to less than one mutant (0.04)  
(4,700 X (3 X 0.021)).  The probability of identifying mutants by chance in only 
one screen was calculated by deducting the probability of identifying a mutant 
in either two or all three screens from the chance that they would be identified 
in one screen only, i.e. 3 X 98 - (6 X 2) - (0.044 X 3). 
Note: All runs of the screen and identification of mutants with a recovery 
defect were carried out by Dr. Poon in the Johnston Laboratory at Dalhousie 
University, Canada. 
175 
 
 
The 88 genes of the ‘primary gene set’ (corresponding to the primary mutant 
set) are shown in Table 6.3.  We have successfully identified all four members of 
the EGO complex in our primary mutant set.  This suggests that the primary 
screen was successful in identifying null mutants that potentially phenocopy ego- 
mutants (Table 6.3). 
 GO Term enrichment in the primary mutant set 6.2.3
Are particular biological processes or components enriched within our primary 
mutant set?  Analysis of the 88 genes was carried out using the Gene Ontology 
(GO) Term Finder on the Saccharomyces Genome Database (SGD) website 
(www.yeastgenome.org) and tested for enrichment in known GO process, GO 
component and GO function terms.  The SGD GO Term Finder software identified 
GO terms that were significantly enriched (p<0.01) within our primary gene set.  
To account for multiple hypothesis testing, a Bonferroni Correction is 
automatically applied by SGD when calculating the p-value.  For each enriched 
GO term, we also calculated the percentage of genes identified in our query set 
relative to the number of genes in the genome associated with that particular 
term; ‘percentage identification’.  We set an arbitrary cut-off of 20% 
identification with the assumption that less than 20% identification was likely 
due to either non-specific GO terminology or poor enrichment.   
Table 6.4 shows the GO terms that were found to be significantly enriched in our 
dataset by SGD and that were above our 20% identification cut-off.  Twelve GO 
process terms were identified, which can be divided into three sub-categories, 
those involved in threonine biosynthesis, those involved in membrane trafficking 
and fusion and those involved in transcription and elongation.  The GO process 
term ‘threonine biosynthetic process’ had the highest percentage identification 
within our mutant set, with 80% of the genes found in our primary screen (Table 
6.4).  The largest category of GO process terms identified was associated with 
membrane trafficking and fusion with 10 such terms found to have greater than 
20% identification (Table 6.4).  The GO process terms that related to 
transcription and elongation have the least percentage identified of all the GO 
Process Terms found (Table 6.4). 
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Gene names of null mutants found in 
any two runs of the primary screen 
Gene names of null mutants found in 
all three runs of the primary screen 
Gene 
Name 
ORF 
Gene 
Name 
ORF 
Gene 
Name 
ORF 
Gene 
Name 
ORF 
BUD30 YDL151C PET54 YGR222W ADH1 YOL086C PHO85 YPL031C 
BUD32 YGR262C RPA49 YNL248C APQ13 YJL075C POC4 YPL144W 
CNM67 YNL225C SAC3 YDR159W ATG11 YPR049C POP2 YNR052C 
CTK1 YKL139W SER2 YGR208W BFR1 YOR198C PRO1 YDR300C 
CTK2 YJL006C SIC1 YLR079W CCR4 YAL021C PRP18 YGR006W 
CTK3 YML112W SPC72 YAL047C CDC40 YDR364C RLR1 YNL139C 
DHH1 YDL160C SPS1 YDR523C CIN8 YEL061C ROX3 YBL093C 
EGO3 YBR077C SSD1 YDR293C DEG1 YFL001W RPB4 YJL140W 
ERG6 YML008C THR1 YHR025W DIA2 YOR080W SEM1 YDR363W-A 
GTR1 YML121W TMA23 YMR269W EFG1 YGR272C SFP1 YLR403W 
HEM14 YER014W UBA4 YHR111W EGO1 YKR007W SHP1 YBL058W 
HOF1 YMR032W UBP15 YMR304W ERG3 YLR056W SNX4 YJL036W 
HOM2 YDR158W UME6 YDR207C FYV6 YNL133C SWI6 YLR182W 
HSL7 YBR133C UMP1 YBR173C GON7 YJL184W THP1 YOL072W 
KEM1 YGL173C VAM7 YGL212W GTR2 YGR163W THR4 YCR053W 
LSM1 YJL124C VPS16 YPL045W HOM3 YER052C TOM5 YPR133W-A 
LST4 YKL176C YKE2 YLR200W LUV1 YDR027C VAM6 YDL077C 
MCH5 YOR306C YPT7 YML001W MNN10 YDR245W VMS1 YDR049W 
MMS22 YLR320W - YDL172C MNN11 YJL183W VPS15 YBR097W 
NPL3 YDR432W   NCS6 YGL211W VPS33 YLR396C 
    PAR32 YDL173W VPS34 YLR240W 
    PAT1 YCR077C YDJ1 YNL064C 
    PEP3 YLR148W YME1 YPR024W 
    PEP5 YMR231W - YDR417C 
    PIB2 YGL023C   
        
Table 6.3 The gene name and ORF number of mutants identified in at least 
two runs of the primary screen 
The gene names and ORF numbers for all 88 null mutants identified in at least 
two runs of the primary screen are listed in alphabetical order by gene name. 
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GO Process 
Number in 
primary 
mutant set 
Number in 
genome 
p-value 
% identification 
in our screen of 
those in 
genome 
Threonine Biosynthetic Process 4/88 5/7167 5.97E-05 80% 
Threonine Metabolic Process 4/88 8/7167 0.00081 50% 
Regulation of SNARE Complex 
Assembly 
5/88 9/7167 1.71E-05 56% 
Regulation of Vesicle Fusion 5/88 10/7167 3.39E-05 50% 
SNARE Complex Assembly 5/88 10/7167 3.39E-05 50% 
Regulation of Vacuole Fusion, Non-
Autophagic 
6/88 13/7167 2.62E-06 46% 
Regulation of Vacuole Organisation 6/88 16/7167 1.18E-05 38% 
Membrane Invagination 10/88 43/7167 3.61E-08 23% 
Single Organism Membrane 
Invagination 
10/88 43/7167 3.61E-08 23% 
Microautophagy 10/88 43/7167 3.61E-08 23% 
Piecemeal Microautophagy of 
Nucleus 
7/88 33/7167 6.19E-05 21% 
Nucleophagy 7/88 34/7167 7.71E-05 21% 
Positive Regulation of DNA-
Templated Transcription, Elongation 
9/88 39/7167 3.72E-07 23% 
Regulation of DNA-Templated 
Transcription, Elongation 
9/88 41/7167 6.03E-07 22% 
  
GO Component  
HOPS Complex 5/88 6/7167 2.15E-07 83% 
EGO Complex 4/88 5/7167 1.53E-05 80% 
CORVET Complex 4/88 6/7167 4.56E-05 67% 
Late Endosomal Membrane 4/88 6/7167 4.56E-05 67% 
Cytoplasmic mRNA Processing Body 8/88 32/7167 4.51E-07 25% 
Endosomal Part 8/88 36/7167 1.24E-06 22% 
     
GO Function  
Amino Acid Kinase Activity 3/88 3/7167 0.00016 100% 
     
Table 6.4 Enrichment of GO terms identified in our primary mutant set 
The 88 primary gene set was tested for enrichment (p<0.01) in GO Terms by using the 
Saccharomyces Genome Database’s GO Term Finder program.  The percentage 
identification in our mutant set compared to the number of genes assigned to a 
particular term in the genome was calculated and only GO terms with over 20% 
identification are included.  GO Term Finder analysis was run in January 2014. 
178 
 
Six GO component terms were found to be significantly enriched in our mutant 
set and three of these terms related to specific complexes; these were the HOPS 
and CORVET complexes and the EGO complex (Table 6.4).  The remaining three 
GO component terms identified, whilst not relating to specific complexes, 
appear to encompass either endosomes or transcription thus complementing the 
results found when testing GO process terms.  Only one GO function term was 
identified as significantly enriched within our mutant set (Table 6.4): all three of 
the genes annotated to the term ‘amino acid kinase activity’ were found in our 
screen and possibly relate to the genes involved in threonine biosynthesis and 
metabolism (Table 6.4). 
GO term analysis identified 21 significantly and strongly enriched GO terms 
within our primary gene set.  Thirty-four genes of the 88 primary gene set were 
identified by GO term analysis and are shown in Table 6.5.  We can summarise 
the significant enrichment of genes found by GO Term analysis into three broad 
categories: ‘threonine biosynthesis’, ‘endosomal trafficking’ and ‘regulation of 
transcription’.  Note that whilst VPS15 and VPS34 were originally identified in 
GO Term analysis as being involved in transcriptional regulation, these proteins 
are more often associated with autophagy and cytoplasm-to-vacuole trafficking 
(Kihara et al. 2001); the vps15∆ and vps34∆ null mutants will therefore be 
analysed in the category of ‘endosomal trafficking’. 
6.2.3.1 GO term enrichment in the ‘single-hit’ mutant set 
Were we justified in only analysing mutants found in two or more runs?  To test 
this, we submitted the gene list corresponding to the mutants found only in any 
one run of the screen (our ‘single-hit mutant set’) to the SGD GO Term Finder.  
As seen in Table 6.6 we found no enrichment of GO process terms or of GO 
function terms.  When testing GO component terms, we found two terms to be 
significantly enriched in the single-hit mutant set (Table 6.6).  Both of these 
terms are broad with a large number of genes in the genome assigned to them 
(Table 6.6).  Our initial run of the GO Term Finder software (January 2014) had 
identified significant enrichment of the GO component ‘mediator complex’ 
within our single-hit mutant set.  However, a subsequent re-run of GO 
component enrichment in August 2014 did not identify the mediator complex as 
being enriched.    
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Threonine 
biosynthesis 
Endosomal trafficking 
Regulation of 
transcription 
Genes identified 
in the primary 
screen 
Known 
complex 
Genes 
identified in 
the primary 
screen 
Known 
complex 
Genes 
identified in 
the primary 
screen 
PRO1 
EGO complex 
EGO1 
CTDK-1 
complex 
CTK1 
THR1 EGO3 CTK2 
THR4 GTR1 CTK3 
HOM2 GTR2  CCR4 
HOM3 
HOPS/CORVET 
complex 
PEP3  PAT1 
 PEP5  DHH1 
 VPS33  SSD1 
 VPS16  XRN1 
 HOPS complex VAM6  LSM1 
 PtdIns 3-kinase 
complex 
VPS15  RPB4 
 VPS34  POP2 
  YPT7  NPL3 
  SHP1  YKE2 
  VAM7  
  SNX4  
  ATG11  
   
Table 6.5 The gene names for which the null mutants were significantly 
enriched in the primary screen by GO Term analysis 
The 34 of 88 genes in our primary gene set that were identified by GO term 
enrichment.  We have grouped the genes within our categories of either 
‘threonine biosynthesis’, ‘endosomal trafficking’ or ‘regulation of transcription.  
Known complexes associated with these genes are also shown. 
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GO Process 
Number in 
single hit 
mutant set 
Number in 
genome 
p-value 
% identification 
in our screen of 
those in 
genome 
NONE IDENTIFIED N/A N/A N/A N/A 
     
GO Component     
Intracellular Part 76/84 5226/7167 0.00712 1% 
Intracellular 76/84 5240/7167 0.00828 1% 
     
GO Function     
NONE IDENTIFIED N/A N/A N/A N/A 
     
Table 6.6 Enrichment of GO Terms of the mutant set found only in any one 
run of the primary screen 
The 84 mutants of the single-hit mutant set were analysed using SGD’s GO Term 
Finder.  The percentage identification in the single-hit mutant set compared to 
the number of genes assigned to a particular term in the genome was calculated.  
GO Term Finder was tested in August 2014. 
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We account for the initial enrichment as a chance anomaly caused by database 
curation.  The lack of any robust and significant enrichment within the single-hit 
mutant set for any specific terms implies that we were justified in eliminating 
this group of single hits from our analysis.  We shall therefore continue to focus 
on the mutants identified in at least two runs of the primary screen for further 
testing. 
 Protein-protein interactions among the gene products of 6.2.4
the mutant set from the primary screen 
We utilised the “Osprey network analysis” software (Breitkreutz et al. 2003) to 
analyse physical interactions among our primary protein set of 88 proteins 
corresponding to the primary mutants identified in our screen.  Osprey displays 
published interactions available on the SGD website. 
We found that 45 of the 88 proteins tested interact with at least one other 
protein in our primary protein set.  Of these 45, seven pairs of protein 
interactions were identified, of which the Vps15p-Vps34p interaction was 
particularly noteworthy (see below).  The remaining 31 proteins were found to 
form three distinct, and dense, protein clusters (Figure 6.1).   
The “EGO” complex  
All four components of the EGO complex were identified as interacting with each 
other (Figure 6.1).  In addition, another protein, Pib2p, in our primary protein 
set seems to be associated with members of the EGO complex (Figure 6.1).  The 
function of Pib2p is currently unknown. 
The “HOPS/CORVET” complex  
All four shared members of the core HOPS and CORVET complexes (Pep3p, 
Pep5p, Vps16p and Vps33p) were identified and form a dense network among 
themselves and with the associated proteins Vam6p, Ypt7p and Vam7p (Figure 
6.1).  The HOPS complex (in association with Vps41p which was only detected in 
one of the three runs of the primary screen) is required for endosomal 
trafficking and fusion to the vacuole (Solinger & Spang 2013).  Ytp7p is a Rab 
family GTPase that acts with the HOPS complex to aid maturation of endosomes 
to the vacuole (Wurmser et al. 2000).   
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Figure 6.1 Protein-protein interactions among the primary protein set 
Osprey software (Osprey 1.2.0, Version 5.0) was used to identify any known 
protein-protein interactions between the 88 proteins of the primary protein set.  
Only proteins which were shown to physically interact with at least one other 
protein in the dataset are shown.  Each protein is coloured according to their 
predominant GO process term; the colour index is also shown.  The variations in 
colour of the connecting interaction lines denote the experiment in which the 
interaction was identified.  Experimental systems from which the interactions 
were identified were: protein-fragment complementation, affinity capture 
western, co-localisation, reconstituted complex, affinity capture mass 
spectrometry, yeast two-hybrid, co-fractionation, co-purification and FRET. 
183 
 
 
Vam7p is a vacuolar SNARE protein that aids membrane fusion and has also been 
shown to interact with the HOPS complex (Stroupe et al. 2006).  Two other 
proteins (Spc72p and Cin8p) were identified to interact with Vam7p but not with 
any members of the core HOPS/CORVET complex (Figure 6.1). 
The “CTDK-I” complex  
The third network identified involves the C-Terminal Kinase Domain 1 complex 
(CTDK-I) (Ctk1p, Ctk2p and Ctk3p) and involves 17 proteins (Figure 6.1).  The 
CTDK-I complex is required for regulation of both transcription and translation 
(Hampsey & Kinzy 2007).  The protein interaction network surrounding the 
CTDK-I complex was less dense than that seen for the HOPS/CORVET complex.  
Of the 17 proteins in the CTDK-I cluster, 11 were also identified by GO Term 
analysis: Ssd1p, Npl3p, Rpb4p, Ctk1p, Ctk2p, Ctk3p, Xrn1p (named Kem1p in 
Osprey), Lsm1p, Dhh1p, Pop2p and Ccr4p.   
The Vps15p-Vsp34p complex  
The two interacting proteins, Vps15p and Vps34p, are the core of the PtdIns 3-
kinase complex (Kihara et al. 2001) and were found in our primary protein set.  
The human homolog of Vps34p is thought to have a role in TORC1 signalling in a 
currently unknown manner (Suzuki & Inoki 2011) hence our focus on this 
particular protein pair. 
 Selection of mutants for secondary screening 6.2.5
We have identified protein interactions among 45 of the 88 proteins in our 
primary set.  Of these, 31 were found to associate in one of three distinct 
clusters which appeared to be distinguished by a known complex.  Each cluster 
was also distinct by the function of the associated proteins.  As a result of GO 
term analysis and visualisation of physical interactions, representatives of each 
of our designated categories were selected for secondary screening. 
The EGO complex is known to be required for recovery from rapamycin and will 
be discounted from further analysis.  Of the remaining 84 mutants, 20 were 
chosen for secondary screening (Table 6.7).  Two of the null mutants categorised 
as being involved in threonine biosynthesis were selected, these were hom2∆ 
and hom3∆ (Table 6.7).   
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Category Null mutant Identified by: 
  GO Term analysis Osprey analysis 
Threonine biosynthesis hom2∆   
 hom3∆   
    
Endosomal trafficking pep3∆   
 pep5∆   
 vps33∆   
 vps16∆   
 vam6∆   
 vps15∆   
 vps34∆   
 shp1∆   
 ypt7∆   
 vam7∆   
 snx4∆   
 atg11∆   
 pib2∆   
    
Regulation of transcription ccr4∆   
 dhh1∆   
 npl3∆   
 ctk1∆   
 yke2∆   
    
Table 6.7 Null mutants selected for secondary screening 
The 20 null mutants selected from the primary mutant set that will be tested for 
their ability to recover from rapamycin.  The analysis (GO Term and Osprey) in 
which the corresponding gene or protein was identified is also shown. 
185 
 
 
We would have liked to have included either pro1∆, thr1∆ or thr4∆ mutants in 
addition to hom2∆ or hom3∆ mutants, but were unable to generate the null 
mutant haploid cells under our laboratory conditions.  TORC1 has been shown to 
localise to the cytoplasmic face of the vacuolar membrane, therefore all null 
mutants categorised as endosomal trafficking, including vps15∆ and vps34∆, 
were selected for secondary screening.  The pib2∆ null mutant, the protein of 
which was found to interact with the EGO complex will also be included in this 
category (Table 6.7).  Finally a selection of null mutants categorised as 
regulating transcription were also selected.  We chose to test null ctk1∆, npl3∆, 
ccr4∆, dhh1∆ and yke2∆ mutants, as identified by GO term and physical 
interaction analysis (Table 6.7).  The 20 null mutants selected are termed our 
‘secondary mutant set’. 
 Secondary screen: Recovery from rapamycin  6.2.6
It is possible that null mutants were identified in the primary screen for reasons 
other than a rapamycin recovery defect, for example an inability to survive the 
lengthy incubation or poor adherence to the robotic pins.  We therefore tested 
the 20 representative null mutants for their ability to recover from a short 
period of treatment with rapamycin. 
Fresh null mutant haploid cells were created by dissection of heterozygote 
diploids for each null mutant in the BY4743 background.  Three independent null 
haploids of each mutant were tested for their ability to recover from rapamycin 
treatment.  Exponentially growing liquid cultures were treated (or not) with 
rapamycin (200 ng/mL) in YPD and incubated at 28˚C with agitation for two 
hours.  Cells were subsequently washed three times in fresh YPD and ten-fold 
serial dilutions created and spotted onto a plain YPD plate.  Plates were 
incubated at 28˚C for two days prior to scanning.  Of the 20 null mutants tested 
(which were originally identified in the primary screen), we found that 14 did 
indeed display a rapamycin recovery defect as shown in Figure 6.2, Figure 6.3 
and Figure 6.4.  Each category of null mutants will be discussed in more detail 
below. 
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6.2.6.1 Threonine biosynthesis mutants 
As seen in Figure 6.2 we found that both of the two null mutants tested, hom2∆ 
and hom3∆, had a rapamycin recovery defect.  It would appear that Hom2p and 
Hom3p are somehow required for recovery from rapamycin. 
6.2.6.2 Endosomal trafficking mutants 
HOPS/CORVET mutants  
We found that none of the five mutants tested efficiently recovered from 
rapamycin treatment (Figure 6.3).  Cells lacking any of the four core proteins of 
the HOPS/CORVET complexes (Pep3p, Pep5p, Vps15p or Vps33p) were unable to 
recover from rapamycin treatment (Figure 6.3).  Loss of the HOPS specific 
subunit, Vam6p, also results in a recovery defect from rapamycin, but appears 
less severe than that observed for cells lacking of any of the core proteins 
(Figure 6.3).  It is therefore possible that the core HOPS/CORVET complex has a 
role in the TORC1 signalling pathway in addition to that of the Vam6p GEF in 
activating the EGO complex (Binda et al. 2009). 
The Vps15p-Vsp34p complex  
Of the two null mutants tested (vps15∆ or vps34∆), neither was able to recover 
from rapamycin treatment (Figure 6.3).  Phosphoinositide 3 kinase activity is 
therefore somehow required for recovery from rapamycin treatment. 
Remaining endosomal trafficking mutants  
Only one of the six remaining mutants classified as ‘endosomal trafficking’ had a 
rapamycin recovery defect (Figure 6.3).  Loss of Shp1p resulted in a rapamycin 
recovery defect (Figure 6.3), Shp1p is a cofactor protein for Cdc48 and is 
involved in membrane fusion and autophagosome biogenesis (Dargemont & 
Ossareh-Nazari 2012).  Loss of any one of Ypt7p, Vam7p, Snx4p, Atg11p, or Pib2p 
did not compromise rapamycin recovery (Figure 6.3).  It is therefore likely that, 
with the exception of shp1∆, these mutants were identified in the primary 
screen for reasons other than an inability to recover from rapamycin.  It is 
possible that Shp1p on the other hand is required for recovery from rapamycin. 
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Figure 6.2 Recovery from rapamycin of hom2∆ and hom3∆ mutants 
Exponentially growing wild-type, hom2∆ and hom3∆ cultures were normalised to 
an OD600nm of ~0.1 in YPD and treated (or not) with rapamycin (200 ng/mL) for 
two hours at 28˚C with agitation.  Cells were washed three times in fresh YPD 
prior to ten-fold serial dilutions being spotted (5 µL) onto a YPD plate which was 
incubated at 30˚C for two days.  Representative images of three repeats of 
individual strains are shown. 
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Figure 6.3 Recovery from rapamycin of endosomal trafficking mutants 
Exponentially growing cultures of wild-type, pep3∆, pep5∆, vps16∆, vps33∆, 
vam6∆, vps15∆, vps34∆, shp1∆, ypt7∆, vam7∆, snx4∆, atg11∆ and pib2∆ cells 
were normalised to an OD of ~0.1 in YPD and treated (or not) with rapamycin 
(200 ng/mL) for two hours at 28˚C with agitation.  Cells were washed three 
times in fresh YPD prior to ten-fold serial dilutions being spotted (5 µL)  onto a 
YPD plate which was incubated at 30˚C for two days.  Representative images of 
three repeats of individual strains are shown. 
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6.2.6.3 Regulation of transcription mutants 
We found that four of the five null mutants tested from the ‘regulation of 
transcription’ category failed to recover from rapamycin treatment.  As seen in 
Figure 6.4, loss of any one of Ccr4p, Dhh1p, Npl3p or Ctk1p resulted in a 
rapamycin recovery defect.  On the other hand, loss of Yke2p did not affect the 
ability of cells to recover (Figure 6.4).  It is possible that the roles of Ccr4p, 
Dhh1p, Npl3p or Ctk1p are required for recovery from rapamycin 
6.2.6.4 Summary 
Of the 20 null mutants tested we have identified 14 that fail to efficiently 
recover from rapamycin treatment.    It is known that Vam6p acts in the TORC1 
signalling pathway via its GEF activity towards the EGO complex.  We shall 
therefore not include vam6∆ mutants in our further phenotyping experiments.  
The remaining 13 null mutants that show a rapamycin recovery defect will be 
characterised further. 
 Tertiary screen I: Viability of null mutants in the presence 6.2.7
of rapamycin 
It is possible that the 13 null mutants fail to recover from rapamycin because 
they lose viability in the presence of rapamycin.  We tested the viability of these 
13 null mutants, using the methylene blue viability stain, in the absence and 
presence of a high concentration of rapamycin (200 ng/mL). 
Exponentially growing cultures were treated (or not) with rapamycin (200 
ng/mL) for two hours in YPD and incubated at 28˚C with agitation.  Following 
the two-hour rapamycin treatment, cells were washed three times with fresh 
YPD and inoculated into fresh YPD for a 24 hour “recovery period” at 28˚C with 
agitation.  Control cultures of untreated and continuously rapamycin (200 
ng/mL) treated cells in YPD were also included and were incubated at 28˚C with 
agitation for 24 hours.  To observe methylene blue staining, cells were exposed 
to the stain and observed by microscopy.   
 
190 
 
 
Figure 6.4 Recovery from rapamycin of regulation of transcription 
representatives 
Exponentially growing cultures of wild-type, ccr4∆, dhh1∆, npl3∆, ctk1∆ and 
yke2∆ cells were normalised to an OD600nm of ~0.1 in YPD and treated (or not) 
with rapamycin (200 ng/mL) for two hours at 28˚C with agitation.  Cells were 
washed three times with fresh YPD prior to ten-fold serial dilutions being 
spotted (5 µL) onto a YPD plate which was incubated at 30˚C for two days.  
Representative images of three repeats of individual strains are shown. 
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Control cultures of heat treated cells (aliquots of cells that had been exposed to 
rapamycin for 24 hours were heated to 85˚C for 10 minutes) were also included 
to ensure rapamycin did not affect the methylene blue stain in these cells.  A 
minimum of 200 cells were counted per culture.   
Wild-type and ego1Δ cultures were included as controls and as expected we 
found no loss of viability in either of these cultures as a result of treatment with 
rapamycin (Table 6.8).  By contrast, cells from heat-treated wild-type and heat-
treated ego1Δ cultures fully stained with methylene blue (Table 6.8).  We found 
that the presence of rapamycin did not result in a substantial proportion of cell 
death for any of the 13 null mutants tested (Table 6.8).  Whilst loss of Ccr4p did 
appear to result in more cell death in the presence of rapamycin than any of the 
other null mutants, the percentage death observed cannot explain the profound 
recovery defect of ccr4Δ mutants.  We therefore conclude that loss of viability is 
unable to explain the profound rapamycin recovery defect observed for any of 
the 13 null mutants tested, as assayed by methylene blue staining. 
 Tertiary screen II: Rapamycin-insensitive growth rate 6.2.8
Do the null mutants that are unable to recover from rapamycin display a slow 
rapamycin-insensitive proliferation rate?  Exponentially growing cultures were 
treated (or not) with rapamycin (200 ng/mL) in YPD and incubated at 28˚C with 
agitation.  The culture density was measured by spectrometry at OD600nm three 
and six hours after the introduction of rapamycin and the growth rate calculated 
between these times.  Growth rates were calculated relative to the average 
growth rate of untreated wild-type cultures.  These results will be considered 
for each category in turn. 
6.2.8.1 Threonine biosynthesis mutants 
Loss of either Hom2p or Hom3p did not compromise the vegetative growth rate 
compared to that of wild-type cultures (Figure 6.5).  However, we found that 
the rapamycin-insensitive growth rate of hom2∆ mutants was significantly slower 
than that of wild-type cultures (p=0.0008) and looks comparable to that of 
ego1∆ mutants (Figure 6.5A & B).   
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  Percentage of dead cells 
  
Untreated 
cells 
24 hours in 
constant 
rapamycin 
(200 ng/mL) 
24 hours following 
washout of 
rapamycin 
(200 ng/mL) 
Heat 
treated 
cells 
 WT <1% <1% <1% >99% 
 ego1Δ <1% <1% <1% >99% 
      
Threonine 
biosynthesis 
hom2Δ <1% <1% <1% >99% 
hom3Δ <1% <1% <1% >99% 
      
Endosomal 
trafficking 
pep3Δ <2% <1% <1% >99% 
pep5Δ <1% <1% <1% >99% 
vps33Δ <1% <1% <1% >99% 
vps16Δ <1% <1% <1% >99% 
     
vps15Δ <4% <4% <7% >99% 
vps34Δ <1% <1% <1% >99% 
     
shp1Δ <3% <17% <11% >99% 
      
Regulation of 
transcription 
ccr4Δ <6% <26% <30% >99% 
dhh1Δ <3% <8% <15% >99% 
npl3Δ <5% <11% <12% >99% 
ctk1Δ <2% <10% <6% >99% 
      
Table 6.8 Percentage of cell death following exposure to rapamycin 
The observed percentage of cell death in exponentially growing cultures, 
continuously rapamycin (200 ng/mL) treated cultures or after a recovery period 
from a two hour rapamycin (200 ng/mL) treatment.  Heat treated cells were 
included as a control.  Note that the percentage of dead cells for mutants 
labelled in bold is a combination of both methylene blue stained cells and those 
that had a ‘ghost cell’ like appearance which is an indicator that the cell has 
lysed (and therefore cannot retain the methylene blue stain). 
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Figure 6.5 The rapamycin-insensitive growth rate of hom2∆ and hom3∆ 
mutant cultures 
Exponentially growing cultures of wild-type, ego1∆, hom2∆ and hom3∆ cells 
were normalised to an OD600nm of ~0.05 (untreated) or ~0.1 (rapamycin treated) 
in YPD.  Normalised cultures were treated (or not) with rapamycin (200 ng/mL) 
in YPD and incubated at 28˚C with agitation for six hours.  At three and six hours 
after the introduction of rapamycin, the culture density was measured by 
spectrometry at OD600nm and the growth rate was calculated between these 
times for each culture.  
A: The growth rates of all cultures were calculated relative to the average 
growth rate of untreated wild-type cultures (0.59 hr-1).  
B: The rapamycin-insensitive growth rate of cultures was calculated relative to 
the average rapamycin-insensitive growth rate of wild-type cultures (0.25 hr-1).  
N=13 independent cultures for wild-type, 11 for ego1∆ and 3 for hom2∆ and 
hom3∆ cultures.  Error bars denote S.E.M.; * p<0.05 relative to equivalently 
treated wild-type cultures. 
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Unfortunately the error bars for the rapamycin-insensitive growth rates for 
hom3∆ cultures are too large to draw a definitive conclusion (Figure 6.5A & B).  
Our data suggests that a slow rapamycin-insensitive growth rate of hom2∆ may 
underpin their inability to recover from the drug. 
6.2.8.2 Endosomal trafficking mutants 
HOPS/CORVET mutants  
As seen in Figure 6.6, we found that loss of any one of the core HOPS/CORVET 
proteins did not result in a slow vegetative growth rate.  However, loss of 
Pep3p, Pep5p, Vps16p or Vps33p resulted in a significantly slow rapamycin-
insensitive growth rate compared to that of wild-type cultures (p=2.0X10-5 for 
pep3∆, 0.02 for pep5∆, 0.02 for vps16∆, 1.2X10-5 for vps33∆) (Figure 6.6A & B).  
The slow rapamycin-insensitive growth rate of these core HOPS/CORVET null 
mutants is indistinguishable from that of ego1∆ cultures (Figure 6.6A & B).  The 
compromised rapamycin-insensitive growth rate of the hop/corvet- cultures 
could therefore explain their inability to recover from rapamycin treatment. 
The Vps15p-Vsp34p complex   
We found that loss of Vps15p or Vps34p resulted in cultures with a modest, and 
significant in the case of vps15∆ cultures, defect in vegetative growth rate 
compared to that of wild-type cultures (p=8.6X10-5 for vps15∆) (Figure 6.6A).  
The rapamycin-insensitive growth rate of vps15∆ and vps34∆ mutant cultures 
was also significantly slower than that of wild-type cultures (p=0.02 for vps15∆ 
and 0.02 for vps34∆) (Figure 6.6A & B) and again appeared similar to that of 
rapamycin treated ego1∆ cultures (Figure 6.6 B).  The slow rapamycin-insensitive 
growth rate of these null mutants could therefore explain their inability to 
recover from rapamycin. 
Remaining endosomal trafficking mutants  
Null shp1∆ cultures were found to have a significantly slower vegetative growth 
rate compared to that of wild-type cultures (p=3x10-8) (Figure 6.6 A).  In the 
presence of rapamycin, the growth rate of shp1∆ cultures was significantly 
slower than that of wild-type cultures (p=0.01) and appeared similar to that of 
ego1∆ cultures (Figure 6.6 B).  A slow rapamycin-insensitive growth rate could 
account for the inability of shp1∆ cultures to recover from the drug. 
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Figure 6.6 The rapamycin-insensitive growth rate of pep3∆, pep5∆, vps16∆, 
vps33∆, vps15∆, vps34∆ and shp1∆ mutant cultures 
Exponentially growing cultures of pep3∆, pep5∆, vps16∆, vps33∆, vps15∆, vps34∆ 
and shp1∆ cells were normalised to an OD600nm of ~0.05 (untreated) or ~0.1 
(rapamycin treated) in YPD.  Normalised cultures were treated (or not) with 
rapamycin (200 ng/mL) in YPD and incubated at 28˚C with agitation for six 
hours.  At three and six hours after the introduction of rapamycin, the culture 
density was measured by spectrometry at OD600nm and the growth rate was 
calculated between these times for each culture.  The growth rates of wild-type 
and ego1∆ cultures from Figure 6.5 (indicated by a dashed border) are included 
for comparison; these growth rates were measured in parallel.  
A: The growth rates of all cultures were calculated relative to that of the 
average growth rate of untreated wild-type cultures (0.59 hr-1) which were 
measured in parallel.  
B: The rapamycin-insensitive growth rate of cultures was calculated relative to 
the average rapamycin-insensitive growth rate of wild-type cultures (0.25 hr-1), 
which were measured in parallel.  
N=13 independent cultures for wild-type, 11 for ego1∆, 7 for pep3∆ and 3 for all 
remaining cultures.  Error bars denote S.E.M.; * p<0.05 relative to equivalently 
treated wild-type cultures. 
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6.2.8.3 Regulation of transcription mutants 
We found that loss of Ccr4p or Dhh1p resulted in a slow vegetative growth rate 
compared to that of wild-type cultures (p=0.006 for dhh1∆ cultures; the 
difference was not significant in ccr4∆ cultures).  The rapamycin-insensitive 
growth rate of dhh1∆ and ccr4∆ cultures was also significantly slower than that 
of wild-type cultures (p=0.007 for ccr4∆, 9.8X10-5 for dhh1∆ cultures) (Figure 
6.7A & B).  Unfortunately the error bars are too large for ctk1∆ cultures to draw 
any firm conclusions.  Due to the initial inconsistency in the phenotype of 
different npl3∆ isolates, the rapamycin-insensitive growth rate of this mutant 
has not been measured.  However, the identification of a slow rapamycin-
insensitive growth rate of ccr4∆ and dhh1∆ cultures is consistent with the 
rapamycin-insensitive growth rate underlying the inability of cultures to recover. 
6.2.8.4 Summary 
All null mutants tested, that were confirmed to have a rapamycin recovery 
defect, also show a slow rapamycin-insensitive growth rate.  Note that the 
results for hom3∆ and ctk1∆ are inconclusive and have not been included in this 
analysis.  We have therefore identified null mutants from the initial primary 
screen that phenocopy ego- mutants, both in terms of their inability to recover 
from rapamycin treatment and their slow rapamycin-insensitive growth rate. 
 Selectivity to rapamycin treatment 6.2.9
We have shown that all null mutants tested (with the exception of hom3∆ and 
ctk1∆ mutants which were inconclusive) have a slow rapamycin-insensitive 
growth rate.  Do these mutations selectively result in a slow rapamycin-
insensitive growth rate?  We re-calculated the results obtained in Section 6.2.8 
to measure the fold decrease in growth rate of rapamycin-treated cultures 
compared that of the equivalently untreated cultures, measured in parallel.  
This re-calculation of the rapamycin-insensitive growth rates observed in Figure 
6.5, Figure 6.6 and Figure 6.7 is shown in Figure 6.8A. 
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Figure 6.7 The rapamycin-insensitive growth rate of ccr4∆, dhh1∆ and 
ctk1∆ mutant cultures 
Exponentially growing cultures of ccr4∆, dhh1∆ and ctk1∆ cells were normalised 
to an OD600nm of ~0.05 (untreated) or ~0.1 (rapamycin treated) in YPD.  
Normalised cultures were treated (or not) with rapamycin (200 ng/mL) in YPD 
and incubated at 28˚C with agitation for six hours.  At three and six hours after 
the introduction of rapamycin, the culture density was measured by 
spectrometry at OD600nm and the growth rate was calculated between these 
times for each culture.  The growth rates of wild-type and ego1∆ cultures from 
Figure 6.5 (indicated by a dashed border) are included for comparison; these 
growth rates were measured in parallel.  
A: The growth rates of all cultures were calculated relative to the average 
growth rate of untreated wild-type cultures (0.59 hr-1), which were measured in 
parallel.  
B: The rapamycin-insensitive growth rate of cultures was calculated relative to 
the average rapamycin-insensitive growth rate of wild-type cultures (0.25 hr-1), 
which were measured in parallel.  
N=13 independent cultures for wild-type, 11 for ego1∆, 4 for dhh1∆ and 3 for the 
remaining cultures.  Error bars denote S.E.M.; * p<0.05 relative to equivalently 
treated wild-type cultures. 
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We found that the slow rapamycin-insensitive growth rate is selectively affected 
by loss of seven of the 10 null mutants tested.  The fold change in growth rate of 
hom2∆, pep3∆, pep5∆, vps16∆, vps33∆, vps34∆ and dhh1∆ mutants in the 
presence of rapamycin was significantly slower than that of wild-type cultures 
(Figure 6.8A & B).  The fold change in growth rate of these mutant cultures, 
with the exception of hom2∆ mutants, was not significantly different to that of 
ego1∆ cultures (Figure 6.8B).  It is possible that loss of Hom2p results in a 
selectively slow rapamycin-insensitive growth rate, but that the defect is not as 
severe as that seen for ego1∆ cultures.  The fold change in growth rate of the 
remaining three mutant cultures (vps15∆, shp1∆ and ccr4∆) was not significantly 
different from that of either wild-type or ego1∆ cultures (Figure 6.8B).  These 
results are therefore inconclusive as to whether the slow rapamycin-insensitive 
growth rate is selective for loss of the protein in the presence of rapamycin.  We 
have therefore identified seven null mutants which show a selectively slow 
rapamycin-insensitive growth rate; it is possible the corresponding proteins are 
required for TORC1 activity. 
 Recovery from rapamycin of ego1∆ pep3∆ double mutants 6.2.10
The results of the primary and subsequent secondary and tertiary screens 
identified null mutants for any of the four members of the core HOPS/CORVET 
complex.  The primary and secondary screens also identified the HOPS specific 
component Vam6p, which has GEF activity towards Gtr1p of the EGO complex  
(Binda et al. 2009).  It has not previously been identified whether the core HOPS 
complex (shared with CORVET) also regulates TORC1.  We found that the 
rapamycin recovery defect was more severe in cells lacking any one of the core 
complex than in cells lacking Vam6p, indicating that the core HOPS/CORVET 
complex has other function(s), independent of Vam6p, in modulating TORC1 
activity.  Does this additional function of the core HOPS/CORVET complex in 
TORC1 regulation also act via the EGO complex?  Double mutants were created 
that lacked both the Ego1p subunit of the EGO complex and the Pep3p subunit of 
the core HOPS/CORVET complex.  The ability of these double mutant cells to 
recover from low concentrations of rapamycin was tested. 
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A 
 
B 
 Compared to WT Compared to ego1∆ 
 p<0.05 p= p<0.05 p= 
hom2∆  1.2x10-4  0.02 
     
pep3∆  3x10-8  0.2 
pep5∆  0.021  0.97 
vps16∆  0.024  0.31 
vps33∆  2x10-5  0.33 
     
vps15∆  0.07  0.63 
vps34∆  0.033  0.53 
     
shp1∆  0.059  0.36 
     
ccr4∆  0.14  0.11 
dhh1∆  0.03  0.53 
     
Figure 6.8 The fold decrease in growth rate in the presence of rapamycin 
compared to equivalent untreated cultures 
A: The fold decrease in growth rate was calculated for the rapamycin-insensitive growth 
rate of cultures shown in Figure 6.5, Figure 6.6 and Figure 6.7.  The fold decrease of the 
rapamycin-insensitive growth rate was calculated relative to the untreated culture 
measured in parallel (values ranged from 0.41 to 0.63 hr-1).  Error bars denote S.E.M.  
B: The p-values of the fold change in growth rate of each mutant relative to that of 
either wild-type or ego1∆ cultures.  A  indicates that the p-value is less than 0.05 
whilst a  indicates that the p-value is above 0.05.  The calculated p-values are also 
shown. 
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Exponentially growing cultures of wild-type, ego1∆, pep3∆ and ego1∆ pep3∆ 
cells were treated (or not) with rapamycin (2, 5, 10 or 200 ng/mL) in YPD for 
two hours at 28˚C with agitation.  Cells were washed three times in fresh YPD, 
ten-fold dilutions were created and spotted to a YPD plate.  Plates were 
incubated for two days at 28˚C to allow for recovery.   
As seen in Figure 6.9, we found that loss of both the EGO and core 
HOPS/CORVET complexes resulted in an indistinguishable phenotype from that of 
the single pep3∆ mutant at all concentrations of rapamycin tested.  These 
results suggest that the EGO and core HOPS/CORVET complex do indeed act in 
the same pathway to promote recovery from rapamycin.   
We found that loss of Pep3p resulted in cells with a more severe recovery defect 
than loss of Ego1p at low concentrations of rapamycin (10 ng/mL).  This result 
suggests that the core HOPS/CORVET complex has a role in aiding recovery from 
rapamycin in addition to any role in the EGO pathway. 
 The rapamycin-insensitive growth rate of hops/corvet- 6.2.11
ego- double mutants 
If the core HOPS/CORVET complex is required for maintaining TORC1 activity in 
addition to that of the EGO complex, does the double ego- hops/corvet- mutant 
have a slow rapamycin-insensitive growth rate in the presence of a high 
concentration of the drug? We can use the measurement of the rapamycin-
insensitive growth rate as a proxy for TORC1 activity in strains lacking the EGO 
complex, core HOPS/CORVET complex or both. 
Exponentially growing cultures of ego1∆ pep3∆ cells were treated (or not) with 
rapamycin (200 ng/mL) in YPD and incubated at 28˚C with agitation.  At three 
and six hours after the introduction of the drug the culture density was 
measured by OD600nm and the growth rate calculated between these time points.  
All growth rates were calculated relative to that of the average untreated wild-
type culture from Figure 6.5, the growth rates of which were measured in 
parallel.  The growth rates of ego1∆ and pep3∆ cultures from Figure 6.6 are 
included as comparisons; again these growth rates were also measured in 
parallel to that of the wild-type and double-mutant cultures.   
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Figure 6.9 Rapamycin recovery of ego1∆ pep3∆ double mutants from 
various concentrations of the drug 
Exponentially growing cultures of wild-type, ego1∆, pep3∆ and ego1∆ pep3∆ 
cells were treated (or not) with rapamycin (2, 5, 10 or 200 ng/mL) in YPD and 
incubated at 28˚C with agitation for two hours.  Cells were washed three times 
in fresh YPD, ten-fold serial dilutions created and spotted (5 µL) onto a plain YPD 
plate.  Plates were incubated at 28˚C for two days prior to scanning.  These 
images represent one of two independent replicates. 
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We found that the rapamycin-insensitive growth rate of the double ego1∆ pep3∆ 
mutant was not significantly different to that of either the ego1∆ or the pep3∆ 
single mutant cultures (p=0.05 compared to ego1∆ and 0.07 compared to pep3∆ 
cultures) (Figure 6.10).   
We conclude that the core HOPS/CORVET and EGO complexes behave as if in a 
co-linear pathway; the core HOPS/CORVET complex supports TORC1 activity via 
the EGO complex alone.  These results also suggest that the more severe 
rapamycin recovery defect phenotype of pep3∆ cultures is not due to loss of 
rapamycin-insensitive functions of TORC1, as assayed by growth rate.  It is 
possible that loss of Pep3p, and by inference disruption of the core 
HOPS/CORVET complex, could affect the uptake of rapamycin into the cell or 
result in an altered threshold of TORC1 activity required for recovery.  
 Could a vacuolar morphology defect explain the 6.2.12
requirement of the core HOPS/CORVET complex in 
rapamycin recovery? 
The HOPS/CORVET complexes are required for vesicle trafficking and for 
maintaining the structure of the vacuole (Cai et al. 2007).  It is thought that the 
TORC1 complex, along with key activators such as the EGO complex, are 
localised to the cytoplasmic face of the vacuolar membrane.  Is it possible that 
the inability of hops/corvet- mutants to recover from rapamycin is due to 
malformed vacuoles and therefore potentially mislocalised TORC1, activators of 
the complex and downstream targets?  If a loss of vacuole morphology results in 
a recovery defect, we would expect any mutant in which vacuole morphology, 
and potentially all endosomal trafficking, is disrupted would also have a 
recovery defect.  Ypt7p is a Rab GTPase for the HOPS complex and is required 
for the homotypic fusion of late endosomes to the vacuole; mutants lacking 
Ypt7p have numerous fragmented vacuoles within the cell (Cai et al. 2007; Haas 
et al. 1995).  Null ypt7∆ mutants were identified in our primary mutant set but 
exhibited a wild-type phenotype with regards to rapamycin recovery in our 
secondary screen (Figure 6.3).  Is vacuolar trafficking indeed disrupted in this 
mutant?  We used the vacuolar stain FM4-64 to visualise the vacuoles of wild-
type, ego1∆, pep3∆, ego1∆ pep3∆ and ypt7∆ cells to test whether disruption of 
vacuolar morphology affects the ability of cells to recover from rapamycin. 
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Figure 6.10 The rapamycin-insensitive growth rate of ego1∆ pep3∆ double 
mutant cultures 
Exponentially growing cultures of ego1∆ pep3∆ cells were treated (or not) with 
rapamycin (200 ng/mL) in YPD and incubated at 28˚C with agitation.  The 
growth rate was calculated from the culture density, as measured by 
spectrometry at OD600nm, at three and six hours after the introduction of 
rapamycin.  All growth rates were calculated relative to that of the average 
untreated wild-type culture (0.59 hr-1) from Figure 6.5, the growth rates of 
which were measured in parallel.  The growth rates of ego1∆ and pep3∆ cultures 
from Figure 6.6 are included as comparisons, these growth rates were also 
measured in parallel to that of the wild-type and double mutant cultures.  The 
vegetative growth rate of the ego1∆ pep3∆ culture was significantly slower than 
that of wild-type cultures (p=0.04) and the rapamycin-insensitive growth rates of 
ego1∆, pep3∆ and ego1∆ pep3∆ cultures were significantly slower than that wild-
type cultures (p=2.1x10-8, 2.0x10-8 and 1.8x10-4 respectfully).  N=13 independent 
cultures for wild-type, 11 for ego1∆, 7 for pep3∆ and 5 for ego1∆ pep3∆ cultures.  
Error bars denote S.E.M. 
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Exponentially growing cultures of wild-type, ego1∆, pep3∆, ego1∆ pep3∆ and 
ypt7∆ cells were treated (or not) with rapamycin (200 ng/mL) in YPD at 28˚C 
with agitation for two hours.  Cells were pelleted, concentrated into YPD (with 
or without rapamycin (200 ng/mL) as appropriate) containing FM4-64 (2 µM) and 
incubated at 30˚C for 30 minutes in the dark.  Cells were diluted into fresh YPD, 
pelleted, then resuspended into YPD (with or without rapamycin (200 ng/mL) as 
appropriate) and incubated at 28˚C with agitation for 90 minutes in the dark (to 
allow time for the stain to traffic to the vacuole).  Cells were washed once with 
water and concentrated into complete synthetic media (which was used to 
reduce autofluorescence).  All samples were kept on ice until assayed by 
microscopy. 
We found that exponentially growing wild-type cells had predominantly one 
small-sized vacuole (Figure 6.11).  Following rapamycin treatment however, the 
vacuole of wild-type cells increased in size and appeared to take up a large 
proportion of the cell (Figure 6.11).  These observations are consistent with low 
TORC1 activity promoting autophagy.  We found that the vacuolar morphology of 
ego1∆ mutants appeared no different from those of wild-type cells both in the 
absence or presence of rapamycin (Figure 6.11).  Exponentially growing pep3∆ 
mutants did not appear to have any defined vacuolar structure, instead the FM4-
64 was widely dispersed throughout the cytoplasm.  When pep3∆ mutants were 
treated with rapamycin, the FM4-64 was found to remain dispersed through the 
cytoplasm but was concentrated in small puncta; no defined vacuole structure 
was observed (Figure 6.11).  These results are consistent with loss of the core 
HOPS/CORVET complex preventing the formation of a vacuole.  The 
concentrated puncta of FM4-64 stain in rapamycin treated pep3∆ cells is 
potentially due to the upregulation of autophagy and accumulation of late 
endosomal vesicles due to the lack of a vacuole with which to fuse.  The 
dispersion of FM4-64 stain in double ego1∆ pep3∆ mutant cells both in the 
absence and presence of rapamycin appeared very similar to that of the single 
pep3∆ mutant (Figure 6.11).  Consistent with the requirement of Ypt7p for 
fusion of endosomes to the vacuole, we found that loss of Ypt7p indeed resulted 
in cells that also had no identifiable vacuole; the FM4-64 stain was distributed 
throughout the cytoplasm both in the absence and presence of rapamycin 
(Figure 6.11).   
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Figure 6.11 Representative images of FM4-64 staining in wild-type, ego1∆, 
pep3∆, ego1∆ pep3∆ and ypt7∆ cells 
Cultures of wild-type, ego1∆, pep3∆, ego1∆ pep3∆ and ypt7∆ cells were treated 
(or not) with rapamycin (200 ng/mL) in YPD for two hours at 28˚C with agitation 
after which they were exposed to the vacuole stain FM4-64 for 30 min at 30˚C.  
The cultures were washed into fresh media, either with or without rapamycin, 
and incubated for 90 minutes at 28˚C with agitation to allow time for the stain 
to localise at the vacuole.  Fluorescent microscopy images of mutant cells of 
were taken with an excitation wavelength of 505-530 nm and an emission 
wavelength of 560 nm.  All images were captured using a 63x oil immersion 
objective and a merge of the bright field and fluorescent image is shown.   
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As seen in the pep3∆ and ego1∆ pep3∆ mutant cells, treatment with rapamycin 
resulted in an increase in defined puncta of FM4-64 staining in ypt7∆ mutants, 
but no clear vacuolar structure was observed (Figure 6.11).  The lack of vacuolar 
morphology in pep3∆ and ypt7∆ mutants is consistent with published results that 
these proteins are required for normal vacuole morphology (Cai et al. 2007).   
Does a vacuolar morphology defect correlate with the inability to recover from 
rapamycin?  We have shown that ypt7∆ mutants, like those lacking Pep3p, do not 
have a recognisable vacuolar structure (Figure 6.11).  Yet unlike pep3∆ mutants, 
loss of Ypt7p does not result in a rapamycin recovery defect (Figure 6.3).  These 
results alone suggest that the morphology of the vacuole does not correlate with 
an ability to recover from rapamycin.  We have also shown that mutants lacking 
the EGO complex or those lacking Pep3p fail to recover from rapamycin 
treatment (Figure 3.1 and Figure 6.3), yet ego1∆ mutants have vacuoles that 
appear wild-type (Figure 6.11).  We conclude that cells are able to recover from 
rapamycin regardless of the presence of a vacuolar structure.  The core 
HOPS/CORVET complex must therefore have functions in addition to that 
required to maintain the vacuole and these functions appear to act, at least in 
part, via the EGO complex to regulate TORC1 activity. 
 Conclusion 6.3
A primary screen was carried out in an attempt to identify null mutants that 
failed to recover following incubation in the presence of rapamycin.  Of the 
~4,700 null mutants tested, 172 failed to recover in at least one run of the 
screen.  We chose to analyse only those null mutants that had been identified in 
any two or more runs of the screen (88 null mutants in total).  As a result of 
testing for GO term enrichment and known protein-protein interactions we 
identified 20 null mutants for further phenotyping.  The results of our secondary 
and tertiary screens can be seen in Table 6.9.  The results of the GO term 
analysis identified three categories of enriched genes which we termed 
threonine biosynthesis, endosomal trafficking and regulation of transcription.  As 
seen in Table 6.9, null mutants were identified in each category that had a 
rapamycin recovery defect and a slow rapamycin-insensitive growth rate that 
was selective for loss of the protein.   
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Secondary 
screen: Tertiary screen: 
 
Category 
Gene 
name 
Rapamycin 
recovery 
defect 
Viable in 
rapamycin 
Slow 
rapamycin-
insensitive 
growth rate 
Selectively 
affects 
growth rate 
in rapamycin 
Threonine 
biosynthesis 
HOM2     
HOM3   ?  
      
Endosomal 
trafficking 
PEP3     
PEP5     
VPS16     
VPS33     
VAM6     
VPS15    ? 
VPS34     
SHP1    ? 
YPT7     
VAM7     
SNX4     
ATG11     
PIB2     
      
Regulation of 
transcription 
CCR4    ? 
DHH1     
NPL3     
CTK1   ?  
YKE2     
      
Table 6.9 Summary of the results of the secondary screens 
A summary of the results for each of the 20 null mutants tested in the secondary 
and tertiary screens.  An indication of whether the slow rapamycin-insensitive 
growth rate is selective for the presence of rapamycin is also shown.  =positive 
result observed; =negative result observed; ?=inconclusive result. 
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From our initial analysis and secondary testing we have confirmed seven null 
mutants that phenocopy loss of the EGO complex. 
By carrying out GO term analysis and protein-protein interaction analysis, as well 
as only selecting representatives of each category, we have potentially 
overlooked additional null mutants from the primary screen that could have a 
rapamycin recovery defect.  It would be worth performing a rapamycin recovery 
secondary screen on the remaining 64 null mutants identified in two or more 
runs of the primary screen to test their ability to recover from the drug.  A 
screen carried out by the De Virgilio group to identify null mutants unable to 
recover from a 24 hour incubation in the presence of rapamycin (200 ng/mL) 
identified eight mutants, all of which were also identified in our primary mutant 
set: ego1∆, ego3∆, gtr2∆, pib2∆, sac3∆, ydj1∆ and ydl172c∆  (Dubouloz et al. 
2005).  It would appear that three of the eight mutants identified in both our 
screen and the De Virgilio screen, sac3∆, ydj1∆ and ydl172c∆, received little 
attention in either our or De Vrigilios subsequent analysis.  Testing the ability of 
these null mutants to recover from rapamycin might identify yet more potential 
regulators of TORC1. 
Null mutants of the core HOPS/CORVET complex survived the primary, secondary 
and tertiary aspects of the screen.  The slow rapamycin-insensitive growth rate 
of core hops/corvet- mutants appears to be selective for loss of any one of the 
four proteins (Table 6.9).  Vam6p, is a known activator of the EGO complex 
(Binda et al. 2009) and is also a subunit of the HOPS complex, however it has not 
been clear whether Vam6p acts independently of the HOPS complex to regulate 
EGO.  We have shown here that loss of the core HOPS/CORVET proteins results in 
a more profound rapamycin recovery defect than loss of Vam6p.  We concluded 
that the core HOPS/CORVET complex therefore has a function in TORC1 
signalling independent of the HOPS subunit Vam6p.  All known regulators of 
TORC1 identified so far appear to act via the EGO complex.  We used a double 
ego- hops/corvet- mutant to test whether the core HOPS/CORVET complex also 
acts via the EGO complex to signal to TORC1.  It would appear that the core 
HOPS/CORVET complex function in regulating TORC1 also acts via the EGO 
complex alone.  Loss of both the EGO and core HOPS/CORVET complexes does 
not result in a slower rapamycin-insensitive growth rate than loss of the core 
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HOPS/CORVET complex alone.  However loss of the core HOPS/CORVET complex 
does result in a more severe recovery defect at low concentrations of rapamycin 
than loss of the EGO complex.  It would therefore appear that the core 
HOPS/CORVET complex has a minor additional role that acts independently of 
the EGO complex. 
It is possible that the additional role of the core HOPS/CORVET complex is 
involved in the uptake of rapamycin; the ability of core hops/corvet- mutants to 
recover from 10 ng/mL rapamycin was less efficient than that of ego- cultures 
yet these two mutants have indistinguishable rapamycin-insensitive growth 
rates, which should dictate the ability to recover.  It is therefore unlikely that 
the additional role of the core HOPS/CORVET complex is affecting the 
rapamycin-insensitive function of TORC1.  One possibility is that loss of vacuolar 
structure and endosomal trafficking in a core hops/corvet- mutant, but only in 
addition to loss of signalling to TORC1 by the complex, impacts the sensitivity of 
cells to the drug. 
The identification of the core HOPS/CORVET complex in regulating TORC1 has 
provided us with a number of questions including: What is the role of the core 
HOPS/CORVET complex in signalling to the EGO complex?  What is the EGO 
independent function of the core HOPS/CORVET complex?  Does loss of the core 
HOPS/CORVET complex alter drug uptake?  We address some of these questions 
in the final discussion chapter. 
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7 Discussion 
Here, we found that rapamycin-insensitive proliferation is key to efficient 
recovery from rapamycin.  Furthermore, we found that rapamycin-insensitive 
activity of TORC1 exists, drives this residual proliferation and accounts for the 
requirement for the EGO complex during recovery.  Finally, we identified novel 
genes whose products may, like the EGO complex, activate TORC1 activity in 
vivo. 
 Rapamycin does not fully inactivate TORC1 7.1
Wild-type cells treated with rapamycin are able to maintain proliferation in the 
constant presence of the drug.  However, proliferation is completely abolished 
in cells lacking the TORC1 subunit Kog1p and, by inference, TORC1 activity.  We 
therefore conclude that rapamycin is only a partial inhibitor of yeast TORC1 
activity.  The identification of rapamycin-insensitive functions of yeast TORC1 
brings the yeast complex in line with that of mammalian cells; mTORC1 has been 
shown to have functions that are not inhibited by rapamycin (Feldman et al. 
2009; Thoreen et al. 2009)  The identification of rapamycin-insensitive functions 
of yeast TORC1 suggests that there is likely to be a whole aspect of yeast TORC1 
signalling that has been hidden from analysis, until now. 
What are the functions of TORC1 that are insensitive to rapamycin?  We have 
shown that proliferation is lowered but not completely abolished by rapamycin 
treatment.  We found that loss of the EGO complex combined with rapamycin 
treatment results in almost no rate of translation in these cells; these results 
suggest that maintaining translation could be a rapamycin-insensitive function of 
yeast TORC1.  One key downstream function insensitive to rapamycin in 
mammalian cells is the activation of the translation repressor 4EBP1 (Feldman et 
al. 2009).  It is therefore probable that aspects of translation are also regulated 
by yeast TORC1 in a rapamycin-insensitive manner.  We found that loss of a 
functional homolog of 4EBP1, Eap1p, resulted in cells with a slow rapamycin-
insensitive proliferation rate.  Whilst the role of Eap1p is thought to be that of a 
translational repressor, it is possible that the protein also functions to positively 
regulate translation via TORC1 in a rapamycin-insensitive manner.  The 
identification of Eap1p as a potential regulator of translation in the TORC1 
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signalling pathway is consistent with previous studies, however the exact role of 
Eap1p in response to TORC1 remains elusive (Cosentino et al. 2000). 
 Is rapamycin-insensitive activity due to a subset of 7.2
TORC1 not bound to rapamycin? 
Is it possible that we observe rapamycin-insensitive functions in yeast due to 
incomplete binding of the Fpr1p-rapamcyin binary complex to TORC1?  We 
believe that this is not the case.  Firstly, Fpr1p is one of the most abundant 10% 
of proteins in the cell, whilst the TORC1 specific subunits are within the least 
25% abundant proteins, as estimated by quantitative proteomics (Wang et al. 
2012).  It is therefore highly unlikely that Fpr1p is limiting for formation of the 
binary Fpr1p-rapamycin complex.  Second, we can estimate the fold increase in 
the amount of intracellular rapamycin compared to the estimated minimum 
inhibitory threshold.  We know that wild-type cultures double approximately 
every five hours in the presence of a high concentration of rapamycin, meaning 
the intracellular pool of rapamycin in cells during recovery is halved every five 
hours.  We found that it took approximately 20 hours for wild-type cultures to 
recover from 200 ng/mL rapamycin (Figure 5.12), suggesting that the 
intracellular pool of rapamycin had halved four times before becoming sub-
inhibitory.  We can therefore predict that the intracellular pool of rapamycin in 
wild-type cells treated with 200 ng/mL rapamycin is 16 (24) times greater than 
the minimum required to inhibit TORC1.  It is highly unlikely that TORC1 is not 
being saturated under these conditions.  Whilst it appears rapamycin is not 
limiting for binding to TORC1, is it possible there is a subset of TOR1 complexes 
that cannot bind rapamycin? 
It is possible that we see rapamycin-insensitive activity due to elevated levels of 
reactive oxygen species (ROS) which can disrupt the ability of TORC1 to bind to 
Fpr1p-rapamycin under stressed conditions (Neklesa & Davis 2008), meaning a 
fraction of TORC1 may not be bound to Fpr1p-rapamycin under our experimental 
conditions.  We do not think this is the case; ROS damage to TORC1 has not been 
detected under normal nutrient-rich conditions (Neklesa & Davis 2008). 
Furthermore, we have carried out preliminary tests of the rapamycin-insensitive 
growth rate of cultures overexpressing a superoxide dismutase in combination 
with a catalase and do not see a change in the rapamycin-insensitive growth rate 
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of these cultures compared to that of wild-type cultures.  We therefore 
conclude that the rapamycin-insensitive growth rate observed is due to inherent 
rapamycin-insensitive functions of TORC1 and not a result of only a fraction of 
the TORC1 complexes being inactivated. 
 The mechanism of rapamycin ‘detoxification’ 7.3
The mechanism of rapamycin detoxification has received little attention.  Here 
we show that rapamycin is not in fact actively metabolised in nor exported from 
the yeast cell, instead the drug is diluted between an increasing number of 
progeny cells: i.e. diluted-by-proliferation.  It must be the case that any drug in 
which residual proliferation occurs is also partially ‘detoxified’ by a mechanism 
of dilution-by-proliferation; however, we are not aware of any other xenobiotic 
for which this mechanism is predominant in reducing drug toxicity. 
It is worth mentioning that, whilst we have identified a mechanism by which 
rapamycin is cleared from cells, it is still unclear how rapamycin enters the cell.  
It is likely that the import mechanism of rapamycin is also regulated by TORC1 
activity.  We have found that wild-type cultures are able to recover from a 
prolonged, at least a 24 hour, treatment period with high concentrations of 
rapamycin.  If rapamycin continues to be taken up by cells throughout this 
treatment period then the intracellular drug pool would grow with time, 
resulting in an increased recovery time.  Knowing that recovery of rapamycin is 
dependent on the incredibly slow mechanism of dilution-by-proliferation, the 
ability of cells to recover from an extremely long treatment time suggests that 
the intracellular amount of the drug is limited.  It is possible that rapamycin 
enters the cell via an amino-acid transporter.  If rapamycin enters via an 
importer that is subsequently removed from the cell surface following the 
inactivation of TORC1 it could explain why intracellular rapamycin potentially 
has a threshold limit.  It may be interesting to test whether maintaining amino 
acid permeases, which are normally degraded following TORC1 inactivation, at 
the cell surface results in an increase in recovery time. 
This work was initially carried out to observe whether or not cells were able to 
recover from rapamycin treatment; however, our assay evolved to measure the 
rapamycin-insensitive growth rate.  We subsequently found that the rapamycin-
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insensitive growth rate dictated whether or not we saw a recovery defect, i.e., 
a continuous phenotype (rapamycin-insensitive growth rate) reflected a 
discontinuous phenotype (ability to recover).  In fact we now rename the 
‘ability’ of cells to recover as the ‘efficiency’ of cells to recover.  We have 
identified a number of null mutants in which the rapamycin-insensitive growth 
rate is significantly slower than that of wild-type cultures yet they do not exhibit 
as profound a recovery defect as that observed for ego- mutants.  It is possible 
that there is a threshold of proliferation rate, influenced by TORC1 activity, that 
dictates the ability of a cell to recover within a specified time.  Cells that 
proliferate slower than the threshold would be classified as having a profound 
recovery defect under the conditions of our experiment.  On the other hand, 
cells that proliferate faster than the threshold would appear able to recover 
from rapamycin treatment, even though their rapamycin-insensitive proliferation 
rate may be slower than that of wild-type cells.  Note that due to the nature of 
recovery from rapamycin, i.e. the mechanism of dilution-by-proliferation, if the 
conditions of the experiment are altered, for example the concentration of 
rapamycin used during treatment, the recovery defect of a mutant may be 
classified differently. 
 Identifying other potential regulators of TORC1 7.4
 Mutants of translational regulators 7.4.1
We found that loss of Ccr4p or Dhh1p resulted in a slow rapamycin-insensitive 
growth rate that was selectively due to loss of either of the proteins.  Ccr4p 
functions in the CCR4-NOT complex to both positively and negatively regulate 
transcription and translation (Liu et al. 1998) whilst Dhh1p functions in 
decapping mRNAs and has been shown to be regulated by the CCR4-NOT complex 
(Coller et al. 2001; Maillet & Collart 2002).  We know, from measuring the 
translation rate of ego1∆ mutants, that maintaining translation is required for 
the ability of cells to proliferate in the presence of rapamycin and therefore 
recover from the drug.  It is therefore possible that cells which have lost either 
of these two proteins (Ccr4p or Dhh1p) fail to recover from rapamycin due to 
excessively low translation rates in the presence of rapamycin.  Measuring the 
translation rates of these mutants, both in the absence and presence of 
rapamycin, will provide an insight into whether this is the case.  If the inability 
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of ccr4∆ and dhh1∆ mutants is due to slow translation, it would suggest that 
these proteins act downstream of TORC1 and are not necessarily regulators of 
the complex. 
 Mutations of the HOM proteins 7.4.2
Four null mutants, the proteins of which are involved in threonine biosynthesis, 
were identified in the primary screen.  Whilst we were only able to test the 
rapamycin recovery phenotype of hom2∆ and hom3∆ mutants, we found that loss 
of either one of these proteins results in a rapamycin recovery defect.  It has 
been shown that Fpr1p acts as part of a feedback loop in the threonine 
biosynthesis pathway to prevent accumulation of the toxic aspartate β-
semialdehyde intermediate (Figure 7.1) (Arévalo-Rodríguez et al. 2004). Fpr1p, 
activated by threonine, binds to Hom3p, the first enzyme in the aspartate to 
threonine (and methionine) biosynthesis pathway (Arévalo-Rodríguez et al. 
2004).  TORC1 is a regulator of cell growth in response to nutrient availability; it 
is possible that when our wild-type strain is treated with rapamycin, Fpr1p is 
saturated and unable to modulate the threonine (and methionine) biosynthesis 
pathway (Figure 7.1).  If this is the case, a wild-type cell treated with rapamycin 
could result in elevated levels of threonine and methionine that could elevate 
TORC1 activity due to the cell sensing high intracellular amino acids.  Therefore 
in cells lacking Hom2p or Hom3p, threonine (and methionine) levels are not 
elevated following rapamycin treatment resulting in less TORC1 activity, a slow 
rapamycin-insensitive growth rate and an inability to recover (Figure 7.1).  It 
would be interesting to observe the phenotype of an ego- hom2∆ or hom3∆ 
double mutant to observe whether disruption of threonine biosynthesis pathway 
signals to TORC1 independently of, or via, the EGO complex. 
 The Vps15-Vps34 complex 7.4.3
We found that both vps15∆ and vsp34p∆ null mutants were unable to recover 
from rapamycin treatment.  The human homolog of Vps34p has for some time 
being implemented in the mTORC1 signalling pathway, yet the role of hVps34 
remains unclear (De Virgilio & Loewith 2006a).  The identification of both vps15∆ 
and vsp34p∆ null mutants in our screen suggests that these two proteins could 
be required for TORC1 activity.   
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Figure 7.1 The role of Hom2p and Hom3p in threonine biosynthesis and 
their potential role in TORC1 activation 
In vegetatively growing cells Fpr1p is regulated by threonine to inhibit the 
homoserine biosynthesis pathway.  We predict that following rapamycin 
treatment this feedback loop is deregulated resulting in an increase in threonine 
production which could signal to TORC1 via amino acid sensing mechanisms 
promoting TORC1 activity.  Loss of either Hom2p or Hom3p would prevent the 
synthesis of threonine in cells treated with rapamycin resulting in decreased 
TORC1 stimulation.  Dashed lines indicate a number of enzymatic steps are 
involved that are not shown on this diagram 
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Vps34p is the only phosphatidylinositol 3-kinase in yeast (Obara & Ohsumi 2011).  
The signalling molecule phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) has 
been implicated in localising the TORC1 downstream target Sch9p to the 
vacuolar membrane (Jin et al. 2014).  Is it possible that loss of the 
phosphatidylinositol 3-kinase activity of the Vps15p-Vps34p complex results in a 
loss of this PI(3,5)P2 signalling molecule and therefore disrupts downstream 
TORC1 signalling?  Fab1p is the only protein in yeast that converts PI(3)P into 
PI(3,5)P2 and loss of Fab1p results in rapamycin hypersensitivity (Jin et al. 
2014).  It is possible that the role of the Vsp15p-Vps34p complex is to provide 
the PI(3)P precursor for Fab1p to create PI(3,5)P2 that is potentially required for 
TORC1 activity in a number of ways, one of which could be to recruit TORC1, its 
regulators and targets to the vacuolar membrane (see Chapter 1).  If PI(3,5)P2 is 
required for TORC1 localisation with its downstream targets, and PI(3,5)P2 is lost 
in cells lacking either Vps15p or Vps34p it would suggest that these proteins are 
in fact implemented in regulating downstream functions of TORC1 rather than 
modulating TORC1 activity itself.  
 The core HOPS/CORVET complex 7.4.4
We identified that loss of any of the four of the core HOPS/CORVET complex 
proteins resulted in a profound recovery defect.  Loss of one of the core 
complex proteins resulted in a more severe phenotype than loss of the HOPS 
specific subunit, Vam6p, which has been shown to act as a GEF towards Gtr1p of 
the EGO complex (Binda et al. 2009).  These results suggest that the core 
HOPS/CORVET complex has a role in TORC1 signalling in addition to providing a 
platform for the Vam6p subunit (Figure 7.2).   
The TORC1 complex, its regulators and targets localise to the vacuolar 
membrane.  Disruption of either endosomal trafficking or the vacuolar structure 
in a hops/corvet- mutant could disrupt TORC1 signalling.  We found that this was 
unlikely; we tested both the vacuolar morphology and the ability to recover from 
rapamycin treatment of a ypt7∆ mutant.  We found that the vesicle structure of 
a ypt7∆ mutant appeared similar to that of a pep3∆ null mutant, in that there 
was no defined vacuole.  However, loss of Ypt7p did not compromise the ability 
of these cells to recover from rapamycin treatment.   
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Figure 7.2 The upstream TORC1 signalling pathway showing the role of the 
core HOPS/CORVET complex 
The core HOPS/CORVET complex has two roles in signalling to TORC1, both of 
which act via the EGO complex: 1) the HOPS complex acts as a GEF to Gtr1p via 
the Vam6p subunit.  2) The core HOPS/CORVET proteins signal to the EGO 
complex in a currently unknown mechanism. 
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We therefore conclude that the core HOPS/CORVET complex has a role in TORC1 
signalling that is different to its role for vesicle trafficking and proper vacuolar 
morphology. 
Whilst the mammalian V-ATPase has been shown to have a role in regulating 
mTORC1, it would appear that this is unlikely to be the case in yeast.  
Preliminary studies from the Gray laboratory have found that mutants lacking a 
functional V-ATPase, and therefore defective vacuole function (Li & Kane 2009), 
are able to fully recover from rapamycin treatment.  These results are 
consistent with other studies that find the V-ATPase is not required for 
rapamycin recovery in yeast (for example Kingsbury et al. 2014).  The ability of 
cells with no functional V-ATPase to recover from rapamycin supports our 
conclusion that the inability of core hops/corvet- mutants to recover from 
rapamycin is due to a function of the complex in addition to that involved in 
maintaining vacuole morphology and function. 
All nutrient signalling to TORC1 identified so far appears to act via the EGO 
complex.  Is this also true for the core HOPS/CORVET complex?  Genetic analysis 
of a double ego1∆ pep3∆ mutant suggests that the signalling of the 
HOPS/CORVET core complex acts via the EGO complex; the phenotype of a 
double ego1∆ pep3∆ mutant was no different to that of a single pep3∆ mutant.  
It would therefore appear that the core HOPS/CORVET complex has two roles in 
activating TORC1; firstly the Vam6p component of the HOPS complex acts as a 
GEF towards Gtr1p of the EGO complex.  Second, the core HOPS/CORVET 
complex has an, as yet unidentified, role in TORC1 signalling that also appears to 
somehow act via the EGO complex.  This conclusion is consistent with a recent 
study that has also shown that the core HOPS/CORVET complex may act via the 
EGO complex to regulate TORC1 (Kingsbury et al. 2014). 
It is also possible that a hops/corvet- core mutant disrupts downstream 
signalling of TORC1.  It has recently been shown that translocation of the GATA 
transcription factors, Gat1p and Gln3p, to the nucleus following TORC1 
inactivation is dependent on at least three of the four core HOPS/CORVET 
proteins (Pep3p, Pep5p and Vps16p; Vps33p was not tested) (Fayyadkazan et al. 
2014).  It is therefore possible that whilst loss of endosomal trafficking does not 
appear to dictate the ability to recover from rapamycin per se, it is possible that 
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loss of upstream signalling and disruption of downstream signalling could explain 
why loss of the core HOPS/CORVET complex results in a profound recovery 
defect.  
 How much TORC1 activity is insensitive to 7.5
rapamycin? 
Why do ego- mutants have no vegetative growth defect?  It appears that TORC1 
activity is ~60% less in exponentially growing ego- mutants compared to wild-
type cells as measured by the phosphorylation state of Sch9p (Binda et al. 2009; 
Panchaud et al. 2013b).  The amount of TORC1 activity in the wild-type cell 
appears to be significantly higher than is required to maintain proliferation 
under normal conditions.  Furthermore, ego- mutant cells do not display any 
other characteristics of cells with low TORC1 activity.  It is possible that 
different consequences of inactive TORC1 are initiated at different thresholds of 
TORC1 activity.  Sch9p phosphorylation aside, it would appear that all other 
hallmarks of inactive TORC1 measured in ego- cells (including the proliferation 
rate, translation rate, autophagy, glycogen accumulation and phosphorylation of 
eIF2α (our results and Dubouloz et al. (2005)) require a larger reduction in 
TORC1 activity.  However, these hallmarks have only been measured in high 
concentrations of rapamycin.  Indeed, in this thesis we have not tested the 
induction of autophagy or the rapamycin-insensitive growth rate in 
concentrations of rapamycin less than 20 ng/mL. It is possible that different 
downstream events are triggered by different threshold concentrations of 
rapamycin. 
What percentage of TORC1 is insensitive to rapamycin?  Sch9p is a rapamycin-
sensitive target of TORC1; in the presence of rapamycin Sch9p is fully 
dephosphorylated (Binda et al. 2009).  Loss of the EGO complex lowers 
rapamycin-insensitive TORC1 activity by at least 60% (Binda et al. 2009; 
Panchaud et al. 2013b).  The absence of a vegetative growth rate defect in ego- 
mutants suggests that ~40% of rapamycin-sensitive TORC1 activity in cells is still 
sufficient to maintain normal proliferation.  The total TORC1 activity is a 
combination of the rapamycin-sensitive activity and the rapamycin-insensitive 
activity.  The phosphorylation state of Sch9p only reports on the rapamycin-
sensitive activity, but we can estimate the rapamycin-insensitive activity from 
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the reduced growth rate of wild-type cultures in the presence of rapamycin.  If 
we assume, as is reasonable, that loss of the EGO complex reduces the total 
TORC1 activity to a level near to a threshold required for normal growth and 
that rapamycin brings the total TORC1 activity down to ~40% below the 
threshold required for normal growth (as estimated by the rapamycin-insensitive 
growth rate of wild-type cultures), then we arrive at the following estimates: 
1. That rapamycin reduces total TORC1 activity by at least 80% in wild-type 
cells. 
2. The corollary is that the rapamycin-insensitive activity of TORC1 is due to 
at most 20% of the total TORC1 activity in a wild-type cell. 
3. The loss of the EGO complex alone reduces the total TORC1 activity by at 
least 50% relative to that in untreated wild-type cells. 
4. That the addition of rapamycin to an ego- mutant results in a maximum of 
5% of TORC1 activity remaining compared to that of an untreated wild-
type cell. 
These results suggest that the EGO complex is a significant contributor to total 
TORC1 activity, even in a wild-type cell in rich media.  However, it would also 
appear that there is a two-fold overabundance in the total TORC1 activity in a 
cell, under normal conditions, which could explain why ego- mutants do not 
have an obvious phenotype.  These estimations of TORC1 activity also suggest 
that the rapamycin-insensitive functions of TORC1 are only a minor fraction of 
the total TORC1 activity in the cell.   
 Does all nutrient signalling to TORC1 act via the 7.6
EGO complex? 
All nutrient-controlled regulators of TORC1 identified so far appear to act via 
the EGO complex.  Yet ego- mutants are viable and do not have a phenotype 
resembling that of starved cells, as would be expected if the EGO complex was 
the only nutrient sensor.  Is it possible that the TORC1 complex is not the 
predominant or sole mechanism by which nutrient availability is sensed by a cell?  
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If TORC1 acts in a signalling network, the modulation of TORC1 activity by ~50% 
afforded by the EGO complex could report on nutrient status in the context of  
other components in the network that are being independently modulated by 
nutrients. 
Tate & Cooper (2013) have demonstrated that five different TORC1 inactivating 
treatments - nitrogen starvation, methionine sulfoximine addition, nitrogen 
limitation, rapamycin addition and leucine starvation, all result in different 
responses with regards to the nuclear relocalisation of the TORC1-regulated 
translation regulator Gln3p.  They argue that context is key to how lowered 
TORC1 activity is interpreted by the cell, i.e., nutrients are sensed via a 
network, only one component of which is TORC1. 
If TORC1 does not act alone to modulate the behaviour of a cell in response to 
nutrients, what other pathways could be involved?  The PKA pathway is one 
likely candidate to act with TORC1 in a larger network.  Numerous studies have 
probed the relationship between the TORC1 and PKA pathways but the details 
are complex and the overall picture remains unclear, as might be expected for 
interactions between hubs acting in a larger network (for example see: 
Ramachandran & Herman 2011; Roosen et al. 2005; Schmelzle et al. 2004; 
Zurita-Martinez & Cardenas 2005).  Both the PKA and TORC1 pathways regulate 
cell growth in response to nutrients and similarly to the TORC1 pathway, the PKA 
pathway also regulates ribosome biogenesis and stress responses (De Virgilio 
2012).  Loss of the downstream target Sch9p is lethal in combination with 
reduced PKA signalling suggesting that these two pathways act independently, 
although it would appear some redundancy does occur between the TORC1 and 
PKA pathways (Roosen et al. 2005).   
 Future work 7.7
 The large-scale genetic screen 7.7.1
Our analysis of the data from the large-scale screen presented in CHAPTER has 
so far identified 10 null mutants that fail to recover from rapamycin treatment 
and have a slow rapamycin-insensitive growth rate.  These 10 gene products may 
have a role in supporting TORC1 signalling.  A combination of GO term and 
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known physical interaction analysis was used to select an initial subset of the 
primary mutant set to study in depth.  However, both of these strategies have 
drawbacks resulting in potentially interesting genes being overlooked; this is 
especially true for genes that have yet to be fully characterised and therefore 
are not well annotated with GO terms.  It would be very worthwhile testing all 
of the remaining 64 null mutants, identified in two or more runs of the primary 
screen, for their ability to recover from rapamycin.  A subsequent test of the 
rapamycin-insensitive growth rate of those identified with a rapamycin recovery 
defect might highlight other potential novel regulators of TORC1. 
Our analysis has so far indicated that the core HOPS/CORVET complex has a role 
in TORC1 signalling, independently of the known GEF function of the HOPS 
component Vam6p but potentially via the EGO complex.  What is the function of 
the core HOPS/CORVET complex in TORC1 signalling?  A co-immunoprecipitation 
assay could be performed to test whether any of the four core HOPS/CORVET 
complex proteins physically interacts with any of the components of the EGO 
complex.  An interaction could indicate that the core HOPS/CORVET complex is 
physically modulating EGO activity and consequently TORC1 activity.  If any 
protein-protein interactions are identified it would be worth testing whether the 
strength of these interactions is different in response to nutrient availability.  
The strength of interactions between regulators of mTORC1 changes depending 
on the presence of nutrients (Bar-Peled et al. 2012).  It is postulated that these 
different binding states are a method of regulating mTORC1 activity in response 
to nutrient availability (Bar-Peled et al. 2012).  Is it possible that yeast also 
using different binding strengths of upstream regulators to modulate TORC1 
activity? 
The results of our secondary and tertiary screens of mutants identified in the 
primary screen identified that loss of either Vps34p or Vps15p resulted in both a 
rapamycin recovery defect and a slow rapamycin-insensitive growth rate.  As 
described in the Introduction, it is currently thought that the human homolog of 
Vps34p has an as yet unidentified role in mTORC1 signalling (Yang et al. 2013) 
and that the signalling molecule PI(3,5)P2, the synthesis of which requires PI3 
(synthesised by Vps34p (Obara & Ohsumi 2011)), has a role in TORC1 signalling in 
yeast (Jin et al. 2014).  It is postulated that PI(3,5)P2 provides a platform for 
TORC1 and its downstream target Sch9p to reside at the vacuole membrane (Jin 
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et al. 2014).  It is therefore unclear whether the role of the Vps34p-Vps15p 
complex is to act upstream of TORC1, as thought to be the case in mammalian 
cells, or whether it is to provide a membrane-bound platform for the TORC1 
complex and its downstream targets.  If the Vps34p-Vps15p complex acts 
upstream of TORC1 (and EGO) then the phenotype of vps34∆ or vps15∆ null 
mutants should be rescued by the presence of a constitutively active allele of 
Gtr1p (Nakashima et al. 1999).  Whilst the work carried out by Jin et al. (2014) 
suggests that loss of Fab1p, and therefore the PI(3,5)P2 signalling molecule, 
results in rapamycin hypersensitivity of fab1∆ mutants, our preliminary results 
suggest that fab1∆ mutants are in fact able to recover from rapamycin 
treatment.  Recovery of fab1∆ mutants from rapamycin treatment indicates that 
Vps34p-Vps15p has a role in supporting TORC1 signalling over and above that 
supported by PI(3,5)P2.  Further work is needed to determine whether it is the 
Vps34p-Vps15p proteins themselves, or the PI3 signalling molecule synthesised 
by Vps34p-Vps15p that is required for TORC1 signalling.  The use of catalytically 
inactive mutants of VPS34 or VPS15 would result in cells that contained the 
proteins but not the PI3 signalling molecule; the ability of these cells to recover 
from rapamycin treatment could then be tested.  
 TORC1 activity 7.7.2
The ability to quantify TORC1 activity within a cell could greatly extend our 
work.  Sch9p is a direct downstream target of TORC1 and is phosphorylated 
when TORC1 is active (Urban et al. 2007).  Previous studies have utilised a gel 
shift assay to determine the phosphorylation status of the C-terminal region of 
Sch9p, following chemical cleavage in vitro, as an indication of TORC1 activity 
(Binda et al. 2009; Panchaud et al. 2013a; Urban et al. 2007).  Alternatively, 
eIF2α is phosphorylated when TORC1 is inactivated and the phosphorylation 
status of eIF2α can be assayed using anti-phosphorylated site-specific antibodies 
on a western blot (Dubouloz et al. 2005).  A combination of measuring the 
phosphorylation status of Sch9p and eIF2α would give a detailed insight into the 
level of TORC1 activity within specific strains and under various conditions.  The 
ability to assay TORC1 activity would indicate whether mutants, such as 
hops/corvet- mutants, have intrinsically low levels of TORC1 activity in the 
presence or absence of rapamycin. 
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 Identify new regulators of TORC1 7.7.3
The results of our large-scale genetic screen have identified potentially novel 
regulators of TORC1; however the screen was only carried out using the non-
essential deletion collection.  How can essential gene products be identified that 
have a role in TORC1 signalling?  Tandem affinity purification (TAP) could be 
performed using known and potential regulators of TORC1, indeed the presence 
of Tco89p in the TOR1 complex was identified by this method (Reinke et al. 
2004).  By identifying protein-protein interactions, additional novel components 
of the TORC1 signalling complex, which may be overlooked by analysing viable 
null mutants alone, could be identified.   
Our results, and those of others, indicate that all nutrient sensing may act via 
the EGO complex.  However, the EGO complex is not essential in yeast.  A 
genetic screen could be performed in which null mutants of every gene are 
screened in an ego- mutant background to identify double mutants that are 
synthetic sick, or lethal, under normal conditions or following either nutrient 
starvation or rapamycin treatment.  It is possible that some null mutants that 
are synthetic sick or lethal in combination with loss of the EGO complex are 
lacking genes required to support TORC1 activity independently of the EGO 
complex. Such large-scale screens could be performed using, for example, a 
synthetic genetic array (SGA) approach (Tong et al. 2001).   
 How does rapamycin enter the cell? 7.7.4
We have shown during this thesis how rapamycin is detoxified in yeast; 
rapamycin is not actively metabolised but is instead detoxified by dilution-by-
proliferation.  But how does rapamycin enter the cell?  The answer is not known; 
however, as speculated in this chapter it is likely that the import mechanism is 
linked to TORC1 activity: we predict that the uptake of rapamycin into a cell 
decreases following treatment with the drug; but is this true?  By utilising a 
radiolabelled version of rapamycin (for example see Levin et al. 2005), the 
uptake of the drug into cells could be directly monitored over time.  It is 
possible that rapamycin enters the cell via an amino acid transporter, in 
particular one that is removed from the cell surface following rapamycin 
treatment.  A number of large-scale studies have tested single null mutants for 
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sensitivity to rapamycin, however none so far have found evidence of single null 
mutants lacking amino-acid transporters that convey rapamycin resistance (for 
examples see Hillenmeyer et al. 2008; Neklesa & Davis 2009).  It is therefore 
likely that rapamycin is entering the cell via multiple amino-acid transporters.  
Firstly, a screen of mutant strains containing combinations of multiple deletions 
of known and potential amino-acid transporters could be performed seeking 
those with strong resistance to rapamycin.  Overexpression of transporters 
through which rapamycin is imported into the cell could result in 
hypersensitivity to the drug, or an inability of cells to recover from a long 
treatment time with rapamycin due to excessive import of the drug.  Therefore 
a second large-scale screen of strains over-expressing amino acid transporters in 
wild-type cells could be performed seeking those that are hypersensitive to the 
drug.   
 What are the rapamycin-insensitive functions of TORC1? 7.7.5
We have demonstrated within this thesis that rapamycin is not a complete 
inhibitor of TORC1; but what functions of TORC1 are insensitive to rapamycin 
treatment?  Metabolomic, proteomic and transcriptomic profiles could be 
generated for wild-type and ego- mutants both in the absence and presence of 
rapamycin and might indicate what functions of TORC1 are resistant to the 
presence of rapamycin.  Any such rapamycin-insensitive functions of TORC1 
identified are likely to be completely new additions to our knowledge of the 
TORC1 signalling pathway. 
 Conclusion 7.8
In over two decades of research into rapamycin action and the TORC1 pathway, 
it appears that much remains to be explored and understood.  We have shown 
that TORC1 has in fact rapamycin-insensitive functions that have yet to be 
uncovered.  How nutrients are signalled to TORC1 remains elusive.  TORC1 likely 
acts as part of a much larger signalling network to control the response of cells 
to environmental change.  Some of the genes identified in Chapter 6 may 
illuminate part of the answers. 
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